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Abstract
Human equilibrative nucleoside transporter 1 (hENT1) is the main mediator of bidirectional nucleoside flux into and out of cells and is found ubiquitously in all tissues.
Inhibitor and substrate interactions with ENT1 are known to be affected by cysteinemodifying reagents. Our aim was to investigate the importance of cysteine residues in
hENT1 function and identify which residues were sensitive to thiol modification for
further application of cysteine scanning mutagenesis on extracellular loop 5. Transporter
function was assessed by the binding of [3H] nitrobenzylmercaptopurine riboside
(NBMPR) and the cellular uptake of [3H]2-chloroadenosine. Treatment of hENT1 with the
neutral sulfhydryl-modifier methyl methanethiosulfonate (MMTS) enhanced [3H]NBMPR
binding but decreased [3H]2-chloroadenosine uptake. The membrane impermeable
positively charged reagent [2-(trimethylammonium)ethyl] methane-thiosulfonate
(MTSET), but not the negatively charged reagent sodium-(2-sulfonatoethyl)methanethiosulfonate (MTSES), inhibited [3H]NBMPR binding and enhanced [3H]2chloroadenosine uptake. Furthermore, all three sulfhydryl modifiers decreased
[3H]NBMPR binding when allowed cytoplasmic access. Site-directed mutagenesis on
Cys222 eliminated the effect of MMTS on NBMPR binding. Mutation of Cys378 abolished
the effect of MTSET on NMBPR binding and indicated that Cys378 is an extracellularlylocated residue. Mutation of Cys414 led to an enhancement of the ability of MTSET to
inhibit NBMPR binding and this effect was eliminated by co-mutation of Cys378.
Mutation of Cys416 abolished the effect of charged sulfhydryl reagents to inhibit NBMPR
binding in isolated membranes. Additionally, Cys416 to serine also eliminated transport
function supporting a conformational linkage between the fifth intracellular loop and
the NBMPR binding domain, and implicates this region in the translocation function of
hENT1. To further confirm the importance of this region, extracellular loop 5 (EL5) was
examined by cysteine scanning mutagenesis as residues in EL5 were individually
mutated to cysteines. Mutation of N379, F390, E391, H392, and D393 to cysteine
abolished uptake of [3H]2-chloroadenosine indicating their role in the transport
mechanism of hENT1. Treatment of EL5 mutants with MTSET inhibited NBMPR binding
iii

in all but the V389C mutant. Co-incubation of NBMPR with MTSET was able to protect
N379C from thiol modification while co-incubation of adenosine with MTSET protected
R384C, Y385C, and L386C from MTSET effects. Our results indicate that adenosine may
bind in close vicinity or in direct contact to these residues to prevent MTSET to attain
access.

Key Words: Equilibrative nucleoside transport, methanethiosulfonate, cysteine
mutagenesis, structure-function
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Chapter 1: Introduction
1.1 Nucleosides
Nucleosides are endogenous purine and pyrimidine heterocyclic nitrogenous bases
attached to a ribose or 2-deoxyribose sugar. The main naturally occurring nucleosides
include adenosine, guanosine and inosine (purines) and thymidine, uridine, and cytidine
(pyrimidines) (Figure 1.1) [1, 2]. The primary functions of nucleosides are to form the
base structural unit of nucleotides and nucleic acids. Once formed, nucleotides are then
involved in multiple events such as DNA/RNA formation (NTP, dNTP), energy supply
(ATP/GTP), and signaling pathways (cAMP, cGMP). The main source of nucleoside
formation is through a series of resourceful enzymatic cascades involving the breakdown
of nucleotides. These pathways are performed by 5’ nucleotidases found intracellularly
and by ectonucleotide hydrolyzing enzymes such as triphosphate diphosphohydrolases
(E-NTPDase), pyrophosphatase/phosphodiesterases (E-NPP), ecto-5’nucleotidase (CD73)
and alkaline phosphatases (AP) located extracellularly on plasma membranes [3-7]
(Figure 1.2). In this cyclical manner, there is a continuous supply of nucleosides and
nucleotides under basal conditions. The generation of these nucleoside pools can have
an important impact on their secondary function as signaling molecules, specifically as
purinergic agonists. For example, adenosine is a ubiquitous signaling molecule in
purinergic pathways by binding to its purinergic receptors (P1) also known as adenosine
receptors that are widely distributed throughout the body [8-10]. These P1 receptors are
a class of G protein-coupled receptors further divided into 4 subtypes (A1, A2a, A2b, and
A3) [11]. The four adenosine receptors subtypes differ in their molecular structure,
tissue distribution, and pharmacological profile and mediate diverse biological effects
[12-16].
For instance, the A1 receptor subtype is found largely in the central nervous
system (CNS) particularly in the cerebral cortex, hippocampus, cerebellum, and spinal
cord. When adenosine binds to pre and postsynaptic A1 receptors, it inhibits

2

Figure 1.1. Chemical structures of physiological nucleosides
Adenosine, inosine and guanosine are purine nucleosides while cytidine, uridine, and
thymidine are pyrimidine nucleosides.

3

Figure 1.2. Schematic pathways of adenosine breakdown and formation
Adenosine is formed from the breakdown of adenosine triphosphate (ATP), adenosine
diphosphate (ADP), and adenosine monophosphate (AMP) by enzymatic activity of
alkaline phosphatase (AP), ecto 5‘ nucleotidase (Ecto-5’-NT), ecto-nucleoside
triphosphate diphosphohydrolase (E-NTPDase), or ecto-nucleotide pyrophosphatase/
phosphodiesterase (E-NPP).

4
neurotransmitter release to cause a depression of neuronal activity. This is especially
important in times of hypoxia and ischemia because adenosine which is released in high
doses during times of stress can act as a neuroprotective agent to reduce neuronal
activity and oxygen consumption [17-19]. Adenosine receptors expressed in the
cardiovascular system can also elicit responses such as cardiac depression and
vasodilation when activated by adenosine. A1 receptor activation in the sinoatrial and
atrioventicular nodes can result in bradycardia and heart block to slow down the heart
rate; this event has been applied to treat supraventricular tachycardia. Alternatively,
adenosine binding to the A2a receptor subtype located on vascular smooth muscles of
coronary arteries can elicit a relaxation response by activation of adenylate cyclase [9,
20]. Thus it is clear that endogenous adenosine plays an important role in human
physiology and can impact a wide variety of processes including cardiovascular function,
neurotransmission, inflammatory reactions, and immune responses.

1.2 Nucleoside analogues
Given the importance of nucleosides as metabolic precursors to biologically important
molecules, their properties have been capitalized upon for the treatment of many
diseases by the design of nucleoside analogues. Cytotoxic nucleoside analogues are used
as antimetabolites that interfere with the synthesis of nucleic acids. These agents can
exert cytotoxicity either by being incorporated into and altering the DNA and RNA
macromolecules themselves, or by interfering with various enzymes involved in
synthesis of nucleic acids, or even by modifying the metabolism of physiological
nucleosides [21-26]. In this manner, nucleoside analogues can be used as antiviral,
chemotherapeutic, and immunosuppressive agents. Currently there are several
analogues that are clinically used for their anticancer properties (Figure 1.3). Specifically,
cladribine and fludarabine are two purine analogues used for their treatment of lowgrade malignant disorders of the blood [27, 28]. Pyrimidine analogues, such as
cytarabine and gemcitabine, are extensively used in the treatment of acute leukaemia;
various solid tumours and some hematological malignant diseases [29-33]. Additionally,
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the fluoropyrimidines 5-fluorouracil and capecitabine have shown to have activity
against colorectal and breast cancers [34-37].
Cytotoxic nucleosides are also used in anti-viral therapy against various highly
active viral diseases such as acquired immunodeficiency syndrome (AIDS) and diseases
caused by the herpes simplex virus (HSV). Anti-viral nucleoside analogues include 2′, 3′dideoxyinosine (ddI, didanosine), 3′-azido-3′-deoxythymidine (AZT, zidovudine, Retrovir),
(-)-β-L-2′, 3′-dideoxy-3′-thiacytidine (3TC, lamivudine), and (-)-β-L-2′, 3′-dideoxy-3′-thia5-fluoro-cytidine (L-FTC, emtricitabine) (Figure 1.4). Once again, they produce their
therapeutic effects by becoming phosphorylated intracellularly and inhibiting viral DNA
synthesis or by involving mitochondrial toxicity. However, all of these anti-viral agents
and the anti-cancer agents described above utilize membrane transporters to gain
access to target cells for further activation by intracellular kinases and cytosolic
metabolic reactions in forming their active phosphate derivatives.

1.3 Nucleoside transporters
Given the importance of nucleosides and their analogues in their roles in extracellular
signaling and intracellular nucleotide generation, the ability of cells to effectively
accumulate these molecules relies on their efficient movement across membranes.
Nucleosides and their analogues are hydrophilic due to the hydrogen bonding nature of
the hydroxyl groups found on the sugar moiety and consequently, the presence of
specialized transporters are necessary to effectively facilitate their import. Additionally,
cells that lack de novo nucleoside synthesis capabilities such as enterocytes, bone
marrow cells, and certain brain cells, rely heavily on these nucleoside transporters to
salvage nucleosides from the extracellular milieu [38-40]. Nucleoside transporters are
characterized into two separate gene families that differ in their structure and transport
mechanism, and are termed concentrative nucleoside transporters (CNT) and
equilibrative nucleoside transporters (ENT) [41-43].

6

Figure 1.3. Chemical structures of anti-cancer cytotoxic nucleoside analogues
Cladribine, cytarabine, fludarabine, capecitabine, and gemcitabine are nucleoside
analogues
used
in
the
treatment
of
certain
cancers.
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Figure 1.4. Chemical structures of antiviral cytotoxic nucleoside analogues
Emtricitabine, lamivudine, zidovidune, and didianosine are nucleoside analogues used in
the treatment of multiple viral infections.
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The concentrative nucleoside transporters (gene SLC28) are sodium-dependent
symporters that move nucleosides unidirectionally into cells in an active energy-costly
process [44, 45]. CNTs are generally found in apical membranes of specialized epithelial
cells of the intestine and kidney and can play a major role in active absorption or
reabsorption processes. There are three sub-families of CNTs that have been cloned,
CNT1, CNT2 and CNT3, that differ in their substrate selectivity and sodium:nucleoside
stoichiometry [46, 47]. CNT1 selectively transports pyrimidine nucleosides and
adenosine while CNT2 transports purines and uridine. CNT3 transports both purine and
pyrimidine nucleosides and functions by translocating two sodium molecules per
nucleoside. These three concentrative nucleoside transporters are plasma membrane
transporters and share a general topology based on 13 putative transmembrane
domains, a long intracellular N-terminus, and an extracellular C-terminus [48].

The equilibrative nucleoside transporters (gene SLC29) are sodium-independent
facilitated diffusers that have been confirmed to transport nucleosides bi-directionally
down concentration gradients [49]. These transporters are found in most if not all cell
types, and can transport a wide variety of purines and pyrimidines and in some cases
nucleobases. There are four subtypes of ENTs (ENT1-4) that have been cloned to date
and differ in their substrate selectivities and inhibitor sensitivities [43, 50] (Table 1.1).
ENT1 and ENT2 were the first transporters to be characterized by their differential
inhibition by nitrobenzylthioinosine (NBMPR), ENT1 being sensitive to NBMPR at a nM
range [51]. ENT2, insensitive to NBMPR, transports nucleosides as well as nucleobases
such as hypoxanthine and is found predominantly in skeletal muscle, although its
expression has been detected in brain, heart, placenta, and kidney. ENT3 and ENT4 have
recently been characterized as members of the ENT family of transporters that are
active in acidic pH. ENT3 is found intracellularly and contains an endosomal/lysosomal
targeting motif and is shown to have elevated expression in human placenta [52, 53].
ENT4 found abundantly in heart and brain is also termed plasma membrane monoamine
transporter (PMAT) because it efficiently transports serotonin and MPP+ at neutral pH
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while only transporting adenosine at acidic pH [54]. All four equilibrative nucleoside
transporters transport adenosine and therefore can influence the many physiological
processes described above such as cardiovascular tone and neurotransmission.

1.4 ENT1 subtype
The ENT1 subtype has been suggested to be the main mediator of adenosine flux and
cytotoxic accumulation of nucleoside analogues, as inhibition of ENT1 has been proven
to increase adenosine levels and adenosine signaling in cardiovascular tissues, CNS, and
kidney [55-57]. Since the ENT1 subtype is highly and widely expressed and mediates the
entry of cytotoxic nucleoside analogues, it is not surprising that the loss of ENT1
expression has been correlated to drug resistance in in vitro models of malignant cancer
cells. Additionally, studies with the ENT1-knock out mouse (ENT1-KO) have found higher
levels of circulating adenosine and ribavirin (a nucleoside drug) compared to their wildtype counterparts suggesting that ENT1 is a major contributor to extracellular adenosine
concentrations and uptake of nucleoside drugs [58, 59]. The ENT1 knock-out mouse was
first created by Choi et al. (2004) through deletion at exons 2-4 of the protein-coding
region of the ENT1 gene. The ENT1 knock-out mice in those studies that were less than 4
months of age, reproduced normally, were viable, showed apparent normal mortality
rates, and had normal brain anatomy [60]. However, these mice had a lower body
weight (8.7% less than wild-type littermates), and were found to show a slower rate of
intoxication and increased preference for ethanol consumption. This enhancement for
ethanol consumption was associated with increased levels of cAMP response element
binding protein (pCREB) in the striatum through an increase in glutamate signaling.
Furthermore, when examining the behaviour of the ENT1-KO mice, it was shown that
they showed less of an anxiety phenotype when compared to their wild-type
counterparts. They also showed a lowered natural aversion to the centre of an open
field indicating that they showed less anxiety; however, the locomotor activity was
similar to that of wild-type [61]. When wild-type mice were injected with NBMPR
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Table 1.1. Characteristics of the Equilibrative Nucleoside Transporter (ENT) Family
members

11
(specific ENT1 inhibitor) in the amygdala, they also showed reduced anxiety indicating
that the behavioural effects in the ENT1-KO mice were due to a loss of ENT1 and not
through developmental changes. Additionally, phenotypic changes have been recently
identified in older ENT1-KO mice (12 months of age) in our lab. Current studies from our
lab (unpublished work from Bone and Warraich et al.) have found ENT1-null mice
acquired spinal stiffness, hind limb dysfunction and eventual paralysis by 12 months of
age. Upon further examination, it was found that the mice showed signs of ectopic
mineralization of paraspinal tissues in the cervical-thoracic region (as early as 2 months
of age) forming lesions that contained high amounts of calcium and phosphorus. These
unpublished studies by Bone and Warraich et al., are the first to identify ENT1 as playing
a role in regulating the calcification of soft tissues.
The cardiovascular system has also been studied in the ENT1-null mouse, as its
substrate adenosine is a significant contributor to vascular tone and heart function.
Initial examination of the ENT1-null mouse found it to be cardioprotected such that
myocardial infarcts were significantly smaller after subjected to ischemia (coronary
occlusion for 30 min and reperfusion for 2h) [55]. Cardiomyocytes isolated from these
mice showed no significant differences in gene expression profiles of the other ENT
subtypes or adenosine receptors indicating that there was no compensation of the loss
of ENT1 in these cells [58]. However, when examining isolated microvascular endothelial
cells from the ENT1-KO mice, there was a 2 fold increase in expression of the A2a
receptor and adenosine deaminase enzyme was observed [62]. Given that there is an
increase in circulating adenosine in KO mice, increased expression of these genes may
reflect compensatory mechanisms in the animal to handle the excess adenosine.
The expression of ENT1 itself is still under investigation with a large body of
evidence opbtained from studies using cultured human cells indicating that hENT1
expression was coordinated with the cell cycle [63-66]. Expression of hENT1 showed a
doubling between the G1 and G2-M phases indicating that cellular deoxynucleotide
levels could play a role in cell cycle regulation by coordinating transporter expression.
Additionally, studies in HeLa and MCF-7 cells showed that ENT1 expression responded to

12
phorbol ester treatment by activation of protein kinase C (PKC) isoforms [67-70]. The
specific targets on mouse ENT1 (mENT1) for PKC-mediated phosphorylation have been
shown to involve serines 279 and 286 and threonine 274 located in the large
intracellular loop betweetn transmembrane 6 and 7 [71]. Alternatively, hENT1 also
contains casein kinase II (CK2) consensus sites which are known to play a role in
regulating proliferation [72, 73]. Inhibition of CK2 phosphorylation was shown to
increase hENT1 activity and NBMPR binding in human osteosarcoma cells [74]. Our own
lab has demonstrated that the expression of a catalytically inactive CKII subunit which
inhibits endogenous CKII activity caused an enhancement in hENT1-specific NBMPR
binding and transport of the substrate 2-chloroadenosine in U2OS cells [75]. Taken
together, these data have demonstrated that ENT1 is a phosphoprotein that can be
directly phosphorylated at several sites which shows that it is involved in a complex
array of pathways in its regulation.
Besides post-translational regulation by phosphorylation, pre-transcriptional
events also regulate hENT1 expression. The promoter sequence of hENT1 (involving one
transcriptional initiation site 58 base pairs downstream of the TATA box) has been
shown to contain consensus sites for ERE, MAZ, Sp1, AP-2, and CREB transcription
factors [76]. Studies investigating hENT1 expression and activity have shown that human
umbilical vein endothelial cells (HUVEC) isolated from gestational diabetic pregnancies
showed a decrease in hENT1 expression [77]. A second study found hENT1 expression
was reduced in HUVECs when exposed to hyperglycemic conditions by the engagement
of nitric oxide, MAP kinase, and PKC. Incubation with N(G)-nitro-L-arginine methyl ester
(L-NAME, nitric oxide synthase inhibitor), PD-98059 (MEK1/2 inhibitor), or calphostin C
(PKC inhibitor) prevented hENT1 downregulation in the hyperglycemic environment
[78]. Additionally, when measuring Sp1 protein levels, they found Sp1 expression
increased when hENT1 promoter activity decreased, suggesting that Sp1 may be a
negative transcriptional factor for hENT1 [79]. These studies link the importance of
hENT1 regulation in certain pathologies such as gestational diabetes where the
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adenosine-modulated placenta to fetus blood flux is damaged and loss of hENT1 causes
a loss of the endothelium ability to remove adenosine from the extracellular space.
Furthermore, ENTs are also predominantly expressed in endothelial cells of the
cardiovascular system with minimal contribution from the CNTs [80]. In human
microvascular endothelial cells (HMEC-1), it was found that, under hypoxic conditions,
ENT1 expression was downregulated in a HIF-1 (hypoxia inducible factor 1)-dependent
manner [81]. These findings indicate that an innate protective mechanism is present
that serves to enhance adenosine signaling in times of cellular stress by decreasing
uptake of nucleosides into cells by ENT1.
1.4.1 Characterization of ENT1
The NBMPR-sensitive transporter ENT1 was first purified from human erythrocytes
which allowed for the cloning of hENT1 from human placental cDNA [82]. Previous
studies examining cells that transported nucleosides relied on the use of radioligand
binding and uptake assays. These initial studies on ENT1 activity found that
nitrobenzylthioinosine bound to high-affinity sites on human and sheep erythrocyte
membranes and on rat, mouse, guinea pig, and dog cortical membranes in a saturable
manner (Kd ~ 0.1-1 nM) [83-88]. Binding data from these studies indicated that NBMPR
had a specific interaction with functional nucleoside-transport sites that could be
inhibited by nitrobenzylthioguanosine (NBTGR), dipyridamole (a vasodilator), and
uridine (substrate). Additionally, transport processes examined in human and sheep
erythrocytes showed [3H]NBMPR inhibition of [14C]uridine influx, consistent with a
simple competitive inhibition model (apparent Ki = 1 nM). Binding of inhibitor to these
sites was competitively blocked by uridine, a well characterized substrate for the
nucleoside transporter (apparent Ki = 1.25 and 0.9 mM, respectively). These apparent Ki
values were found to be close to the apparent Km for uridine equilibrium exchange in
human erythrocytes, indicating that NBMPR competes directly with nucleosides for the
permeation site of the nucleoside transporter, and that the inhibitor binds preferentially
to the external membrane surface [85].
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Human ENT1 is 456 amino acids and is 78% identical in sequence to rat ENT1 and
79% identical to mouse ENT1 [82, 89, 90]. Splice variants of hENT1 are not reported,
however, there are multiple variants found in mouse shown to possess different
functional characteristics [75, 91]. One functional splice variant mENT1.2 altered at the
end of exon 7, lacks a potential casein kinase II phosphorylation site and has shown to
be widely expressed with mENT1.1. This mouse variant, mENT1.2, was also found to
have an altered affinity for the prototypical ENT1 inhibitor NBMPR. Another splice
variant of mouse ENT1 involving the exclusion of exon 11 during pre-RNA processing is
widely distributed in multiples tissues. This functional variant termed mENT1Δ11 bound
inhibitors and transported substrates with high affinities and was predicted to possess
nine TM domains and cytoplasmic COOH and NH2 termini. Additionally, rat ENT1 is
found to be inhibited by NBMPR but is resistant to inhibition by the vasodilator
compounds dilazep, draflazine and dipyridamole [82] (Figure 1.5).
Human, mouse and rat ENT1, transport a wide range of purine and pyrimidine
nucleosides with affinities ranging from 0.05 mM for adenosine to 0.6 mM for cytidine.
However ENT1 subtypes are unable to transport the pyrimidine base uracil. Human and
rat ENT1 also poorly transport the antiviral nucleosides ddC, ddI and AZT (compared to
the anti-neoplastic analogues). These anti-viral drugs are pyrimidine nucleoside
analogues that lack the C3- hydroxyl group, revealing the importance of the hydroxyl
group for permeant recognition by ENT1 [92]. In contrast, the anticancer analogues such
as gemcitabine and fludarabine are transported readily and efficiently by the ENT1
subtype [93].
ENT1 is expressed ubiquitously in all tissues but at differing levels. For example,
hENT1 is found in brain tissue with higher expression in the frontal and parietal lobes of
the cortex [94]. In the rat kidney cortex, rENT1 is found on the basolateral surface of the
tubular epithelial cells similarly seen in hENT1-GFP tagged proteins in MDCK cells in vitro
[45]. Additionally, rENT1 found in high abundance in the sinoatrial node of the heart is
suggested to play a role in modulating the chronotropic effects of adenosine [95].
Therefore though ENT1 is found throughout the body, its abundance can vary depending
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on tissue and cell location. Furthermore, though ENT1 is primarily expressed as a plasma
membrane transporter, there are also studies that suggests it can also be detected in
nuclear membranes and endoplasmic reticulum [96]. Functional human ENT1 is also
found in the mitochondria where it has been suggested to play a part in the
mitochondrial toxicity effects of the antiviral agents [97]. This feature seems to be
specific for the human homologue, as rat and mouse ENT1 lack the mitochondrialtargeting motif (PEXN). These subpopulations of intracellular ENT transporters are
thought to contribute to the nucleoside passage between the cytosol and lumen of
cellular compartments and could also correspond to a pool of intracellular transporters
available for membrane recruitment at crucial time points.

1.4.2 Homologues of ENT1
Following the initial cloning of hENT1, homologues of mammalian ENTs have been
detected in protozoa, fungi, plants, nematodes, and insects due to their sequence
similarity to mammalian ENTs [50, 98] (Figure 1.6). Within the nematode Caenorhabditis
elegans genome, there are five genes encoding equilibrative nucleoside transporters,
two of which (CeENT1 and Ce ENT2) are closely related with 94% sequence similarity.
The substrate specificities of the CeENTs closely resemble those of hENT1 and hENT2.
However, their sequence similarities to hENT1 and hENT2 are between 15-24% and they
both differ from the mammalian transporters in that they are not sensitive to NBMPR,
dilazep, or draflazine. Dipyridamole, on the other hand, does show moderate inhibition
of CeENT1 and Ce ENT2 at an IC50 300 nM, indicating that inhibitors with different
structures interact with the protein at different residues. The CeENTs also are capable of
transporting the cytotoxic dideoxynucleosides (ddI, ddC, AZT) with high efficiency [99,
100].
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Figure 1.5. Chemical structures of ENT inhibitors
Nitrobenzylmercaptopurine riboside (NBMPR), dipyridamole, dilazep, and draflazine are
potent inhibitors of hENT1.
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The parasite Plasmodium falciparum, which is the causative microbe in malaria,
also possess ENT family members that have been designated as PfENT1-4 [40, 101, 102].
The PfENTs have broad substrate specificity and have 18% sequence identity to hENT1
and hENT2. Similar to the CeENTs, PfENTs are not proton dependent and have
conserved sequence motifs in the region of the transmembrane spanning segments
confirmeing that they are members of the ENT protein family. The majority of
transporter expression has been detected during the erythrocytic stages of the parasite
which are known to be responsible for the clinical pathogenesis of the disease. PfENTs
are efficient in transporting natural nucleosides with apparent affinities (Km) of 320 µM
similarly reported for mammalian ENTs. However, PfENTs are not sensitive to NBMPR or
the inhibitory vasodilators up to the mM concentrations.
Mammalian ENTs are also homologous to the active, proton-linked transporters
in kinetoplastid protozoa in Leshmania and Trypanosoma [103-105]. Transporters in the
Trypanosoma brucei, include two high affinity transporters (P1 and P2) that differ in
their substrate selectivity [106-108]. The P1 transporters mediate the movement of
adenosine and inosine with higher affinity (low Km) than the PfENTs. P2 transporters
passage adenosine and the nucleobase adenine and was initially identified through its
sequence similarity from the Leishmania donovani nucleoside transporter LdNT1.1.
In Leishmania donovani, there are also two nucleoside transport processes, one
selective for adenosine and pyrimidine nucleosides (LdNT1.1 and LdNT1.2) and the other
for inosine and guanosine (LdNT2) [109-111]. Comparing LdNT1.1 and LdNT1.2, they
have almost identical sequences and transport adenosine at high affinities of Km < 1 µM
however uridine is also transported at a much lower affinity. The LdNT2 transporter
selectively carries inosine with a high affinity (Km 0.3 µM) as well as guanosine (Km 1.7
µM). Despite the functional difference from mammalian transporters in the fact that
they are proton linked and therefore not equilibrative diffusers, they are confirmed to
belong to the ENT family due to their amino acid sequences and membrane topologies.
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Figure 1.6. The Equilibrative Nucleoside Transporter family rootless phylogenetic tree.
The blue box highlights hENT1 and the red boxes highlight homologs of hENT1 described
in Section 1.4.1
Permission to use copyrighted material : adapted from Acimovic and Coe, 2002 [112]
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1.5 Clinical relevance of hENT1
1.5.1 Inhibitors: NBMPR and the vasodilators
The influence of ENT1 on the extracellular levels of adenosine, a nucleoside with
physiological activity, indicates that it is a viable target for drug therapy in multiple
pathologies. Inhibition of hENT1 is of particular importance because it is the main
contributor of adenosine uptake and clearance from the extracellular space [49, 98]. By
blocking the removal of adenosine, there is enhancement of adenosine signaling
through adenosine receptors which can impact the neurological, cardiovascular, and
immunological systems [113]. NBMPR and the coronary vasodilators such as
dipyridamole, dilazep, and draflazine (Figure 1.5) inhibit ENT1 leading to enhanced
extracellular concentrations of adenosine [114-117]. Studies in murine cardiomyocytes
show that adenosine uptake is sodium independent, saturable, and inhibited by NBMPR,
dilazep, and dipyridamole [118]. In endothelial cells, the inhibition of hENT1 by
draflazine provided increased A1/A3 signaling shown to be beneficial in the
ischemic/reperfused

myocardium

[119,

120].

Additionally,

administration

of

dipyridamole during percutaneous transluminal coronary angioplasty in humans also
reduced the incidence of abrupt vessel closure by inhibition of ENTs [121]. The ENT1-KO
mice also been have shown to have a cardioprotected phenotype especially during times
of ischemia/reperfusion by having enhanced circulating adenosine levels compared to
wildtype [55].
In addition to blocking adenosine reuptake, hENT1 inhibitors have shown to be
useful in anti-cancer therapy as well. For example, the cytotoxic effect of cladribine
uptake by nucleoside transporters is complemented with co-treatment of NBMPR to
prevent drug efflux [122]. Therefore selective inhibition of ENTs may be useful in
combined drug therapy in the treatment of many cancers to improve drug efficacy.
1.5.2 Substrates: Cytotoxic nucleoside analogues
A frequent avenue in drug therapy for cancer and viral diseases utilizes cytotoxic
nucleoside analogues. The ENTs play an important part for entry of these drugs inside
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the target cells. Specifically, human ENT1 has been shown to enhance the transport of
chemotherapeutic agents such as cladribine, cytarabine, fludarabine, gemcitabine, and
capecitabine (Figure 1.3) [93, 123, 124]. These nucleoside analogues function in a variety
of ways: by incorporation into nucleic acids, through interfering with the nucleic acids
synthesis, and by modifying the metabolism of endogenous nucleosides. By depleting
the endogenous pools of nucleosides, the cytotoxic nucleosides increase their chances
for incorporation into newly forming DNA and RNA. Expression of hENT1 in highly
proliferating cells such as the malignant cancerous cells contributes to the selectivity for
nucleoside analogues since they require higher transport of nucleosides for their
replication [125]. For example, in acute lymphoblastic leukaemia cells, hENT1 expression
was correlated to increased sensitivity to cladribine [126]. In accord with this evidence,
the downregulation of hENT1 was also suggested to contribute to clinical resistance of
cytarabine and gemcitabine given that ENT1 is the major route of entry for these drugs
[127]. Specifically, leukemic cells resistant to Ara-C treatment showed a downregulation
in hENT1 gene expression [128]. Moreover, hENT1 is now known as a positive predictive
marker of patients receiving gemcitabine treatments for pancreatic cancer and
metastatic lung disease [127, 129].

Recent studies highlight the importance in measuring hENT1 levels as a
predictive tool for better drug therapy protocols that are specific to individual patients
as levels of hENT1 in patients with different breast cancers, Hodgkin’s disease, and
pancreas adenocarcinoma have shown a significant range of distribution. Additionally,
the expression of hENT1 has been shown to be positively correlated with a three-fold
increase in the survival of patients receiving gemcitabine treatment [130]. Imaging
analogues of NBMPR for specific binding to hENT1 have proven useful in determining
the abundance of transporter expression at the plasma membrane to guide drug
treatment protocols [131]. Given that cancer cells have a higher demand for
extracellular nucleosides to maintain their increased proliferation rates, nucleoside
analogues are relatively specific for target cells. With higher levels of hENT1 being a
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predictive marker in pancreatic cancer and non-small cell lung cancer, it is of significant
importance to improve the selectivity and specificity of drugs for cancer cells to help
decrease normal cell toxicity and death.
1.6 Molecular characteristics of hENT1
1.6.1 Membrane topology and protein structure determinants
The original hydropathy plot of hENT1 indicated a 2-D topology of an intracellular Nterminus, 11 transmembrane domains (TM), an extracellular C-terminus, and a large
intracellular loop linking TM6 and 7 (Figure 1.7) [90]. This generated figure was then
confirmed and supported using biochemical studies using antibodies as topological
probes in combination with glycosylation scanning mutagenesis [132]. Additionally,
hENT1 is shown to have a glycosylation site in the extracellular loop 1 at residue Asn48,
however, this modification does not seem to have an essential role in either activity or
expression at the plasma membrane [133]. Given that rat ENT1 had a different inhibitor
profile sensitivity to vasodilator compounds [134], studies based on human and rat
chimeras identified regions containing TM 3-6 to have a significant role in hENT1
functionality in both inhibitor binding and substrate interactions [135]. This region is
thought to form the major site of interaction with NBMPR and substrates as multiple
studies have shown their ability to competitively inhibit each other [86, 136]. Mutational
analyses within this region have also validated the importance of this domain. For
example, mutations of Gly154 and Ser160 in TM4 affected permeant translocation and
NBMPR binding, indicating that they possessed dual roles recognizing inhibitors and
substrates [137, 138].

Mutation of Gly154 to serine caused a loss of NBMPR binding and decreased
affinities of hENT1 for adenosine and cytidine. The important roles of glycine residues
have also been implicated in hENT1 structure as mutations at the conserved Gly179 and
Gly184 residues altered hENT1 activity and reduced plasma membrane expression
respectively [139]. Although TM3 is crucial for ENT1 function, characterization of other
point

mutations

throughout

the

transporter

has

also

revealed

important
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Figure 1.7. Predicted 2-D topology of hENT1 created in TMPPres2D [140]
The primary amino acid sequence of hENT1 was inserted into the TMPPres 2D program
and predicted the membrane-spanning regions and their orientation.
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structural/functional roles for other regions of hENT1. In particular, mutations of Met89
and Leu92 in TM2 produced changes in transporter affinities for adenosine, guanosine,
NBMPR and dipyridamole [138, 141]. Additionally, Leu442 in TM11 was found to be
involved in dipyridamole sensitivity when Met33 in TM1 was first mutated to isoleucine
[100]. This study indicated a functional interaction between TM1 and TM11, regions
outside the predicted crucial domain (TM3-6) and implicated Met33 in dipyridamole and
NBMPR binding interactions. Additionally, the highly conserved residue Trp29 was found
to have a selective role in pyrimidine transport activity (uridine and cytidine) [142].
Mutation of Trp29 also decreased the ability of the inhibitors to interact with hENT1. A
helical wheel projection of this transmembrane helix (TM1) suggested that Trp29 and
Met33 were in close proximity and therefore validates the importance of this region in
hENT1 activity.

Further evidence for the involvement of the terminal domains was revealed by
mutations at Phe334 and Asp338 in TM8 altered the ability of hENT1 to be inhibited by
the coronary vasodilators [143]. Specifically, Phe334 (TM8) mutated to tyrosine
increased the rate of transport of 2-chloroadenosine suggesting an altered conformation
state of hENT1 to accept the substrate. Mutational analysis of the LdNT2 transporter has
also implicated a role for TM8 in ENT functions, where hydrophilic residues Asp341 and
Arg345 (corresponding to Phe334 and Asp338 in hENT1) are essential for expression and
function of the transporter [110]. As a result of these studies (summarized in Figure 1.8),
it is suggested that though there is one overlapping recognition site for inhibitors and
substrates, there are multiple regions that contribute to ENT1 function. In effect, each
individual mutation that was examined did not alter all interactions with different
inhibitors or substrates which indicates that each ligand has its own individual points of
contact with hENT1. As hENT1 is shown to have therapeutic potential through its
inhibition as well as its cytotoxic nucleoside translocation, development of specific drugs
to recognize and preferentially select for hENT1 may prove helpful. Understanding the
structure and mechanism of action of hENT1 in terms of where the permeants bind and
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how they interact with the protein can help in the design of such drugs. However, there
are no 3-D models of hENT1 given its unyielding nature for biophysical techniques such
as x-ray crystallography, therefore the advancement of such rational drug design has
been slow moving.

1.6.2 Pharmacophore modeling
One way to gain an understanding of the binding determinants of nucleosides and
inhibitors to their transporters is to use a computational approach to model in vitro
affinity data. In silico studies can be used as a tool to direct the exploration of new ligand
to nucleoside transporters. Given that the structure of ENTs have not yet been
elucidated, studies predicting ligand interactions have employed the use of ligand-based
quantitative structure-activity relationships (QSAR). Current biological tested models of
inhibitor and substrate interactions have found that on NBMPR, the nitrobenzyl moiety
is critical for high-affinity binding to the transporter. Specifically, electron-withdrawing
substituents at the 6-position benzyl substituent have been indicated to contribute to
high affinity binding of the transporter [144, 145]. Addition of a nitro group at that
position enhanced affinity by 50-fold compared to NBMPR itself. A specific feature of the
nitro group was its electron-withdrawing capabilities as well as its negative charge,
suggesting that negative charges interact with positively charged moieties in the binding
site of the transporter.

Given the size of the nitrobenzyl moiety and the enhanced interaction with the
nitro group, these data suggest that the area where NBMPR binds is in a large pocket
that is able to accommodate its chemical structure containing an area of positively
charged residues. A separate study analyzing the ability of C2-purine position-substituted
analogs of NBMPR to inhibit ENT1 has identified that substitutions at the C 2 lead to a
general decrease in the ability of the analogues to inhibit hENT1 activity compared to
NBMPR [146]. These data suggest that C2 interacts with the transporter in a very specific
manner and any addition to that area via steric bulk sizes or charges impacts on the
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Figure 1.8. Topology model of hENT1 with amino acid residues that have been
identified as structurally or functionally important determinants.
The 2-D topology of hENT1 is shown with residues identified to be important for ENT
activity indicated by the blue filled circles.
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ability of the purine portion of NBMPR to bind with hENT1. Additionally, examination on
the structure-activity relationship of ENTs to substrates found the requirement of sugar
moiety for transporter interaction specifically with the presence of the C 3 hydroxyl [92].
Selective structural determinant for ENT1 also include C2 and C5 in comparison to ENT2
requiring only the C5 interaction [147, 148]. Further investigations using bioinformatics
found incorporation of electrostatic and steric features at the C 3 position and a negative
charge at the 2,7 position of the purine (3,5-position pyrimidine) to contribute to
enhanced affinity to hENT1, validating again a positively charged region within the ligand
binding pocket [149, 150]. These 3-D QSAR models are based on correlations between
ligand affinities and variations on their structural features and validated the importance
of the substrates C3 position and the pentose ring structure for hydrogen bond
formation (Figure 1.9). As mentioned previously, these models should assist the design
of high-affinity nucleoside transporter inhibitors and substrates; however, caution
should be taken when interpreting these data before assessment in biological models.

1.6.3 Mechanism of translocation function
It is believed that nucleoside transporters share a common evolutionary origin with the
MFS (Major Facilitator Superfamily) of transporters of which the majority function as
monomers, transporting substrates in an “alternating access mechanism” [85, 151, 152].
In this manner, ENT1 is also predicted to have an extracellular and intracellular substrate
site that when bound, produces a conformational change in the transporter to reorient
itself and release the substrate on the opposite side of the membrane (Figure 1.10). In
this case, there would be two primary conformations for ENT1 that alternated regardless
of substrate binding, one inward facing and one outward facing. However, only one site
would be accessible at any time. NBMPR binds specifically to the extracellular site of the
protein and would potentially lock it into this conformation in this model [46, 153].
Additionally, depending on the permeant bound, hENT1 may be able to alter the rate at
which the conformation would change. For example, hENT1 expressed in human
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Figure 1.9. Generated pharmacophore model aligned against NBMPR obtained from
PHASE.
Chemical structure of NBMPR shown on the right beside the Pharmacophore model. Red
points indicating hydrogen-bond acceptors (oxygen), orange points for aromatic groups,
green indicated for hydrophobic regions, blue points indicate nitrogen, yellow points
showing sulfur, gray is showing carbon and white highlights hydrogen.
Permission to use copyrighted material : adapted from Zhu and Buolamwini, 2008. [149]
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erythrocytes showed a rapid conformation change with pyrimidine nucleosides and a
slower change with 2-chloroadenosine [51]. However, there are other complex models
of hENT1 that have been proposed where the transporter may exist as an oligomer with
allosteric sites. Several studies have found the presence of higher molecular weight
bands on immunoblots probing for ENT1 in multiple tissues in rats. From our own lab,
photoaffinity labelling of mouse ENT1 with [3H]NBMPR found that mENT1 was present
at a higher molecular weight band at approximately 100 kDa, or twice the size of the
ENT1 monomer. Additionally, unpublished data from Cunningham F. et al., found hENT1
at a higher molecular mass complex (147-180 kDa) compared to its monomer size (55
kDa) under native conditions using the blue native gel electrophoresis technique. It has
been previously suggested that there are two permeant recognition sites for hENT1, one
that is a high affinity site for NBMPR and substrates and a second lower affinity site
which may allosterically modulate the higher affinity site. Data from [ 3H]NBMPR
inhibition studies using dipyridamole and the lidoflazine analogues as competitive
inhibitors found them to have pseudo-Hill coefficients that were not equal to unity
indicating the presence of co-operativity or multiple sites. Additionally, studies
examining the rates of dissociation of [3H]NBMPR binding found nucleosides to enhance
dissociation rates versus inhibitors such as dipyridamole and dilazep decreased
dissociation rates. This suggests the presence of a second site that can influence the first
high affinity site which could indicate either multiple sites or co-operativity. However,
there is still not enough evidence to distinguish between the two possibilities and
mechanisms.

1.6.4 Predicted 3-D topology of ENT1
Clearly, understanding the structure, function, and mechanism of hENT1 would be of
considerable value in drug discovery. Current homology and comparative modeling of
ENT1 have generated several putative configurations of the transporter since the
primary sequences have been validated and secondary structures have been proposed.
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Figure 1.10. Schematic depicting the alternating access model for ENT1.
The substrate/nucleoside binding site will be alternately exposed from the extracellular
milieu (outward facing) to the cytoplasm (inward facing). NBMPR shown in dashed lines
would only access ENT1 from the extracellular side and lock it in the outward facing
conformation.
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Recent high resolution crystal structures of the prokaryotic transporters lactose
permease LacY and the glycerol-3-phosphate transporter GlpT [154, 155] have identified
important structural and molecular mechanisms of membrane proteins. Surprisingly
both transporters show similar folding patterns though they are functionally different.
Therefore, new investigations using comparative modeling of unknown transporter
structures revolve around the premise that all MFS transporters share a similar folding
pattern. Analysis of the primary and secondary sequences of nucleoside transporters
have led to the generation of putative models of ENTs that are based on the known 3-D
models of proteins in the MFS superfamily.
One model from Baldwin et al. compared PfENT1, a Plasmodium falciparum ENT
against the template of the bacterial GlpT [40]. This model suggested that TMs 1, 2, 4, 5,
8 and 11 are surrounding the solvent-accessible permeant binding site which has also
been shown for the LacY transporter. An alternative modeling approach utilized the
template-independent ab initio technique. In this manner, the ENT model would be
based solely on its primary sequence and a combination of different algorithms and
modeling techniques. The proposed ab initio model of the LdNT1.1 transporter also
found TM domains 1, 2, 4, 5, 7, 8, 10 and 11 to surround the general hydrophilic crevice
further validating the previous model on PfENT1 (Figure 1.11) [156]. However, this study
also suggested that TM1, 10, and 11 directly line the substrate translocation pathway.
Our lab has identified a functional splice variant of mouse ENT1 where the last three TM
helices and associated loops were missing [157]. This splice variant (mENT1Δ11) was
able to both bind NBMPR and translocate 2-chloroadenosine which is contradictory to
the proposed 3-D model. Therefore though the models are good foundations to build
future studies upon, caution needs to be taken when interpreting these generated
models to different species of ENT1 and there is need for them to be experimentally
tested.
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Figure 1.11. Structural model of LdNT1.1 based on ab initio analysis.
Transmembrane helices are indicated by rigid cylinders and are numbered 1–11 shown
from the cytoplasmic side. Three hypothetical ab initio models for LdNT1.1 derived from
Rosetta modeling are presented and compared with a model obtained by threading
analysis upon the template of the 3-glycerol-phosphate transporter of E. coli.
Permission to use copyrighted material: from Valdes et al., 2009 [156]
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1.6.5 Thiol modifications
Generally, interactions and orientations comprising the translocation domains are not
well defined as there is limited information on the 3-D structure of ENT1. Therefore,
useful ways to determine important residues in hENT1 structure and function include
mutational techniques and chemical modifying reagents. Chemically modifying a
particular amino acid can identify if it is or is not an important residue in the binding of
ligands or function of the protein. Since cysteines contain sulfhydryl groups which may
form important disulfide bonds in protein folding they are an amino acid of interest. The
sulfhydryl moiety of a Cys residue may be located in one or more possible regions: a
water accessible region on the extracellular surface; a hydrophobic region of the
transmembrane domains; or the cytoplasmic region of the cell’s interior. Depending on
its location, a cysteine residue will react differently to sulfhydryl compounds of with
various physiocochemical properties. For example, a cysteine residue located
extracellularly in a negatively charged environment may be more accessible to a thiol
modifying reagent that is positively charged versus a cysteine located in the lipophilic
transmembrane domain which would be more readily accessed by a neutral thiol
modifying reagent. Additionally, mutation or modification of endogenous cysteine
residues that could interact directly with substrates and inhibitors will alter transporter
function and/or inhibitor binding. By determining whether the endogenous Cys residue
can be protected from the effects of thiol modification with co-incubation with either
substrate or inhibitor, information regarding whether they are located within or close to
the permeation site will be provided. Since inhibitors and substrates of hENT1
competitively inhibit each other and therefore are predicted to interact with the
transporter in one site but with a separate set of determinants, it will be conducive in
finding their separate points of contact.
A previous study of rat ENT2 found an exofacial Cys involved in the functionality
of

the

transporter

[158].

Chemical

modification

of

rENT2

with

p-

chloromercuribenzylsulfonate (pCMBS) (a membrane impermeable sulfhydryl-specific
reagent) inhibited rENT2 activity via interaction of pCMBS with Cys140 in TM4.
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Additionally, uridine at high concentrations was able to block these effects indicating
that Cys140 was located at the exofacial, solvent accessible side of TM4 (given that
pCBMS is negatively charged and unable to cross membranes) and was either directly
involved in the substrate translocation pathway or in close proximity. The corresponding
residue in hENT1 is Gly154 in TM4 which, when mutated to serine, caused a decrease in
affinity for the inhibitors NBMPR, dilazep, and dipyridamole in addition to a decrease in
affinity for adenosine and cytidine [137]. This suggested that Gly154 was in an important
region of the permeant binding site. Not surprisingly, this region of TM 3-6 has already
been implicated in both inhibitor and nucleoside binding in hENT1 [134]. Within this
region, there are three cysteine residues (Cys 193 in TM5, Cys213 in TM6, and Cys 222 in
TM6) that could also potentially contribute to the active site.
The localization of functionally important sulfhydryl groups within membrane
proteins has also been achieved through the comparison of the reaction with
membrane-permeant and membrane-impermeant sulfhydryl-reactive derivatives [159161]. Specific reagents used in this thesis include the MTS reagents that all contain a
methanethiosulfonate (MTS) moiety attached to a neutral methyl (MMTS) group or
various charged groups: ethyltrimethylammonio (MTSET) or ethylsulfonate (MTSES)
(Figure 1.12). These reagents add a positive or negative charge at the position of a
previously neutral Cys residue, and could cause structural changes in the transporter
that can be measured by functional assays. The selectivity and reactivity of these
reagents compared to their less reactive counterparts (NEM and pCMBS) is highly
desirable for cysteine modifying studies. Additionally, as they come in a variety of sizes
and charges, their properties can be exploited to determine if affected residues are in an
aqueous or lipid phase of the membrane. These reagents have been exploited in many
studies to assess various features of the structure of channel proteins. Recently, they
have been used to assess the transmembrane topology of the pore-forming regions of K+
channels and their relatives, the cyclic nucleotide-gated channels [162-166].

34

MTSES (-)

MTSET (+)

MMTS (neutral)

Figure 1.12. Chemical structures of methanethiosulfonate reagents (MTS): MTSES,
MMTS, and MTSET
MTS reagents are thiol modifying reagents that react rapidly and specifically with
cysteine groups.
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1.7 Substituted cysteine accessibility method
Substituted cysteine accessibility method (SCAM) is a method that has been proven
helpful in examining membrane topology and structure of membrane-bound
transporters [162, 167]. This technique utilizes site-directed mutagenesis in combination
with specific chemical modifying reagents that react with cysteine sulfhydryls. Mutation
of a residue to a cysteine can first identify if the loss of the mutated residue was critical
for expression and/or function and if the introduced cysteine at that location alters
function. Secondly, after the residue is mutated to a cysteine, the protein can be
treated with a multitude of thiol modifiers with different characteristics (sizes, charges,
membrane permeabilities) to assess if modification alters protein function. If the data
shows that the cysteine mutant protein was sensitive to different thiol modifiers
compared to the wild-type protein, it may provide evidence as to the location and type
of environment of where the introduced cysteine lies. In this manner, if the sequential
mutations are carried out on specific domains of a protein (whole transmembrane
domains), the resulting data can provide evidence as to which parts of the protein are
exposed to the extracellular side as well as determine which residues line the pore or
are involved in substrate binding.
By using this technique, information on transmembrane configurations can be
elucidated for integral membrane proteins. Such studies have been applied to an array
of mammalian transporters such as the glucose transporter (Glut1), glutamate
transporter (GltT), and the Na+/H+ exchanger 1 (NHE1) [168-170]. However, in order to
use cysteine scanning mutagenesis, there is a necessity of having a membrane protein
that lacks any endogenous sulfhydryl groups or one that is insensitive to sulfhydryl
modification. Most studies employ the use of molecular mutational techniques to
remove existing cysteines in order to acquire a cysteine-less construct. This cysteine-less
construct must still have wild-type functional characteristics in order to obtain biological
meaningful data.
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Results of the investigations in determining the role of cysteine functional groups
within ENT1 have proven to be variable, apparently due to the use of different species
and cell types [171-173]. The outcomes of these studies prove to be debatable as one
study using murine myeloma cells found the affinity of NBMPR to ENT1 to be lowered by
NEM treatment but had no effect on Bmax. Alternatively, in other models, NEM had
complex effects on the transporter, where it inhibited function or ligand binding at low
concentrations but enhanced function/binding at higher concentrations; this once again
could be attributed to differences in cell lines and treatment conditions. In our own lab,
a previous study has implicated cysteines to be of importance in the binding of NBMPR
to ENT1. In mouse ENT1, N-ethylmaleimide (NEM) (a membrane permeable thiol
modifying reagent) produced a concentration-dependent biphasic effect on NBMPR
binding affinity (Kd) as well as binding sites (Bmax) in intact cells [174]. As NEM is targeted
to block free sulfhydryls by forming covalent thioether bonds at cysteine residues, the
resulting loss of NBMPR binding is attributed to a loss of reactive cysteine residues.
Additionally, NEM effects were lost when cells were co-incubated with NBMPR,
adenosine, or uridine indicating that the sulfhydryls modified by NEM are located within
the

binding

domains

of

these

agents.

This

same

study

found

p-

chloromercuribenzylsulfonate (pCMBS), a membrane-impermeable negatively charged
thiol modifying reagent, to cause no effect in intact cells but a decrease in Bmax and Kd
with broken cell preparations supporting a role for intracellular cysteines in ENT1-ligand
interactions. A second study in our lab found that the functional truncated slice variant
mENT1Δ11, missing the last three TM domains (TM9-11) and associated extracellular
and intracellular loops 5, could not be photolabeled with [3H] NBMPR and showed a
decrease in NEM sensitivity on NBMPR binding and [ 3H] 2-chloroadenosine uptake
[156,[157] These data suggest that the loss of the last three TM domains and associated
extracellular loop (EL5) leads to a change in reactive residues in the area of the NBMPR
binding pocket. It is suggested that TM9-11 and EL5 must have a peripheral role in the
NBMPR binding pocket crucial for photoaffinity labeling.
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Chapter 2: Rationale
It is well established that nucleoside transporters modulate the flux of physiologically
important nucleosides and cytotoxic nucleoside analogues into and out of cells [43, 93,
175]. As mentioned in Chapter 1, ENT1 is the main contributor to the regulation of
extracellular concentrations of adenosine available to purinergic receptors and is
therefore a viable therapeutic target for drug development [98, 114-117]. Additionally,
the successful delivery of nucleoside-based drugs into their intracellular sites of action is
dependent on functional nucleoside transporters at the plasma membrane, highlighting
the role that nucleoside transporters play in targeted chemotherapies [123, 124, 176,
177]. However, the current understanding of ENT1 structures is limited to predicted
topologies and low resolution homology modeling. The generation of specific drugs that
can target hENT1 will be greatly assisted if the structure and mechanism of how ENTs
function is elucidated. Identifying the specific regions and residues that contribute to the
inhibitor binding pocket and substrate translocation site will be important to further
refine the current structural model of ENT1. Since integral membrane proteins like
hENT1 are not readily amenable to crystallization procedures, alternative techniques
such as cysteine scanning mutagenesis are required to access information on its
structure.
As mentioned previously, results from previous studies attempting to identify the
importance of cysteine residues in ENT1 function are variable given the use of different
models, species of ENT1, reagents and treatment conditions. However, the general
findings from these studies suggest that modification of cysteine residues alters the
function of ENT1. This thesis further probes the general finding by utilizing site-directed
mutagenesis techniques and specific sulfhydryl reagent treatments to attempt a
systematic analysis of the ligand binding site of hENT1 to better understand the
molecular mechanisms of nucleoside transport and its structure.
2.1 Hypothesis #1:
There is a cysteine in a hydrophobic environment that, when modified, affects NBMPR
binding.
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Rationale #1:
A previous study by Vyas et al., examined a range of group-specific amino acid modifiers
for their effects on NBMPR binding and found that treatment with phenylglyoxal (targets
arginines), diethylpyrocarbonate (targets histidines),

acetic anhydride, succinic

anhydride, or ethyl acetimidate (targets lysines) had no effect on NBMPR binding [174].
However, treatment with trinitrobenzylsulfonic acid (TNBS) inhibited NBMPR binding.
Since TNBS reacts with lysine (amino groups) and cysteines (sulfhydryl groups), and ethyl
aceimidate produced no effect on NBMPR binding, the effect of TNBS was suggested to
be due to cysteine groups. This suggestion was further confirmed using the sulfhydryl
modifiers NEM and pCMBS which are more selective for sulfhydryl groups on cysteines.
Treatment with NEM (a neutral membrane permeable thiol modifier) produced an
irreversible biphasic inhibition on cells and cell membrane preparations and a decrease
in NBMPR binding affinity (Kd) as well as binding sites (Bmax) in intact Ehrlich cells. In
contrast, the membrane-impermeable negatively charged reagent pCMBS had no effect
on intact cells. As NEM is targeted to block or alkylate free sulfhydryls from cysteine
residues, the resulting loss of NBMPR binding is attributed to a loss of reactive cysteine
residues.

Additionally, NEM effects were lost when cells were co-incubated with NBMPR,
adenosine, or uridine indicating that the sulfhydryls modified by NEM are located within
the binding domains of these agents. Given that NEM but not pCMBS produced effects,
we hypothesize that there is a cysteine residue that contributes to NBMPR binding
located in a hydrophobic region of hENT1. Human ENT1 has 7 cysteine residues (C87,
C193, C213, C222, C297, C333, and C439) predicted to be in TM helices and therefore
may be located in potential hydrophobic regions (Figure 2.1). One or more of these
residues may be accessible for neutral thiol modifiers and impact the functional site of
hENT1. Additionally, another study examining mouse ENT1 found that NEM had no
effect on NBMPR binding to mENT1Δ11, (a mouse ENT1 variant missing the last three
transmembrane domains TM9-11) [157]. This indicated that cysteines residing in TM9-11
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and interacting loops in ENT1 were responsible for NEM effects to full length mENT1. In
human ENT1 there are four cysteines residues in that region (Cys378 in TM9, Cys 414 in
IL5, Cys 416 in IL5, and Cys 439 in TM11) indicating that they could also be targeted for
sulfhydryl modification to impact transporter function.
2.2 Hypothesis #2:
There is a cysteine residue in a cytoplasmic region of hENT1 that, when modified, affects
NBMPR binding.
Rationale #2:
As previously mentioned, the study by Vyas et al. examined the effects of pCMBS
(membrane impermeable thiol modifier) on mouse and human ENT1 function. In intact
cells, pCMBS had no effect on NBMPR binding to mouse or human ENT1. However,
when pCMBS was applied to broken cell preparations of Ehrlich cells and human
erythrocyte membranes, NBMPR binding (Bmax and Kd) decreased by 100%. Given that
pCMBS cannot cross the cell membrane and had no effect to intact cells, this indicated
that the inhibition to NBMPR binding to cell membranes was caused by modification of
intracellular cysteine residues. We therefore hypothesize that intracellular cysteine
residues impact the binding site of NBMPR. There are two likely cytoplasmic cysteines
(Cys414 and Cys416) found in the C-proximal half of hENT1. It is possible that these
residues contribute to the extracellular facing NBMPR binding site.
2.3 Hypothesis #3:
Residues in EL5 are involved in the NBMPR binding pocket and permeant recognition
site.
Rationale #3:
The study by Robillard et al., examining mENT1Δ11, (a mouse ENT1 variant lacking the
last three TM domains TM9-11 and associated loops EL5 and Il5) found that the
functional truncated splice variant could not be photolabeled with [3H]NBMPR
compared to the full length wild-type variant mENT1. Therefore, this suggested that the
loss of the C-terminal region of mENT1 causes either a loss of residues involved in
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NBMPR cross-linking or a shift in ENT1 conformation which prevented the residues to
become accessible for covalent attachment to NBMPR. Given that the region of ENT1
that is predicted to covalently attach with NBMPR after UV exposure is in the N-terminal
half of the protein [178-180], these data suggested that the loss of the last three TM
domains and associated extracellular loop (EL5) lead to a change in reactive residues in
the area of the NBMPR binding pocket available for covalent modification. It was
suggested that TM9-11 and EL5 must have a peripheral role in the NBMPR binding
pocket crucial for photoaffinity labeling. Therefore we hypothesized that residues in the
extracellular loop five are involved in the NBMPR binding pocket and permeant
recognition site.

Experimental objectives:
The aim of this research project was to perform cysteine mutagenesis combined with
thiol modifications on endogenous cysteine residues of hENT1 and on the residues of
extracellular loop 5 to expand the current knowledge of hENT1 structure and to isolate
the specific residues that are important in the functional characteristics of hENT1.
Utilizing site-directed mutagenesis with the addition of sulfhydryl reagent treatments,
this thesis attempted a systematic analysis of a portion of the extracellular binding
pocket of hENT1 to better understand the molecular mechanisms of nucleoside
transport and the structure of hENT1.
2.4 Specific Aims:
1. To determine the sensitivity and accessibility of endogenous cysteines in hENT1
with methanethiolsulfonate reagents of varying sizes and charges by:
a. Determining the cysteine residue(s) involved in MMTS effects (neutral
membrane permeable thiol modifier)
b. Determining the cysteine residue(s) involved in MTSET effects (positively
charged, membrane impermeable thiol modifier)
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Figure 2.1. Predicted 2-D topology of hENT1 with location of 10 endogenous cysteine
residues indicated in light blue circles.
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a. Determining the cysteine residue(s) involved in MTSES effects (negatively
charged, membrane impermeable thiol modifier)

2. Create an extracellular-cysteine-less mutant for SCAM analysis of extracellular
binding determinants of substrates and inhibitors
3. To determine the effects of mutating residues in EL5 to cysteines on NBMPR
binding and 2-chloroadenosine uptake
4. To probe the accessibility of the introduced cysteines in EL5 to MTSET and
determine if they are protected by hENT1 ligands
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Chapter 3: Materials and Methods
3.1 Materials:
[3H]NBMPR (5.5-20.1 Ci/mmol), [3H]2-chloroadenosine (9.1 Ci/mmol), and [3H]-labeled
water (1 mCi/g) were obtained from Moravek Biochemicals (Brea, CA). Methyl
methanethiosulfonate (MMTS), [2-(trimethylammonium)ethyl]methanethiosulfonate
bromide (MTSET), and sodium (2-sulfonatoethyl)methanethiosulfonate (MTSES) were
acquired from Toronto Research Chemicals (Toronto, ON). Culture-grade phosphatebuffered

saline

(PBS), Modified

Eagle's Medium

(MEM), G418

(Geneticin),

penicillin/streptomycin, trypsin/EDTA, sodium pyruvate, nonessential amino acids, and
Lipofectamine LTX and Lipofectamine 2000 were purchased from Invitrogen
(Burlington, ON). Bovine growth serum (BGS) was supplied by ThermoScientific, Hyclone
Laboratories (Utah, USA). T175 flasks, T75 flasks, T25 flasks, 12-well plates and 24-well
plates were purchased from BD Biosciences (Bedford, MA). Cloning cylinders were
supplied by Bel-Art Products (Pequannock, NJ). Oligonucleotide primers were obtained
from Sigma-Genosys (Oakville, ON). NBMPR, 2-chloroadenosine, dipyridamole,
nitrobenzylthioguanosine riboside [NBTGR; S-(4-nitrobenzyl)-6-thioguanosine], and
p3×FLAG-CMV10 vector were purchased from Sigma-Aldrich (Oakville, ON). The QIAprep
Spin miniprep kit was provided by Qiagen (Mississauga, ON).

TRIZOL Reagent,

Superscript First Strand Synthesis System for RT PCR, Platinum Pfx DNA Polymerase,
and the PureLink Quick Gel Extraction Kit were purchased from Invitrogen (Burlington,
ON). Dilazep (N,N′-bis[3-(3,4,5-trimeth-oxybenzo-yloxy)propyl]-homo-piperazine) was
provided by Asta Werke (Frankfurt, Germany) and draflazine [2-(aminocarbonyl)-4amino-2,6-dichlorophenyl)-4-[5,5-bis(4- fluorophenyl) pentyl]-1-piperazine acetamide
2HCl] was acquired from Janssen Research Foundation (Beerse, Belgium). 2Bromohexadecanoic acid (2-bromopalmitic acid [2-Br]) was purchased from Sigma
Aldrich (Oakville, ON). The primary monoclonal mouse anti-FLAG Ab and secondary goat
anti-mouse Ab were purchased from Sigma Aldrich (Oakville, ON). The primary
monoclonal mouse anti-Na+, K+-ATPase Ab were purchased from AbNova (Cambridge,
MA., USA). Cell lysis buffer (10X) and LumiGLO chemiluminescent substrate were
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purchased from Cell Signaling Technology (Danvers, MA). The mammalian protease
inhibitor cocktail was purchased from Calbiochem (Billerica, MA).

The Bradford

colorimetric protein assay kit was purchased from Thermo Fisher Scientific (Waltham,
MA). Pierce Cell Surface Protein Isolation Kit was purchased from ThermoScientific
(Rockford, IL). PK15-NTD (Pig Kidney nucleoside transporter-deficient) cells and hENT1pcDNA3.1 were generously provided by Dr. Ming Tse (Johns Hopkins University,
Baltimore, MD). 5'-S-[2-(1-[(fluorescein-5-yl) thioureido]-hexanamido) ethyl]-6-N-(4nitrobenzyl)-5'-thioadenosine (FTH-SAENTA) was generously donated by Dr. John K.
Buolamwini (The University of Tennessee Health Science Centre, Memphis, TN).
3.2 Plasmid generation:
EcoRV and KpnI restriction sites were added, respectively, to the 5’ and 3’ ends of the
cDNA encoding hENT1 (primers 5` EcoRV: 5`AGCGCGGATATCGATGACAACCAGT3` and 3`
Kpn I: 5`TAGCTAGGTACCTCACAC AATTGCCCG3`) (Sigma Aldrich), and the resulting
construct was ligated into p3×FLAG-CMV-10 using standard techniques. Briefly, the
p3xFLAG-CMV-10 expression vector was digested with KpnI and EcoRV restriction
enzymes (Fermentas, Burlington, ON) at 37°C for 1 hr, after which the hENT1 cDNA was
ligated into it with a femtomolar vector/insert ratio of 1:3, using a T4 DNA Ligase Kit
(Invitrogen, Burlington, ON). The resulting expression plasmid, hENT1-p3xFLAG (Nterminal epitope tag-DYKYYYD), was amplified and purified using the QIAprep Spin
Miniprep Kit (Qiagen, Mississauga, ON). The sequence of the vector was confirmed by
DNA sequencing at the Robarts Research Institute Sequencing Facility (London Regional
Genomics Centre, London, ON).
3.3 Single amino acid mutagenesis
Single amino acid substitutions were introduced into the hENT1-p3xFLAG template using
the Stratagene Quikchange mutagenesis kit (Stratagene, Mississauga, ON) following the
manufacturer’s instructions. Primers for all mutations are listed in Table 2. Briefly, 25 ng
of hENT1-p3xFLAG template and 125 ng each of the respective forward (5’) and reverse
(3’) primers were added to a PCR mixture containing 10X reaction buffer,
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deoxyribonucleotide triphosphates (dNTPs), ddH2O and PfuUltra High Fidelity DNA
polymerase (2.5 U/l). The reactions were overlaid with 30 l of mineral oil and cycled
in a Perkin-Elmer 480 thermal cycler using the following parameters: 95C for 30 sec (1
cycle); 95C for 30 sec, 55C for 1 min and 68C for 8 min (16 cycles). Completed
reactions were placed on ice for 2 min and then incubated with 1 l of Dpn I restriction
enzyme (10 U/l) at 37C for 1 hr to digest parental dsDNA. Digested plasmid DNA was
transformed into XL1-Blue supercompetent cells, plated onto LB-ampicillin agar plates
containing 80 g/ml X-gal and 20 mM IPTG and incubated overnight at 37C. The next
day, viable colonies were picked, shaken overnight (250 rpm, 37C) in LB broth
containing 0.1 mg/ml ampicillin, and plasmid DNA was extracted using the QIAprep
Spin Miniprep Kit (Qiagen, Mississauga, ON). The hENT1-p3xFLAG and hENT1-mutantsp3xFLAG were sequenced by DNA sequencing at Robarts Research Institute Sequencing
Facility (London Regional Genomics Centre, London, ON). The resulting sequence was
compared with the full published coding region of hENT1 (GenBank accession number:
gi:1845345e).

3.4 Stable cell line generation:
The PK15 cells of pig kidney epithelial tissue were donated from Dr. Ming Tse (Johns
Hopkins University, Baltimore, MD, USA) were initially made nucleoside transport
deficient by treating them first to with ethylmethanesulfonate, a chemical mutagen, and
secondly to the cytotoxic nucleosides cytarabine (AraC) and tubericidin. After a 3 week
treatment period, viable cells that survived the cytotoxic nucleoside exposure were
screened for [3H]uridine transport to determine whether or not resistance was due to
the absence of nucleoside uptake [181]. After confirmation of nucleoside transport
deficiency, the PK15-NTD cells were transfected with hENT1-p3xFLAG (wild-type) or Sersubstituted hENT1-mutations using Lipofectamine 2000. Near (90%) confluent cells
were incubated with 1.6 µg of plasmid, 4.8 µl of Lipofectamine and 200 µl of
OptiMEM. After 24 hr incubation, transfected cells were placed under a three week
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Table 3.1. List of the PCR primers used for single site-directed mutagenesis of cysteine
residues to serine residues on the hENT1 template. Underlined base pairs indicate the
mutation site.

Cysteine Mutation

Prime sequence (5’ to 3’)

C87S Forward

CAATGTCATGACCCTATCTGCCATGCTGCCCCTGC

C87S Reverse

GCAGGGGCAGCATGGCAGATAGGGTCATGACATTG

C193S Forward

CCATGATCTCCGCTATTGCCAGTGGCTC

C193S Reverse

GAGCCACTGGCAATAGCGGAGATCATGG

C213S Forward

CGGCTACTTTATCACAGCCTCTGCTGTTATCATTTTGACC

C213S Reverse

GGTCAAAATGATAACAGCAGAGGCTGTGATAAAGTAGCCG

C222S Forward

GACCATCATCTCTTACCTGGGCCTGCC

C222S Reverse

GGCAGGCCCAGGTAAGAGATGATGGTC

C297S Forward

GTCCTGGCTTTCTCTGTCTCCTTCATCTTCAC

C297S Reverse

GTGAAGATGAAGGAGACAGAGAAAGCCAGGAC

C333S Forward

CGTTACTTCATTCCTGTGTCCTCTTTCTTGACTTTC

C333S Reverse

GAAAGTCAAGAAAGAGGACACAGGAATGAAGTAACG

C378S Forward

CCACTGCTGCTGCTGTCCAACATTAAGCCCCG

C378S Reverse

CGGGGCTTAATGTTGGACAGCAGCAGCAGTGG

C414S Forward

GGCTACCTCGCCAGCCTCTCTATGTGCTTCGGGCCCAAG

C414S Reverse

CTTGGGCCCGAAGCACATAGAGAGGCTGGCGAGGTAGCC

C416S Forward

CTCGCCAGCCTCTGCATGTCTTTCGGGCCCAAGAAAGTG

C416S Reverse

CACTTTCTTGGGCCCGAAAGACATGCAGAGGCTGGCGAG

C439S Forward

CATCATGGCCTTCTTCCTGTCTCTGGGTCTGGCACTGGGG

C439S Reverse

CCCCAGTGCCAGACCCAGAGACAGGAAGAAGGCCATGATG
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selection period using 500 µg/ml G418 in modified Eagle's medium supplemented with
10% (v/v) bovine growth serum (BGS), 100 U of penicillin, 100 µg/ml of streptomycin, 0.1
mM nonessential amino acids, and 1 mM sodium pyruvate (Selection media). Individual
cell colonies were selected and expanded in media containing 300 µg/ml G418
(Maintenance media) at 37°C in a 5% CO2 humidified atmosphere. Each individual
monoclonal population of cells were then checked for hENT1 transcript by collecting
mRNA, performing reverse-transcription PCR, and sequencing. Briefly, total RNA was
isolated

using TRIZOL

reagent

(Invitrogen,

Burlington, ON) following the

manufacturer’s instruction. Isolated mRNA was then reverse transcribed to cDNA using a
Superscript First Strand Synthesis kit and amplified using Platinum Pfx DNA
Polymerase. Primers for

the

hENT1

GACAACCAGTCACCAGCCTCAGGACAG;

cDNA
reverse

(forward
primer:

primer:

hENT1

hENT1

5’
3’

–
-

CACACAATTGCCCGGAACAGGAAGGAG) were used to amplify the extracted cDNA in a
Perkin-Elmer 480 Thermal Cycler using the following conditions: 2 min at 94C; 15 s at
94C, 30 s at 55C, 1.5 min/kb at 68C (for 35 cycles); 7 min at 68C. PCR amplified DNA
samples were then resolved on a 1.0% agarose gel and visualized under UV light. Bands
that were found at the corresponding the hENT1 cDNA size (1377 kb) were isolated and
purified using the PureLink Quick Gel Extraction Kit. Purified PCR products were then
sequenced as before.
3.5 Transient transfections:
PK15-NTD cells were transfected with empty-p3xFLAG (empty control), wild-type hENT1p3xFLAG, and mutants hENT1-C416A, hENT1-439A, or EL5-mutants-p3xFLAG (16
individual mutants) using Lipofectamine LTX following the manufacturer’s instruction
(Invitrogen, Burlington, ON). Briefly, 18.75 μg plasmid DNA was incubated with 3.75 ml
Opti-MEM media, 18.75 μl Plus reagent, and 46.87 μl of Lipofectamine LTX for 30
min. After 30 min, the DNA-Lipofectamine complex was slowly added to near (90%)
confluent cells grown in T75 flasks void of antibiotics and incubated for at least 24 hrs
before their utilization.
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3.6 Crude Cell Membrane Preparations:
PK15-NTDs expressing hENT1-p3xFLAG or hENT1-mutants-p3xFLAG were harvested from
T175 flasks by 0.05% Trypsin/0.53 mM EDTA. Cells pellets were then resuspended in 5
mM sodium phosphate buffer containing a mammalian protease inhibitor cocktail
(Calbiochem, Billerica, MA) for 30 min on ice. Cells were then sonicated using a Sonic
Dismembrator model 150 for 30 s and then centrifuged at 3,000× g for 30 min at 4oC to
pellet nuclei and whole cells. The supernatant containing the crude cell membranes
were then centrifuged for 1 hr at 30,000 × g at 4oC to pellet the membranes. The
remaining membrane pellet was then resuspended in 5 mM sodium phosphate buffer
and protease inhibitor cocktail mix and protein content was determined by the Bradford
colormetric assay. Resuspended crude membranes were either used immediately for
subsequent assays or frozen at -80C to be used at a later date.
3.7 Treatment with MTS reagents:
PK15-NTD cells expressing hENT1-p3xFLAG or hENT1-mutants-p3xFLAG were harvested
from culture flasks using 0.05% Trypsin/0.53 mM EDTA, diluted with media containing
10% (v/v) BGS, collected by centrifugation at 6,000xg, and washed twice with
phosphate-buffered saline (PBS; 137 mM NaCl, 6.3 mM Na2HPO4, 2.7 mM KCl, 1.5 mM
KH2PO4, 0.5 mM MgCl2 • 6H2O, 0.9 mM CaCl2 • 2H2O, pH 7.4, 22°C). Cell pellets were
then suspended in PBS for [3H]NBMPR binding assays or sodium-free N-methyl-Dglucamine (NMG) buffer (pH 7.25, containing 140 mM NMG, 5 mM KCl, 4.2 mM KHCO 3,
0.36 mM K2HPO4, 0.44 mM KH2PO4, 10 mM HEPES, 0.5 mM MgCl2, and 1.3 mM CaCl2) for
[3H]2-chloroadenosine uptake assays. Cell suspensions were incubated with 0.1%
dimethylsulfoxide (DMSO, control) or MTS reagents dissolved in DMSO. Cell suspensions
were then washed three times with PBS or NMG, depending on the assay type, by
centrifugation to remove un-reacted MTS reagents. A concentration versus time course
analysis was performed with each MTS reagent to optimize the concentration and
incubation period needed for a maximal distinguishable effect. In some experiments, 10
nM NBMPR or 1 mM adenosine was included in the MTS treatment protocol to assess
the ability of these ENT1 ligands to protect the cells from MTS modification.
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3.8 [3H]NBMPR binding assay:
PK15-NTD cells expressing empty-p3xFLAG, hENT1-p3xFLAG or hENT1-mutants-p3xFLAG
(~75,000 cells per assay) were suspended in PBS and incubated with [ 3H]NBMPR for 45
min at room temperature (~22°C). Cells were collected on Whatman Binder-Free Glass
Microfiber Filters: Type 934-AH using a 24-port Brandel cell harvester, washed twice
with Tris buffer (10 mM Tris, pH 7.4, 4°C) and analyzed for 3H content using standard
liquid scintillation counting techniques. Specifically bound [3H]NBMPR was defined as
total binding minus cell-associated [3H]NBMPR in the presence of 10 µM
nitrobenzylthioguanosine riboside (NBTGR) (nonspecific binding). Nonlinear regression
was used to fit hyperbolic curves (GraphPad Prism 4.03) of specific [ 3H]NBMPR binding
against the free concentration of [3H]NBMPR, in order to determine Kd and Bmax values.
Curves were fitted using one-site specific binding based on the equation Y = Bmax*X/(Kd +
X), where Y= specific binding and X= concentration of radioligand.
3.9 5’-S-[2-(1-[(fluorescein-5-yl) thioureido] hexanoamido) ethyl]-6-N (2-nitrobenzyl) -5’thio adenosine (FTH-SAENTA) Inhibition Assay:
PK15-NTD cells transfected with hENT1-p3xFLAG, C416A-p3xFLAG, C439A-p3xFLAG or
EL5-mutants-p3xFLAG were incubated with 5 nM [3H]NBMPR for 40 min in the presence
and absence of 100 nM FTH-SAENTA (membrane impermeable) or 10 µM NBTGR (nonspecific binding) and then processed as described above for the [ 3H]NBMPR binding
assays. FTH-SAENTA would displace only the extracellular binding sites of [ 3H]NBMPR as
the large fluorescein tag prevents access to intracellular pools [143, 182]. Data was
calculated as the total amount of NBTGR-sensitive [3H]NBMPR binding inhibited by FTHSAENTA which represented the percentage of sites expressed at the membrane.
3.10 [3H]2-chloroadenosine uptake assay:
Uptake was initiated by the addition of suspended cells (~750,000 cells per assay) in
NMG buffer to [3H]2-chloroadenosine layered over 200 µl of silicon/mineral oil (21:4
vol/vol) in 1.5-ml microcentrifuge tubes. Parallel assays were conducted in the absence
(total

uptake)

and

presence

(non-transporter-mediated

uptake)

of

5

µM

NBMPR/dipyridamole to determine the ENT1-mediated uptake of substrate in each
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condition. Initial rates of uptake were determined from time-courses of cellular uptake
of [3H]2-chloroadenosine and calculated an incubation time of 5 s for measuring
transport studies [157]. After the defined incubation time of 5 s, uptake was terminated
by centrifugation for 10 s (~12,000 × g). Aqueous substrate and oil layers were removed
by aspiration, and pelleted cells were digested in 1 M NaOH overnight (12–16 h). A
sample of the digest was removed and analyzed for 3H content using standard liquid
scintillation counting techniques. Uptake data are presented as pmol/µl of intracellular
volume after correction for the amount of extracellular 3H in the cell pellet. Total volume
was determined by incubating cells with 3H2O for 3 min and processed as above.
Extracellular water space was estimated by extrapolation of the linear time course of
nonmediated uptake to zero time. To determine Km, curves were fitted using the
Michaelis-Menten equation: Y = Vmax*X/(Km + X), where Y= rate of mediated uptake and
X= substrate concentration.
3.11 Inhibition studies:
PK15-NTD cells transfected with hENT1-p3xFLAG or the hENT1-mutant-p3xFLAG were
incubated with 0.5 nM [3H]NBMPR for 40 min in the presence and absence of a range of
concentrations of test inhibitor, and then processed as described above for the
[3H]NBMPR binding assays. IC50 values were determined as the concentration of
inhibitor that produced a 50% decrease in the specific binding of [ 3H]NBMPR. For
inhibition of uptake, cells were incubated with 10 µM [3H]2-chloroadenosine in the
presence and absence of a range of concentrations of test inhibitor layered over 200 µl
of silicon/mineral oil (21:4 vol/vol) in 1.5-ml microcentrifuge tubes. Assays were
processed as described above for the [3H]2-chloroadenosine uptake assays. Ki values
were derived from IC50 values based on the equation of Cheng and Prusoff [183] using
the Kd for [3H]NBMPR binding or the Km for [3H]2-chloroadenosine uptake determined
under the same conditions. Cheng-Prusoff equation: Ki= IC50/(1+[L]/Kd), where [L]=
concentration of free radioligand used and Kd= dissociation constant of the radioligand
for the receptor. Data were fitted using the one-site sigmoid dose-response with
variable slope model (GraphPad Prism 4.03), using the following equation:
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Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)), where Y= % total binding and
X= logarithm concentration of the inhibitor. Top and bottom are the maximal and
minimal limits constrained to 100% and 0% of total site-specific binding, respectively.
3.12 Cell Surface Biotinylation:
The biotinylation and isolation of cell surface proteins for Western blot analysis was
performed as per manufacturer’s instructions (Thermo Scientific, Rockford, IL, USA). In
brief, untransfected and transiently transfected wild-type hENT1 and C416A PK15-NTD
cells were grown in four T75 flasks, washed with cold PBS and incubated for 30 min with
cold membrane-impermeable Sulfo-NHS-SS-Biotin on a rocking platform at 4oC. The
cells were harvested and washed with Tris-Buffered Saline (TBS) with subsequent
centrifugation at 500 × g for 3 min. Cell pellets were lysed, sonicated, and vortexed
periodically on ice for 30 min. Cell lysate was spun at 10,000 × g for 2 min at 4°C after
which the supernatant was added to the column of NeutrAvidin Agarose and incubated
for 60 min at 20oC with end-over-end mixing using a rotator. The column was then
washed and cell surface protein was eluted from the column using end-over-end mixing
for 60 min incubation with SDS-PAGE and DTT sample buffer. The eluted protein
samples were then used for Western blot analysis.
3.13 Western Blot Analysis:
Cell surface expression levels of wild-type hENT1-p3xFLAG and C416A-p3xFLAG were
estimated by western blot analysis where biotinylated samples were loaded into 12%
polyacrylamide gels (1.5 M Tris pH 8.8, 0.1% sodium dodecyl sulfate (SDS), bisacrylamide, 0.05% ammonium persulfate (APS), 0.05% TEMED) and run in the MiniPROTEAN Tetra Cell electrophoresis system for ~1 hr at 120 V.

Following

electrophoresis, gels were transferred to polyvinylidene fluoride (PVDF) membranes
using a Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell at 440 mA, 20 V limit for
45 min. Membranes were blocked for 1 hr at room temperature with 5% skim milk-TBST
buffer (0.5 mM Tris, 13.8 mM NaCl, 2.7 mM KCl, 0.05% Tween-20), and then incubated
overnight at 4C with primary monoclonal mouse anti-FLAG Ab (1:2,500 in 5% skim milk-
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TBST). Membranes were washed with TBST and incubated for 1 hr at room temperature
with secondary goat anti-mouse HRP conjugated antibody (1:25,000 in 5% skim milkTBST), and then washed further with TBST. Membranes were incubated for 1 min with
LumiGLO chemiluminescent reagent and then imaged using the Molecular
ImagerVersaDoc 5000 MP System (Bio-Rad Laboratories, Hercules, CA). Na+/K+ATPase was used as a cell surface loading control after membranes were stripped with
mild Stripping Buffer (200 mM glycine, 1% Tween-20, and 0.1% SDS; pH 2.2). Following
this, membranes were washed twice with PBS and TBST before being blocked for 1 hr
with 5% skim milk. The membranes were incubated overnight at 4C with primary
mouse antibody to Na+/K+-ATPase (1:2,500 in 5% skim milk/TBST). After three washes
with TBST, membranes were incubated for 1 hour at room temperature with secondary
goat anti-mouse HRP conjugated antibody (1:25,000 in 5% skim milk/TBST). After a final
three washes, the membranes were visualized as above.
3.14 Data analysis and statistics:
Data are presented as means ± SEM with hyperbolic curves fitted using Graphpad Prism
5.0 software. Where appropriate, statistical analysis was performed using a One-way
ANOVA (Dunnett’s), or a paired student’s t test with p<0.05.
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Chapter 4: Results
Many attempts have been made to determine the role of cysteines in nucleoside
transport function; however results from those studies have been inconsistent. Within
the murine system, NEM and pCMBS treatments have indicated the involvement of two
cysteines in ENT1 function [157, 174]. In our own lab, the membrane permeable thiol
modifying compound NEM significantly inhibited binding of the selective probe NBMPR
at low concentrations, while at high concentrations enhanced binding. Additionally, the
negatively charged membrane impermeable reagent pCMBS inhibited NBMPR binding
when allowed access to the intracellular side. This suggested that there are two cysteine
residues involved in the two distinct effects. To extend these previous studies,
experiments were carried out with a different set of sulfhydryl-reactive MTS reagents of
different sizes and charges to probe the locations of cysteines. These reagents possess
enhanced sensitivity and reaction rates against cysteine residues in comparison to NEM
and pCMBS. Changes in hENT1 functionality were assessed by measuring binding of the
prototypical inhibitor [3H]NBMPR and the transport kinetics of the substrate [3H]2chloroadenosine.

4.1 Validation that hENT1-p3XFlag functions in PK15-NTD cells:
Initial studies confirmed that the PK15-NTD cells transfected with empty-vector were
devoid of nucleoside transport activity and did not bind [3H]NBMPR (Vector only from
Figure 4.1A). After stable transfection of wild-type hENT1-p3xFLAG, PK15-hENT1 cells
specifically bound [3H]NBMPR with a Kd of 0.4 ± 0.02 nM to a maximum of 3.6 ± 0.2 x105
ENT1 sites/cell (Figure 4.1A). Membranes prepared from the PK15-hENT1 transfectants
had an affinity for [3H]NBMPR of 0.1 ± 0.02 nM and bound 1.2 ± 0.1 pmol/mg protein
(Figure 4.1B). PK15 cells transfected with hENT1 cDNA accumulated [3H]2chloroadenosine via a NBMPR-sensitive transport process with a Vmax of 9.5 ± 0.8
pmol/µl/s and Km of 71 ± 8 μM (Figure 4.1C). Fundamentally, PK15-hENT1 cells bound
NBMPR with high affinity (nM) and transported 2-chloroadenosine with high affinity
(µM). These characteristics are consistent with a fully functional ENT1-type transporter,
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and are similar to previous reports of hENT1 constructs expressed in this cell model
[181] indicating that the N-terminus FLAG epitope did not significantly affect transporter
functionality.

4.1.1 Inhibitor profile for PK15-hENT1 cells
To determine if there were any compound specific differences and sensitivities for the
coronary vasodilators in transfected hENT1-FLAG-tagged constructs, the PK15-hENT1
cells were incubated with increasing concentrations of competitive inhibitors to
determine their ability to alter [3H]NBMPR binding or [3H]2-chloroadenosine uptake. The
coronary vasodilators: Dipyridamole, dilazep, and draflazine inhibited the binding of
[3H]NBMPR with Ki values of 22 ± 8, 1.9 ± 0.4, and 3.3 ± 0.7 nM, respectively (Figure
4.2A).

Additionally, dipyridamole, dilazep, NBMPR, and NBTGR inhibited [ 3H]2-

chloroadenosine influx with Ki values of 111 ± 35, 10.4 ± 1.7, 2.0 ± 1.0, and 8.6 ± 1.9 nM,
respectively (Figure 4.2B). These values reflect the inhibitor’s capacity to effectively
block the permeation site as previously seen in other studies [98, 133, 157, 184].
Draflazine, dipyridamole, and dilazep are competitive inhibitors of the binding of NBMPR
and substrate uptake in a variety of experimental models indicating that the expression
vector and FLAG-tag did not alter the hENT1 binding site for these inhibitors and verified
the mammalian cell model [86, 171, 185].

4.1.2 DTT treatment had no effect on PK15-hENT1 cells
In the analysis of the amino acid sequence of hENT1, there were five potential disulfide
bridges that were identified using a network predictor site, DiANNA 1.1 web server,
utilizing all of the ten endogenous cysteines highlighted in Figure 2.1. In this model, the
potential bridges would link [C87-C378]; [C193-C222]; [C213-C333], [C297-C414], and
[C416-C439]. To determine the presence and importance of these potential disulfide
bridges, PK15-hENT1 cells and cell membranes were treated with dithiothreitol (DTT)
and assessed for [3H]NBMPR binding. Dithiothreitol treatment (2 mM, 10 min, room
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Figure 4.1. Characterization of PK15-hENT1. [3H]NBMPR binding of PK15-hENT1 cells
(Panel A), PK15-hENT1 membranes (Panel B) and [3H]2-chloroadenosine uptake of
PK15-hENT1 cells (Panel C). Specific binding of PK15-hENT1 or PK15-NTD cells was
determined by total bound minus non-specific bound where cells or membranes were
incubated with a range of concentrations of [3H]NBMPR in the presence (nonspecific
binding) and absence of 10 µM NBTGR (total binding). Each point represents the mean ±
SEM from at least 11 experiments done in duplicate. Nonlinear regression analysis was
used to fit hyperbolic curves to the site-specific binding of [3H]NBMPR plotted against
the free [3H]NBMPR concentration at steady-state. (Panel C) Concentration-dependent
uptake of [3H] 2-chloroadenosine to PK15-hENT1 or PK15-NTD cells incubated with a
range of concentrations of [3H]2-chloroadenosine for 5 seconds in the presence or
absence of 10 µM dipyridamole/NBTGR. Each point represents the mean ± SEM of the
cellular accumulation of [3H]2-chloroadenosine from at least ten independent
experiments conducted in duplicate.
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Figure 4.2. Inhibitor profile for PK15-hENT1 cells. (Panel A) Inhibition of [3H]NBMPR
binding to PK15-hENT1 (□) draflazine, (○) dilazep, and (●) dipyridamole. Data are shown
as percent of control binding where control is determined as specific binding of 0.5nM
[3H]NBMPR in the absence of inhibitor. (Panel B) Inhibition of [3H] 2-chloroadenosine
uptake to PK15-hENT1 by (●) NBMPR, (Δ) dipyridamole, (□) NBTGR, and (○) dilazep. Data
is shown as percent of control binding where control is determined as mediated uptake
of 10 µM [3H] 2-chloroadenosine in the absence of inhibitor. Each point represents the
mean ± SEM of at least five experiments done in duplicate.
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Figure 4.3. Effect of DTT on PK15-hENT1 activity. Effect of 2mM DTT treatment to
[3H]NBMPR binding of PK15-hENT1 cells (Panel A) and PK15-hENT1 membranes (Panel
B). Cells or membranes were treated with 2 mM DTT for 10 min at room temperature
and then incubated with a range of concentrations of [ 3H]NBMPR (abscissa) in the
presence (nonspecific binding) and absence of 10 µM NBTGR (total binding). Each point
represents the mean ± SEM from at least four experiments done in duplicate. Nonlinear
regression analysis was used to fit hyperbolic curves to the site-specific binding of
[3H]NBMPR plotted against the free [3H]NBMPR concentration at steady-state.
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temperature) of the PK15-hENT1 cells and membranes had no effect on the binding of
[3H]NBMPR (Figure 4.3A and 4.3B), suggesting that the potential sulfhydryl bonds
between cysteine residues were not contributing to protein structure of importance to
NBMPR binding. Alternatively, this suggested that all ten cysteines possessed free
sulfhydryl groups that were potentially available to react with the MTS reagents.

4.2 Optimization of MTS reagents
To defined an optimal incubation period, MTS reagents were initially used at a
concentration taken from the literature, MTSET 1 mM, MTSES 10 mM, and MMTS 5 mM
[162]. These were then incubated with PK15-hENT1 cells for various times (1-15 min)
and analyzed for [3H]NBMPR binding. A 10 min incubation period revealed significant
decreases in Bmax at MTSET 1.0 mM and an increase in Bmax at MMTS 5 mM with no
further increases or decreases observed at 15 minutes (Figures 4.4A, 4.4B, 4.4C). This
incubation period was subsequently used while varying the concentrations of MTS
reagents and functional characterization of hENT1. Optimal concentrations of MTS
reagents were determined to be 1 mM MMTS, 5 mM MTSES, 5 mM MTSET where their
DMSO-treated control produced no effect, indicating that the vehicle was not
contributing to the observed effects.

4.3 Effects of MTS reagents on hENT1 function and ligand binding:
As mentioned previously the MTS reagents: MTSES, MMTS, MTSET (Figure 1.12) were
used in this study due to their selectivity to cysteines as well as their reactivity in mild
conditions. Because they come in a variety of charges, sizes, and lipophilicity they are
able to better probe the location of cysteines and provide information about their
environment. These MTS reagents tested the surface accessibility of cysteines by
covalent modification at thiol side chains which may cause a change in transporter
function and hence further elucidate the contributions of cysteines to hENT1 structure
and function.
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Figure 4.4. Varying incubation times with MTS reagents to PK15-hENT1 cells. Cells were
treated with (Panel A) 5 mM MMTS, (Panel B) 10 mM MTSES, (Panel C) 1 mM MTSET for
incubation periods of 1 min to 15 min and then assessed for [3H]NBMPR binding. Bmax
were calculated. Nonlinear regression analysis was used to fit hyperbolic curves to the
site-specific binding of [3H]NBMPR plotted against the free [3H]NBMPR concentration at
steady-state. Each bar represents the mean ± SEM from at least four experiments done
in duplicate. * Indicates a significant change in Bmax from the MTS reagent at that time
point compared to the Bmax from DMSO-treated PK15-hENT1 cells (P < 0.05 one-way
ANOVA : Dunnett’s post-test).
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4.3.1 Effects of MMTS on NBMPR Binding: the NBMPR binding site is sensitive to neutral
thiol modification
MMTS, which like NEM is a neutral membrane-permeable reagent, caused a significant
62 ± 11% increase in the number of NBMPR binding sites in intact cells with no change in
binding affinity (Figure 4.5A). However, in isolated membranes prepared from these
cells, MMTS inhibited binding by about 30% (Figure 4.5B). To investigate further the
difference in MMTS effect on intact cells (enhancement) versus membranes (inhibition),
intact cells were treated with MMTS (or DMSO as control) and then used to prepare
isolated membranes for analysis of [3H]NBMPR binding. The membranes derived from
cells treated with MMTS had significantly lower binding (Bmax = 1.7 ± 0.2 pmol/mg) than
did membranes prepared from cells treated with DMSO alone (controls, Bmax = 2.2 ± 0.4
pmol/mg) (Figure 4.6A). Similarly, the binding of [3H]NBMPR to broken cell preparations
(no separation of membrane components) was also decreased by treatment with MMTS
(Figure 4.6B). In addition, to determine whether transmembrane ion gradients played a
role in these divergent effects of MMTS, cells were treated with MMTS in either PBS (pH
7.4), NMG (pH 7.25), or 50 mM Tris-HCl of varying pH (6.0, 7.2, or 8.2). There were no
differences in the results obtained when using the PBS, NMG, and Tris-HCl (pH 7.2–7.4)
incubation conditions. However, incubating cells with MMTS in 50 mM Tris at pH 8.2
eliminated completely the ability of MMTS to enhance the binding of [3H]NBMPR (Figure
4.7A, 4.7B, 4.7C). Finally, the competitive inhibition of [3H]NBMPR by dipyridamole,
draflazine and dilazep was assessed for potential changes after MMTS treatment.
Treatment of the neutral thiol reagent had no effect on the ability of dipyridamole,
dilazep or draflazine to inhibit the binding of [3H]NBMPR to wild-type hENT1 (Figure 4.8).
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Figure 4.5. Treatment of hENT1 with MMTS. Effects of MMTS on [3H]NBMPR binding by
PK15-hENT1 cells (Panel A), cell membranes (Panel B) and on [3H]2-chloroadenosine
uptake by PK15-hENT1 cells (Panel C). Cells or membranes were incubated with either 1
mM MMTS or 0.1% DMSO (Control) for 10 min, washed thrice, and then incubated with
a range of concentrations of [3H]NBMPR (abscissa) in the presence and absence of 10
µM NBTGR to define total and nonspecific binding or then assessed for their capacity to
accumulate [3H]2-chloroadenosine (5 s incubation) in the presence and absence of 5 µM
NBTGR/dipyridamole. Each point represents the mean ± SEM from at least 5
experiments done in duplicate. * Significant difference from control Bmax for NBMPR
binding studies and control Vmax for uptake studies (Student's t test for paired samples, P
<0.05)
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Figure 4.8. Effects of MMTS treatment of hENT1 on inhibitor binding. Inhibition of
[3H]NBMPR binding by a range of concentrations of inhibitors on cells that were
pretreated with either 0.1% DMSO (solid lines, closed symbols) or 1 mM MMTS (dashed
lines, open symbols). Each point is the mean ± SEM from at least four experments.
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4.3.1.1 Effect of pH on PK15-hENT1 activity
Given that MMTS effects were abolished when treatment took place in basic pH
medium, we considered the fundamental effects of pH on hENT1 function. To compare
the effect of pH on PK15-hENT1 activity, we utilized 50 mM Tris at pH 6.2, 7.2, and 8.2
for our incubation media due to its buffering range at that pH. Cells expressing
recombinant wildtype hENT1 cells were harvested, washed in the described buffer and
incubated with a range of [3H]NBMPR concentrations to determine site-specific binding.
Specific binding of [3H]NBMPR in pH 6.2 and 7.2 yielded near identical Bmax values of 3.9
± 0.7 x 105 ENT1 sites/cell and 3.5 ± 0.6 x 105 ENT1 sites/cells, respectively. However,
specific binding of [3H]NBMPR in pH 8.2 showed an increased Bmax of 6.3 ± 0.8 x 105
ENT1 sites/cell or a 45% increase compared to pH 7.2 (Figure 4.9A). Affinities for all
three pH were not significantly different, pH 6.2 Kd = 0.1 ± 0.02 nM, pH 7.2 Kd = 0.1 ±
0.01 nM, and pH 8.2 Kd = 0.1 ± 0.003 nM. To determine if the change in Bmax at pH 8.2
could be due to the loss of K+ and/or Cl- ion gradients (our experiments were repeated
using NMG buffer at pH 7.4 and 8.2 and found a similar results where incubation in NMG
at pH 8.2 caused an increase in Bmax by 52 ± 20% compared to NMG at pH 7.2 (Figure
4.9B). Additionally, affinities for [3H]NBMPR were not significantly different; pH 7.4 Kd =
0.14 ± 0.02 nM, pH 8.4 Kd = 0.18 ± 0.04 nM. To determine if the increase seen in
[3H]NBMPR Bmax represented an increase in functional hENT1 transporters at the
membrane, [3H]2-chloroadenosine uptake assays were performed with NMG buffer at
pH 7.4 and pH 8.4. Initial rates of uptake for wildtype hENT1 were unaffected by the
change in pH (Figure 4.9C); pH 7.4 Vmax = 6.5 ±1.2 pmol/µl/s versus pH 8.4 Vmax = 6.6 ±
1.5 pmol/µl/s.

4.3.2 Effects of MMTS on 2-chloroadenosine uptake: substrate transport by hENT1 is
sensitive to neutral thiol modification
MMTS inhibited the NBMPR-sensitive uptake of [3H]2-chloroadenosine by PK15-hENT1
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Figure 4.9. NBMPR binding to hENT1 is sensitive to pH. Effect of pH on [3H]NBMPR
binding of cells transfected with wild-type hENT1 incubated with Tris (Panel A) or NMG
(Panel B) and the effect of pH on [3H]2-chloroadenosine uptake (Panel C). Intact cells
were incubated in 50 mM Tris at pH 6.2, pH 7.2, or pH 8.2 (Panel A) or in NMG at pH 7.4
or pH 8.2 (Panel B) and then exposed to a range of concentrations of [3H]NBMPR in the
presence and absence of 10 µM NBTGR to define the amount of site-specific binding of
this ligand in each cell. Panel C shows intact cells incubated in NMG at pH 7.4 or pH 8.2
and then assessed for [3H]2-chloroadenosine mediated uptake using a 5 s incubation
time in the presence and absence of 5 µM NBTGR/dipyridamole to define the
transporter-mediate uptake component. Each point is the mean ± SEM from at least 4
experiments conducted in duplicate. * Indicates a significant effect of pH 8.2 relative to
pH 7.2 Bmax (Students t-test for paired samples, P < 0.05).
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cells (by 36 %) (Figure 4.5C), and led to a significant decrease in the ability of
dipyridamole (Ki = 413 ± 124 nM), NBMPR (Ki = 5.8 ± 1.0 nM) and dilazep (Ki = 16 ± 2 nM)
to inhibit [3H]2-chloroadenosine uptake (Figure 4.10A). On the other hand, the ability of
substrates such as adenosine and inosine to inhibit [3H]2-chloroadenosine uptake was
unaffected by MMTS treatment (Figure 4.10B).

4.3.3 Protection of hENT1 from the effects of MMTS
To determine if the effects of MMTS could be blocked with either inhibitor or substrate,
PK15-hENT1 cells were treated with MMTS in the presence of unlabelled NBMPR or
adenosine. Given that the inhibitor binding site is predicted to overlap the substrate
translocation site but with a different set of binding determinants, both the prototypical
inhibitor (NBMPR) and substrate (adenosine) were used in these protection studies at
concentrations that were above their calculated affinities to the transporter. Coincubation of cells with MMTS and either adenosine (1 mM) or NBMPR (10 nM)
produced a similar enhancement of [3H]NBMPR binding in intact cells as did MMTS alone
(Figure 4.11A, 4.11B).

4.3.4 Effects of MTSES on NBMPR binding and on 2-chloroadenosine uptake: the NBMPR
binding pocket is sensitive to negatively charged thiol modification of cytoplasmic
cysteines.
The negatively charged reagent pCMBS in previous studies produced either no effect on
intact cells or a much smaller effect compared to NEM on ENT1 function in different cell
models and conditions. We assessed the effects of the negatively charged reagent,
MTSES, on PK15-hENT1 cells. The negatively charged membrane-impermeable thiol
modifier MTSES had no effect on [3H]NBMPR binding in whole cells but did inhibit
[3H]NBMPR binding to isolated membranes (~60% inhibition to 0.43 ± 0.11 pmol/mg)
(Figures 4.12A, 4.12B). The inability of MTSES to affect NBMPR binding of whole cells
mimics previous studies in our lab by Vyas et al. and Robillard et al. where pCMBS was
only able to inhibit NBMPR binding in broken cell preparations [157, 174]. In addition to
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Figure 4.10. Effects of the treatment of hENT1 with MMTS on the inhibition of
substrate uptake. Inhibition of [3H]2-chloroadenosine uptake by a range of
concentrations of inhibitors (Panel A) and of substrates (Panel B) by cells that have been
pretreated with either 0.1% DMSO (solid lines, closed symbols) or 1 mM MMTS (dashed
lines, open symbols). Each point is the mean ± SEM from at least four experiments.
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Figure 4.11. NBMPR and adenosine are unable to protect against MMTS effects. Effect
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significant difference between the MMTS, NBMPR/MMTS or adenosine/MMTS treated
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Figure 4.12. Effect of MTSES on hENT1. Effects of MTSES on [3H]NBMPR binding of
PK15-hENT1 cells (Panel A), cell membranes (Panel B) and on [3H]2-chloroadenosine
uptake by PK15-hENT1 cells (Panel C). Cells or membranes were incubated with either 5
mM MTSES or 0.5% DMSO (Control) for 10 min, washed thrice, and then incubated with
a range of concentrations of [3H]NBMPR (abscissa) in the presence and absence of 10
µM NBTGR to define total and nonspecific binding (Panel A and B) or cells were assessed
for their capacity to accumulate [3H]2-chloroadenosine (5 s incubation) in the presence
and absence of 5 µM NBTGR/dipyridamole (Panel C). Each point represents the mean ±
SEM from at least five experiments. * Significant difference from control Bmax (Student's
t test for paired samples, P <0.05).
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having no effect in whole cell NBMPR binding, MTSES treatment of PK15-hENT1 cells had
no effect on [3H]2-chloroadenosine uptake (Figure 4.12C).

4.3.5 Effects of MTSET on NBMPR binding and 2-chloroadenosine uptake: the NBMPR
binding pocket and substrate translocation site are sensitive to a thiol modifier with a
positive charge
Previous studies on ENT1-thiol modification have limited their thiol reagents to ones of
neutral or negative charge. Our study widened the scope of cysteine accessibility by
using a positively charged sulfhydryl reagent, MTSET. Though MTSET and MTSES are
similar in size, they differ in charge and therefore may provide additional information on
hENT1 structure as any differences in effects between them may be attributable to the
charge difference. Treatment of PK15-hENT1 cells with the membrane-impermeable
MTSET produced a slight but significant decrease (13 %) in [3H]NBMPR binding in intact
cells (Figure 4.13A). This same treatment also decreased binding to isolated membranes
(by about 60% to 0.42 ± 0.18 pmol/mg) (Figure 4.13B). When testing the sensitivity of
hENT1 transport mechanism to the thiol modification by a positively charged reagent,
MTSET increased the Vmax of [3H]2-chloroadenosine uptake by 45 % with no change in
Km (Figure 4.13C).

4.4 Summary of MTS effects
In all cases, the effects on [3H]NBMPR binding and [3H]2-chloroadenosine uptake
reflected a change in maximum (Bmax, Vmax) rather than a change in affinity (Kd, Km) for
the ligand. As summarized in Table 4.1, the neutral membrane permeable MMTS caused
significant effects in both binding Bmax and uptake Vmax. The negatively charged
membrane impermeable reagent MTSES produced no changes in whole cell hENT1
functionality. The positively charged membrane impermeable reagent MTSET caused a
decrease in binding Bmax and an enhanced uptake Vmax. All three MTS reagents produced
a significant decrease in NBMPR binding in broken cell membrane preparations. This
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Figure 4.13. Effect of MTSET on hENT1. Effects of MTSET on [3H]NBMPR binding by
PK15-hENT1 cells (Panel A), cell membranes (Panel B) and on [3H]2-chloroadenosine
uptake by PK15-hENT1 cells (Panel C). Cells or membranes were incubated with either 5
mM MTSET or 0.5% DMSO (Control) for 10 min, washed thrice, and then incubated with
a range of concentrations of [3H]NBMPR (abscissa) in the presence and absence of 10
µM NBTGR to define total and nonspecific binding (Panel A and B) or assessed for their
capacity to accumulate [3H]2-chloroadenosine (5 s incubation) in the presence and
absence of 5 µM NBTGR/dipyridamole (Panel C). Each point represents the mean ± SEM
from at least 5 experiments done in duplicate. * Significant difference from control Bmax
for NBMPR binding studies and control Vmax for uptake studies (Student's t test for
paired samples, P <0.05)
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suggests there is a hENT1 cysteine being modified by the positively charged reagent
MTSET that could not be accessed by the negatively charged reagent MTSES in whole
cells. In addition to this predicted-extracellular cysteine, there is also a second cysteine
that is being modified by the membrane permeable reagent MMTS to cause an increase
in NBMPR binding located within a lipophilic environment. Lastly, there is a cysteine
located cytoplasmically that is contributing to NBMPR binding. This is yet another
cysteine given that modification of this cytoplasmic cysteine with all three MTS reagents
results in a decrease in NBMPR binding. These results support our first and second
hypotheses where we hypothesized that there were two seperate cysteines located in
two separate environments that when modified would affect hENT1 function; one of
these cysteines was predicted to be in a hydrophobic environment, and the second
cysteine was predicted to be in a cytoplasmic location.

4.5 Mutation of 10 endogenous cysteines
The preceding studies indicated the importance of cysteine residues to hENT1 function.
Therefore to determine which cysteines were involved in the effects observed with MTS
reagents (Table 4.1), we systematically mutated each cysteine to serine (a modest
change in reactive side chain and size) and assessed mutant function. Additionally, the
cysteine to serine mutants were tested for their sensitivity to MTS reagents and
examined to see if they contributed to those effects in wild-type hENT1. The intent of
this approach was to determine the cysteine responsible for the MTSET effects.
Subsequently, the residue could be removed to construct an extracellular cysteine-less
mutant unresponsive to MTSET to create a template for future cysteine mutagenesis
studies in mapping the extracellular binding domain of NBMPR.
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Table 4.1. Summary of the effects of MTS reagents on [3H]NBMPR binding (Bmax) and
[3H]2-chloroadenosine (Vmax) by cells and cell membranes transfected with hENT1.
Data shown are the percent change mean ± SEM from at least four independent
experiments.

MTS
Reagent

[3H]NBMPR binding of [3H]NBMPR binding of [3H]2-chloroadenosine
intact cells (% control cell
membrane
(% uptake (% control Vmax)
Bmax)
control Bmax)

MMTS

62 ± 11% increase in Bmax

43±5% decrease in Bmax

36 ± 16% decrease in
Vmax

MTSET

13 ± 4% decrease in Bmax

71±10% decrease in Bmax

45 ± 24% increase in
Vmax

MTSES

No effect

29±12% decrease in Bmax

No effect
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4.5.1 Mutation of C87 to serine
hENT1-C87S cells bound [3H]NBMPR with a Kd of 0.3 ± 0.06 nM which is not significantly
different from that obtained for wild-type hENT1 (Figure 4.14A, Table 4.2). Likewise,
membranes prepared from these cells had a Kd of 0.2 ± 0.04 nM which is similar to that
determined for wild-type hENT1 membranes (Figure 4.14B). However, the Km for [3H]2chloroadenosine uptake (27 ± 3 µM) was significantly lower than that seen for wild-type
hENT1 (71 ± 8 µM) (Figure 4.14C, Table 4.2). The Bmax of [3H]NBMPR binding and the
Vmax of [3H]2-chloroadenosine uptake by hENT1-C87S cells were 1.4 ± 0.1 x 105 ENT1
sites/cell and 6.5 ± 0.4 pmol/µl/s (Figure 4.14A, 4.14C), respectively, giving a Vmax/Bmax
ratio of 4.6 ± 0.5 X 10-5 pmol/ENT1/s which is significantly greater than the Vmax/Bmax
ratio of for the wild-type hENT1 (calculated from all control data sets).

4.5.1.1 C87S MTS treatment
As seen for the wild-type hENT1, MMTS treatment increased the Bmax of [3H]NBMPR
binding to hENT1-C87S by 49 ± 12%, and decreased the Vmax of [3H]2-chloroadenosine
influx by 20 ± 14% with no significant change in Kd (Figure 4.15A, 4.15C). Neither MTSES
nor MTSET had any effect on [3H]NBMPR binding to intact hENT1-C87S transfected cells
(Figure 4.16A, 4.16C). However, as in wild-type hENT1, MTSET enhanced (51 ± 24%) the
Vmax of [3H]2-chloroadenosine uptake by hENT1-C87S and MTSES had no effect (Figure
4.16B, 4.16D). In isolated membranes MMTS decreased the Bmax of [3H]NBMPR binding
(from 0.7 ± 0.05 to 0.3 ± 0.01 pmol/mg), with no significant change in Kd (Figure 4.15B).

4.5.2 Mutation of C193 to serine
hENT1-C193S cells bound [3H]NBMPR with a Kd of 0.2 ± 0.03 nM to a maximum of 2.5 ±
0.3 x 105 ENT1 sites/cell (Figure 4.17A, Table 4.2). Membranes prepared from these cells
had a Kd of 0.1 ± 0.02 nM and a [3H]NBMPR Bmax of 17 ± 2 pmol/mg protein (Figure
4.17B). The Km and Vmax for [3H]2-chloroadenosine uptake were 39 ± 5 µM and 5.1 ± 0.6
pmol/ µl/s (Figure 4.17C, Table 4.2), respectively, resulting in a Vmax/Bmax ratio of 2.0 ±
0.3 pmol/ENT1/s which is similar to that seen in for the wild-type hENT1.
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Figure 4.14. Characterization of PK15-C87S. [3H]NBMPR binding of PK15-C87S cells
(Panel A) and PK15-C87S membranes (Panel B) and [3H]2-chloroadenosine uptake of
PK15-C87S cells (Panel C). For panels A and B, cells and membranes were incubated
with a range of concentrations of [3H]NBMPR (abscissa) in the presence (nonspecific
binding) and absence of 10 µM NBTGR (total binding). Specific binding was determined
by total bound minus non-specific bound. Each point represents the mean ± SEM from at
least four experiments done in duplicate. For panel C, cells were incubated with a range
of concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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Table 4.2. Summary of effects of cysteine mutations on the binding of [3H]NBMPR to
PK15-hENT1 cells and the uptake of [3H]2-chloroadenosine by PK15-hENT1 cells. Data
shown are the means ± SEM from at least four independent experiments. * Significant
difference from wildtype hENT1 affinities (P < 0.05 one-way ANOVA : Dunnett’s posttest). n/d indicates that values were not determined

NBMPR Binding
Bmax

2-chloroadenosine Uptake
Kd

Vmax

Km

(# ENT1 sites/cell)
(nM)
x 105

(pmol/µl/s)

(µM)

PK15-NTD

n/d

n/d

n/d

n/d

PK15- hENT1

3.6 ± 0.20

0.38 ± 0.02

9.5 ± 0.75

71 ± 7.7

PK15-C87S

1.4 ± 0.12

0.30 ± 0.06

6.5 ± 0.40

27 ± 2.5*

PK15-C193S

2.5 ± 0.30

0.24 ± 0.03

5.1 ± 0.56

39 ± 4.7*

PK15-C213S

2.8 ± 0.62

0.45 ± 0.10

22 ± 2.8

77 ± 10

PK15-C222S

2.0 ± 0.16

0.29 ± 0.04

9.3 ± 1.3

63 ± 11

PK15-C297S

1.3 ± 0.25

0.30 ± 0.04

5.7 ± 0.68

61 ± 13

PK15-C333S

4.3 ± 0.40

0.37 ± 0.06

6.7 ± 0.75

39 ± 5.0*

PK15-C378S

4.7 ± 0.35

0.39 ± 0.03

11 ± 1.0

57 ± 6.3

PK15-C414S

2.1 ± 0.23

0.45 ± 0.05

6.3 ± 0.42

35 ± 5.0*

PK15-C416A

4.6 ± 2.3

0.10 ± 0.02

n/d

n/d

PK15-C439A

8.6 ± 1.4

0.50 ± 0.10

8.4 ± 0.80

165 ± 32
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Figure 4.15. Effect of MMTS treatment on C87S activity. Effects of MMTS on
[3H]NBMPR binding of PK15-C87S cells (Panel A), cell membranes (Panel B) and on
[3H]2-chloroadenosine uptake by PK15-C87S cells (Panel C). Cells or cell membranes
were incubated with either 1 mM MMTS or 0.1% DMSO (Control) for 10 min, washed
extensively, and then incubated with a range of concentrations of [ 3H]NBMPR in the
presence and absence of 10 µM NBTGR to define total and nonspecific binding (Panel A
and B). Panel C describes the concentration-dependent uptake of [3H]2-chloroadenosine
of cells treated for 10 min with 1 mM MMTS or 0.1% DMSO (Control) and washed three
times. Cells were incubated with a range of concentrations of [ 3H]2-chloroadenosine for
5 s in the presence (Non-mediated) or absence (Total uptake) of 5 µM
dipyridamole/NBTGR. Each point represents the mean ± SEM of the cellular
accumulation of [3H]2-chloroadenosine from at least four independent experiments
conducted in duplicate. * Significant difference from control Bmax for NBMPR binding
studies and control Vmax for uptake studies (Student's t test for paired samples, P <0.05)
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Figure 4.16. Treatment of C87S with MTSET and MTSES. Effects of MTSET (Panel A and
B) and MTSES (Panel C and D) on [3H]NBMPR binding and on [3H]2-chloroadenosine
uptake by hENT1-C87S expressed in PK15-NTD cells. For Panel A and C, cells were
incubated with either 5 mM MTSET (Panel A), or 5 mM MTSES (Panel C) for 10 min,
washed extensively, and then incubated with a range of concentrations of [ 3H]NBMPR in
the presence and absence of 10 µM NBTGR to define total and nonspecific binding. Each
point represents the mean ± SEM from at least 5 experiments done in duplicate. For
Panel B and D, cells were incubated with either 5 mM MTSET (Panel B) or 5 mM MTSES
(Panel D) for 10 min, washed extensively, and then incubated with a range of
concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Each point represents the mean ±
SEM of the cellular accumulation of [3H]2-chloroadenosine from at least four
independent experiments conducted in duplicate. * Significant difference from control
Bmax for NBMPR binding studies and control Vmax for uptake studies (Student's t test for
paired samples, P <0.05)
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Figure 4.17. Characterization of PK15-C193S. [3H]NBMPR binding of PK15-C1963S cells
(Panel A) and PK15-C193S membranes (Panel B) and [3H]2-chloroadenosine uptake of
PK15-C193S cells (Panel C). For panels A and B, cells and membranes were incubated
with a range of concentrations of [3H]NBMPR (abscissa) in the presence (nonspecific
binding) and absence of 10 µM NBTGR (total binding). Specific binding was determined
by total bound minus non-specific bound. Each point represents the mean ± SEM from at
least four experiments done in duplicate. For panel C, cells were incubated with a range
of concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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4.5.2.1 Effects of MTS treatment on the function of C193S
MMTS treatment more than doubled (106 ± 28% increase) the number of [ 3H]NBMPR
binding sites in hENT1-C193S cells relative to wild-type hENT1 (Figure 4.18A), and this
effect was significantly greater than that observed for any of the other hENT1 mutants
tested in this study. Also, unlike that observed for the wild-type hENT1 and other
mutants, MMTS did not affect the rate of [ 3H]2-chloroadenosine uptake in the C193S
cells (Figure 4.18B).

Likewise, the membrane-impermeable reagents (MTSET and

MTSES) had no effect on either [3H]NBMPR binding or [3H]2-chloroadenosine uptake in
these cells (Figure 4.19A, 4.19B).

4.5.3 Mutation of C213 to serine
hENT1-C213S cells bound [3H]NBMPR with a Kd of 0.4 ±0.1 nM to a maximum of 2.8 ±
0.6 x 105 ENT1 sites/cell (Figure 4.20A, Table 4.2). Membranes prepared from these cells
had a Kd of 0.2 ± 0.02 nM and a [3H]NBMPR Bmax of 0.7 ± 0.03 pmol/mg protein (Figure
4.20B). The Km and Vmax for [3H]2-chloroadenosine uptake were 77 ± 10 µM and 22 ± 3
pmol/ µl/s (Figure 4.20C, Table 4.2), respectively, resulting in a Vmax/Bmax ratio of 7.9 ±
2.0 pmol/ENT1/s which is significantly greater than that of wild-type hENT1. The cells
transfected with hENT1-C213S appeared to increase in their transport and binding
capacity with time. In this way they were distinct from the other hENT1-mutants tested,
which remained relatively consistent in their binding and transport capacity throughout
the study.

4.5.3.1 C213S MTS treatments
The effects of the MTS reagents were comparable to that seen for the wild-type hENT1
cells. MMTS treatment induced a 56 ± 20% increase in [ 3H]NBMPR binding Bmax and a
40 ± 7% decrease in the Vmax of [3H]2-chloroadenosine uptake (Figure 4.21A, 4.21B).
MTSET inhibited [3H]NBMPR binding by a significant 18 ± 12%, but had no effect of
[3H]2-chloroadenosine uptake (Figure 4.22A, 4.22B), which makes this mutant similar to
C193S in that regard. MTSES had no effect on either [3H]NBMPR binding or [3H]2-
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Figure 4.18. Effects of MMTS treatment on C193S activity. Effects of MMTS on
[3H]NBMPR binding (Panel A) and [3H]2-chloroadenosine (Panel B) uptake by hENT1C193S expressed in PK15-NTD cells. Cells were incubated with either 1 mM MMTS or
0.1% DMSO (Control) for 10 min, washed extensively, and then incubated with a range
of concentrations of [3H]NBMPR in the presence and absence of 10 µM NBTGR to define
total and nonspecific binding. Panel B describes the concentration-dependent uptake of
[3H]2-chloroadenosine of cells treated for 10 min with 1 mM MMTS or 0.1% DMSO
(Control) and washed three times. Cells were incubated with a range of concentrations
of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or absence (Total
uptake) of 5 µM dipyridamole/NBTGR. Each point represents the mean ± SEM of the
cellular accumulation of [3H]2-chloroadenosine from at least four independent
experiments conducted in duplicate. * Significant difference from control Bmax (Student's
t test for paired samples, P <0.05).
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Figure 4.19. Treatment of C193S with MTSET and MTSES. Effects of MTSET and MTSES
on [3H]NBMPR binding (Panel A) and [3H]2-chloroadenosine (Panel B) uptake by hENT1C193S expressed in PK15-NTD cells. Cells were incubated with either 5 mM MTSET (blue
squares), or 5 mM MTSES (green squares) for 10 min, washed extensively, and then
incubated with a range of concentrations of [3H]NBMPR in the presence and absence of
10 µM NBTGR to define total and nonspecific binding. Panel B describes the
concentration-dependent uptake of [3H]2-chloroadenosine of cells treated for 10 min
with either 5 mM MTSET or 5 mM MTSES and washed three times. Cells were then
incubated with a range of concentrations of [3H]2-chloroadenosine for 5 s in the
presence (Non-mediated) or absence (Total uptake) of 5 µM dipyridamole/NBTGR. Each
point represents the mean ± SEM of the cellular accumulation of [3H]2-chloroadenosine
from at least five independent experiments conducted in duplicate.
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Figure 4.20. Characterization of PK15-C213S. [3H]NBMPR binding of PK15-C213S cells
(Panel A) and PK15-C213S membranes (Panel B) and [3H]2-chloroadenosine uptake of
PK15-C213S cells (Panel C). For panels A and B, cells and membranes were incubated
with a range of concentrations of [3H]NBMPR (abscissa) in the presence (nonspecific
binding) and absence of 10 µM NBTGR (total binding). Specific binding was determined
by total bound minus non-specific bound. Each point represents the mean ± SEM from at
least four experiments done in duplicate. For panel C, cells were incubated with a range
of concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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Figure 4.21. Treatment of C213S with MMTS. Effects of MMTS on [3H]NBMPR binding
(Panel A) and [3H]2-chloroadenosine (Panel B) uptake by hENT1-C213S expressed in
PK15-NTD cells. Cells were incubated with either 1 mM MMTS or 0.1% DMSO (Control)
for 10 min, washed extensively, and then incubated with a range of concentrations of
[3H]NBMPR in the presence and absence of 10 µM NBTGR to define total and
nonspecific binding. Specific binding was calculated as the difference between the total
and nonspecific binding components. Each point represents the mean ± SEM from at
least 5 experiments done in duplicate. Panel B describes the concentration-dependent
uptake of [3H]2-chloroadenosine of cells treated for 10 min with 1 mM MMTS or 0.1%
DMSO (Control) and washed three times. Cells were incubated with a range of
concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate. * Significant difference from control Bmax for NBMPR binding studies and
control Vmax for uptake studies (Student's t test for paired samples, P <0.05)
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Figure 4.22. Treatment of C213S with MTSET and MTSES. Effects of MTSET (Panel A
and B) and MTSES (Panel C and D) on [3H]NBMPR binding and on [3H]2-chloroadenosine
uptake of hENT1-C213S expressed in PK15-NTD cells. For Panel A and C, cells were
incubated with either 5 mM MTSET (Panel A), or 5 mM MTSES (Panel C) for 10 min,
washed extensively, and then incubated with a range of concentrations of [3H]NBMPR in
the presence and absence of 10 µM NBTGR to define total and nonspecific binding. Each
point represents the mean ± SEM from at least 5 experiments done in duplicate. For
Panel B and D, cells were incubated with either 5 mM MTSET (Panel B) or 5 mM MTSES
(Panel D) for 10 min, washed extensively, and then incubated with a range of
concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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chloroadenosine uptake in the C213S mutants (Figure 4.22C, 4.22D).

4.5.4 Mutation of C222 to serine
hENT1-C222S cells bound [3H]NBMPR with a Kd of 0.3 ±0.04 nM to a maximum of 2.0 ±
0.2 x 105 ENT1 sites/cell (Figure 4.23A, Table 4.2). Membranes prepared from these cells
had a Kd of 0.08 ± 0.01 nM and a [3H]NBMPR Bmax of 0.5 ± 0.05 pmol/mg protein (Figure
4.23B). The Km and Vmax for [3H]2-chloroadenosine uptake were 63 ± 11 µM and 9.3 ±
1.3 pmol/ µl/s (Figure 4.23C, Table 4.2), respectively, resulting in a Vmax/Bmax ratio of 4.7
± 0.8 pmol/ENT1/s, which is significantly greater than that of wild-type hENT1.

4.5.4.1 C222S MTS treatments
MMTS treatment had no significant effect on [3H]NBMPR binding to hENT1-C222S in
intact cells (Figure 4.24A), making this the only mutant studied that did not respond to
MMTS with an increase in [3H]NBMPR binding. MTSES had no effect on NBMPR binding
however MTSET induced a slight inhibition of [3H]NBMPR binding, similar to that seen in
the hENT1 wild-type cells and the C213S mutants (Figure 4.25A). The C222S cells were
also similar to the C87S and C213S mutants and the hENT1 wild-type cells in that MMTS
caused a significant decrease (53 ± 21%) in the maximal rate of [3H]2-chloroadenosine
uptake (Figure 4.24B).

Neither MTSET nor MTSES affected [3H]2-chloroadenosine

uptake by the hENT1-C222S cells (Figure 4.25B). The hENT1-C222S mutant was also the
only one of those studied that did not show a significant decrease in [3H]NBMPR binding
Bmax in isolated cell membranes treated with MMTS. Additionally, when C222S intact
cells were treated with MMTS (or DMSO as control) and then used to prepare isolated
membranes for analysis of [3H]NBMPR binding, the membranes derived from cells
treated with MMTS had Bmax that were not significantly different than those membranes
prepared from cells treated with DMSO alone (Figure 4.26A, 4.26B).

MMTS did

however, appear to decrease the affinity of [3H]NBMPR for its binding sites in the C222S
cells relative to wild-type hENT1 (Kd of 0.2 ± 0.03 and 0.08 ± 0.01 nM in C222S and
hENT1 wild-type, respectively).

MTSET treatment, on the other hand, almost
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Figure 4.23. Characterization of PK15-C222S. [3H]NBMPR binding of PK15-C222S cells
(Panel A) and PK15-C222S membranes (Panel B) and [3H]2-chloroadenosine uptake of
PK15-C222S cells (Panel C). For panels A and B, cells and membranes were incubated
with a range of concentrations of [3H]NBMPR (abscissa) in the presence (nonspecific
binding) and absence of 10 µM NBTGR (total binding). Specific binding was determined
by total bound minus non-specific bound. Each point represents the mean ± SEM from at
least four experiments done in duplicate. For panel C, cells were incubated with a range
of concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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Figure 4.24. Treatment of C222S with MMTS: NBMPR binding to C222S is insensitive to
MMTS. Effects of MMTS on [3H]NBMPR binding (Panel A) and [3H]2-chloroadenosine
(Panel B) uptake by hENT1-C222S expressed in PK15-NTD cells. Cells were incubated
with either 1 mM MMTS or 0.1% DMSO (Control) for 10 min, washed extensively, and
then incubated with a range of concentrations of [ 3H]NBMPR in the presence and
absence of 10 µM NBTGR to define total and nonspecific binding. Specific binding was
calculated as the difference between the total and nonspecific binding components.
Each point represents the mean ± SEM from at least 5 experiments done in duplicate.
Panel B describes the concentration-dependent uptake of [3H]2-chloroadenosine of cells
treated for 10 min with 1 mM MMTS or 0.1% DMSO (Control) and washed three times.
Cells were incubated with a range of concentrations of [ 3H]2-chloroadenosine for 5 s in
the presence (Non-mediated) or absence (Total uptake) of 5 µM dipyridamole/NBTGR.
Transporter-mediated uptake (Mediated) was calculated as the difference between the
total and non-mediated uptake components. Each point represents the mean ± SEM of
the cellular accumulation of [3H]2-chloroadenosine from at least four independent
experiments conducted in duplicate. * Significant difference from control Vmax (Student's
t test for paired samples, P <0.05).
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Figure 4.25. Treatment of C222S with MTSET and MTSES. Effects of MTSET and MTSES
on [3H]NBMPR binding (Panel A) and [3H]2-chloroadenosine (Panel B) uptake by hENT1C222S expressed in PK15-NTD cells. Cells were incubated with either 5 mM MTSET (blue
squares), or 5 mM MTSES (green squares) for 10 min, washed extensively, and then
incubated with a range of concentrations of [3H]NBMPR in the presence and absence of
10 µM NBTGR to define total and nonspecific binding. Specific binding was calculated as
the difference between the total and nonspecific binding components. Each point
represents the mean ± SEM from at least 5 experiments done in duplicate. Panel B
describes the concentration-dependent uptake of [3H]2-chloroadenosine of cells treated
for 10 min with either 5 mM MTSET or 5 mM MTSES and washed three times. Cells were
then incubated with a range of concentrations of [ 3H]2-chloroadenosine for 5 s in the
presence (Non-mediated) or absence (Total uptake) of 5 µM dipyridamole/NBTGR.
Transporter-mediated uptake (Mediated) was calculated as the difference between the
total and non-mediated uptake components. Each point represents the mean ± SEM of
the cellular accumulation of [3H]2-chloroadenosine from at least four independent
experiments conducted in duplicate. * Significant difference from control Bmax (Student's
t test for paired samples, P <0.05).
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Figure 4.26. Cell membrane treatment of C222S with MMTS.
Effects of MMTS on [3H]NBMPR binding to hENT1-C222S cell membranes isolated from
cells pre-treated with MMTS (Panel A) and hENT1-C222S cell membranes treated with
MMTS (Panel B). PK15-C222S cells and membranes were incubated with a range of
concentrations of [3H]NBMPR (abscissa) in the presence (nonspecific binding) and
absence of 10 µM NBTGR (total binding). Each point represents the mean ± SEM from at
least four experiments done in duplicate. Nonlinear regression analysis was used to fit
hyperbolic curves to the site-specific binding of [3H]NBMPR plotted against the free
[3H]NBMPR concentration at steady-state.
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Figure 4.27. Cell membrane treatment of C222S with MTSET. Effect of MTSET on
[3H]NBMPR binding by PK15-C222S cell membranes. Membranes were incubated with
either 5 mM MTSET or 0.5% DMSO (Control) for 10 min, washed thrice, and then
incubated with a range of concentrations of [3H]NBMPR (abscissa) in the presence and
absence of 10 µM NBTGR to define total and nonspecific binding. Specific binding
(ordinate) was calculated as the difference between the total and nonspecific binding
components. Each point represents the mean ± SEM from at least 5 experiments done in
duplicate. * Significant difference from control Bmax (Student's t test for paired samples,
P <0.05).
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completely eliminated [3H]NBMPR binding to the isolated membranes (0.04 ± 0.01
pmol/mg protein versus 0.4 ± 0.01 pmol/mg protein in the control cells) (Figure 4.27).

4.5.4.2 C222S pH effects
Mutation of C222 to serine abolished the effects of MMTS treatment similarly to the
way alkaline pH abolished the effects of MMTS treatment in wild-type hENT1. Given that
wild-type hENT1 showed enhanced binding in alkaline pH, and that MMTS is targeted to
C222, we hypothesized that C222 was also involved in the pH effects seen in wild-type.
PK15-C222S cells were incubated with NMG buffer at pH 7.4 and 8.4 and we found
specific binding of [3H]NBMPR in pH 7.4 and 8.4 yielded near identical Bmax values of 4.9
± 0.1 x 105 ENT1 sites/cell and 5.2 ± 0.1 x 105 ENT1 sites/cells respectively (Figure 4.28).

4.5.5 Mutation of C297 to serine:
hENT1-C297S cells bound [3H]NBMPR with a Kd of 0.3 ± 0.04 nM, which is not
significantly different from that obtained in wild-type hENT1 (Figure 4.29A, Table 4.2).
Membranes prepared from these cells had a Kd of 0.1 ± 0.01 nM and a [3H]NBMPR Bmax
of 0.4 ± 0.01 pmol/mg protein (Figure 4.29B). Similarly, the Km for [3H]2-chloroadenosine
uptake was 61 ± 13 µM for C297S-hENT1 which is not significantly different to the wildtype Km values as previously calculated (Figure 4.29C, Table 4.2). The Bmax of [3H]NBMPR
binding and the Vmax of [3H]2-chloroadenosine uptake by hENT1-C297S cells were 1.3 ±
0.2 x 105 ENT1 sites/cell and 5.7 ± 0.6 pmol/µl/s, respectively, giving a Vmax/Bmax ratio of
4.5 ± 0.9 X 10-5 pmol/ENT1/s.

4.5.5.1 C297S MTS treatments
When treated with MMTS, hENT1-C297S showed a similar enhancement in Bmax of
[3H]NBMPR binding by 52 ± 4% with no significant change in K d as previously described
in the wild-type (Figure 4.30A). In contrast, hENT1-C297S lost sensitivity to MMTS in
relation to [3H]2-chloroadenosine uptake (Figure 4.30B). Treatment with MTSET yielded
opposite results where [3H]NBMPR binding was unaffected and [3H]2-chloroadenosine
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Figure 4.28. NBMPR binding to C222S is insensitive to pH. Effect of pH on [3H]NBMPR
binding to PK15-C222S cells. Intact cells were incubated in NMG buffer of pH 7.2 or pH
8.2 and then exposed to a range of concentrations of [ 3H]NBMPR in the presence and
absence of 10 µM NBTGR to define the amount of site-specific binding of this ligand in
each cell. Each point is the mean ± SEM from at least 4 experiments conducted in
duplicate.
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Figure 4.29. Characterization of PK15-C297S. [3H]NBMPR binding of PK15-C297S cells
(Panel A) and PK15-C297S membranes (Panel B) and [3H]2-chloroadenosine uptake of
PK15-C297S cells (Panel C). For panels A and B, cells and membranes were incubated
with a range of concentrations of [3H]NBMPR (abscissa) in the presence (nonspecific
binding) and absence of 10 µM NBTGR (total binding). Specific binding was determined
by total bound minus non-specific bound. Each point represents the mean ± SEM from at
least four experiments done in duplicate. For panel C, cells were incubated with a range
of concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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Figure 4.30. Treatment of C297S with MMTS. Effects of MMTS of [3H]NBMPR binding
(Panel A) and [3H]2-chloroadenosine (Panel B) uptake by hENT1-C297S expressed in
PK15-NTD cells. Cells were incubated with either 1 mM MMTS or 0.1% DMSO (Control)
for 10 min, washed extensively, and then incubated with a range of concentrations of
[3H]NBMPR in the presence and absence of 10 µM NBTGR to define total and
nonspecific binding. Specific binding was calculated as the difference between the total
and nonspecific binding components. Each point represents the mean ± SEM from at
least 5 experiments done in duplicate. Panel B describes the concentration-dependent
uptake of [3H]2-chloroadenosine of cells treated for 10 min with 1 mM MMTS or 0.1%
DMSO (Control) and washed three times. Cells were incubated with a range of
concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate. * Significant difference from control Bmax (Student's t test for paired samples,
P <0.05).
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Figure 4.31. Treatment of C297S with MTSET and MTSES. Effects of MTSET (Panel A
and B) and MTSES (Panel C and D) on [3H]NBMPR binding and on [3H]2-chloroadenosine
uptake of hENT1-C297S expressed in PK15-NTD cells. For Panel A and C, cells were
incubated with either 5 mM MTSET (Panel A), or 5 mM MTSES (Panel C) for 10 min,
washed extensively, and then incubated with a range of concentrations of [ 3H]NBMPR in
the presence and absence of 10 µM NBTGR to define total and nonspecific binding. Each
point represents the mean ± SEM from at least 5 experiments done in duplicate. For
Panel B and D, cells were incubated with either 5 mM MTSET (Panel B) or 5 mM MTSES
(Panel D) for 10 min, washed extensively, and then incubated with a range of
concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Each point represents the mean ±
SEM of the cellular accumulation of [3H]2-chloroadenosine from at least four
independent experiments conducted in duplicate. * Significant difference from control
Vmax (Student's t test for paired samples, P <0.05).
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uptake Vmax remained sensitive to MTSET enhancement (Figure 4.31A, 4.31B). MTSES,
the negatively charged impermeable reagent, had no effect on either [3H]NBMPR or
[3H]2-chloroadenosine kinetics (Figure 4.31C, 4.31D).

4.5.6 Mutation of C333 to serine:
hENT1-C333S cells bound [3H]NBMPR with a Kd of 0.4 ± 0.06 nM to a maximum of 4.3 ±
0.4 X 105 ENT1 sites/cell (Figure 4.32A, Table 4.2). Membranes prepared from these cells
had a Kd of 0.2 ± 0.01 ƞM and a [3H]NBMPR Bmax of 2.4 ± 0.4 pmol/mg protein (Figure
4.32B). Transport of [3H]2-chloroadenosine by hENT1-C333S had a Km and Vmax of 39 ± 5
µM (Figure 432C, Table 4.2) and 6.7 ± 0.7 pmol/ µl/s, respectively. The Vmax/Bmax ratio
was calculated at 1.5 ± 0.2 X 10-5 pmol/ENT1/s which is similar to wild-type hENT1,
however the Km of hENT1-C333S is significantly lower than wild-type indicating a greater
affinity for the substrate.

4.5.6.1 C333S MTS treatments
The effect of MMTS on hENT1-C333S [3H]NBMPR binding produced similar effects
compared to wild-type as the neutral reagent caused a 77 ± 13% enhancement in Bmax
(Figure 4.33A). In contrast, MMTS was unable to produce an effect on the [3H]2chloroadenosine uptake of hENT1-C333S (Figure 4.33B). Additionally, treatment with
either MTSES or MTSET did not produce any effects on [ 3H]2-chloroadenosine uptake or
[3H]NBMPR binding (Figure 4.34A, 4.34B).

4.5.7 Mutation of C378 to serine:
hENT1-C378S cells bound [3H]NBMPR with a Kd of 0.4 ± 0.03 nM to a Bmax of 4.7 ± 0.4 x
105 ENT1 sites/cell (Figure 4.35A, Table 4.2). Membranes prepared from these cells had
a Kd of 0.1 ± 0.01 nM and a [3H]NBMPR Bmax of 1.9 ± 0.12 pmol/mg protein (Figure
4.35B). The transport kinetics of [3H]2-chloroadenosine by hENT1-C378S were calculated
to have a Vmax of 11 ± 1.0 pmol/ µl/s and Km of 57 ± 6 µM (Figure 4.35C, Table 4.2). The
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Figure 4.32. Characterization of PK15-C333S. [3H]NBMPR binding of PK15-C333S cells
(Panel A) and PK15-C333S membranes (Panel B) and [3H]2-chloroadenosine uptake of
PK15-C333S cells (Panel C). For panels A and B, cells and membranes were incubated
with a range of concentrations of [3H]NBMPR (abscissa) in the presence (nonspecific
binding) and absence of 10 µM NBTGR (total binding). Specific binding was determined
by total bound minus non-specific bound. Each point represents the mean ± SEM from at
least four experiments done in duplicate. For panel C, cells were incubated with a range
of concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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Figure 4.33. Treatment of C333S with MMTS. Effects of MMTS of [3H]NBMPR binding
(Panel A) and [3H]2-chloroadenosine (Panel B) uptake by hENT1-C333S expressed in
PK15-NTD cells. Cells were incubated with either 1 mM MMTS or 0.1% DMSO (Control)
for 10 min, washed extensively, and then incubated with a range of concentrations of
[3H]NBMPR in the presence and absence of 10 µM NBTGR to define total and
nonspecific binding. Specific binding was calculated as the difference between the total
and nonspecific binding components. Each point represents the mean ± SEM from at
least 5 experiments done in duplicate. Panel B describes the concentration-dependent
uptake of [3H]2-chloroadenosine of cells treated for 10 min with 1 mM MMTS or 0.1%
DMSO (Control) and washed three times. Cells were incubated with a range of
concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate. * Significant difference from control Bmax (Student's t test for paired samples,
P <0.05).
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Figure 4.34. Treatment of C333S with MTSET and MTSES.
Effects of MTSET and MTSES on [3H]NBMPR
binding (Panel A) and [3H]2chloroadenosine (Panel B) uptake by hENT1-C333S expressed in PK15-NTD cells. Cells
were incubated with either 5 mM MTSET (blue squares), or 5 mM MTSES (green
squares) for 10 min, washed extensively, and then incubated with a range of
concentrations of [3H]NBMPR in the presence and absence of 10 µM NBTGR to define
total and nonspecific binding. Specific binding was calculated as the difference between
the total and nonspecific binding components. Each point represents the mean ± SEM
from at least 5 experiments done in duplicate. Panel B describes the concentrationdependent uptake of [3H]2-chloroadenosine of cells treated for 10 min with either 5 mM
MTSET or 5 mM MTSES and washed three times. Cells were then incubated with a range
of concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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Figure 4.35. Characterization of PK15-C378S. [3H]NBMPR binding of PK15-C378S cells
(Panel A) and PK15-C378S membranes (Panel B) and [3H]2-chloroadenosine uptake of
PK15-C378S cells (Panel C). For panels A and B, cells and membranes were incubated
with a range of concentrations of [3H]NBMPR (abscissa) in the presence (nonspecific
binding) and absence of 10 µM NBTGR (total binding). Specific binding was determined
by total bound minus non-specific bound. Each point represents the mean±SEM from at
least four experiments done in duplicate. For panel C, cells were incubated with a range
of concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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Vmax/Bmax ratio was determined to be 2.3 ± 0.2 X 10-5 pmol/ENT1/s which is similar to
wild-type hENT1.

4.5.7.1 C378S MTS Treatments
After treatment with MMTS, hENT1-C378S [3H]NBMPR Bmax increased by 49 ± 14% and
decreased [3H]2-chloroadenosine Vmax by 40 ± 12% (Figure 4.36A, 4.36B) adhering to
wild-type trends seen with MMTS treatment. MTSET and MTSES treatment had no effect
on either [3H]NBMPR binding or [3H]2-chloroadenosine transport similar to that seen in
the hENT1-C333S mutant (Figure 4.37A, 4.37B).

4.5.8 Mutation of C414 to serine:
hENT1-C414S cells bound [3H]NBMPR with a Kd of 0.4 ± 0.05 ηM to a Bmax of 2.1 ± 0.2 X
10-5 ENT1 sites/cell (Figure 4.38A, Table 4.2). Membranes prepared from these cells had
a Kd of 0.08 ± 0.01 nM and a [3H]NBMPR Bmax of 1.5 ± 0.1 pmol/mg protein (Figure
4.38B). [3H]2-chloroadenosine transport function remained intact as it achieved
mediated uptake at a Vmax and Km of 6.3 ± 0.4 pmol/ µl/s and 35 ± 5 µM (Figure 4.38C,
Table 4.2), respectively providing a Vmax/Bmax ratio of 3.0 ± 0.3 X 10-5 pmol/ENT1/s.

4.5.8.1 C414S MTS treatments
Treatment with MMTS increased [3H]NBMPR Bmax by 98 ± 12% indicating a significant
difference compared to the other cysteine mutants (Figure 4.39A). Additionally, [3H]2chloroadenosine Vmax decreased by 30 ± 13% with MMTS incubation as observed in
preceding studies (Figure 4.39B). MTSES did not affect [3H]NBMPR binding or [3H]2chloroadenosine transport by the hENT1-C414S cells (Figure 4.39C, 4.39D). When
comparing MTSET effects of hENT1-C414S to wild-type hENT1, it was surprising to note
the mutant transporter showed enhanced inhibition of [3H]NBMPR Bmax by 50 ± 9%
(Figure 4.40). Since MTSET effect was greater in hENT1-C414S than wild-type this
suggested that the loss of the intracellularly located residue was inducing a

104

B
8.0×10

5

C378S - Control
C378S + MMTS
*

6.0×10 5
4.0×10

5

2.0×10 5
0
0.0

0.5

1.0

1.5

[ 3H] NBMPR (nM)

2.0

2.5

Initial rate of uptake (pmol/ l/s)

Specific Bound (ENT1/cell)

A

15

10

*
5

0
0

50

100

150

[ 3H] 2-chloroadenosine ( M)

Figure 4.36. Treatment of C378S with MMTS. Effects of MMTS of [3H]NBMPR binding
(Panel A) and [3H]2-chloroadenosine (Panel B) uptake by hENT1-C378S expressed in
PK15-NTD cells. Cells were incubated with either 1 mM MMTS or 0.1% DMSO (Control)
for 10 min, washed extensively, and then incubated with a range of concentrations of
[3H]NBMPR in the presence and absence of 10 µM NBTGR to define total and
nonspecific binding. Specific binding was calculated as the difference between the total
and nonspecific binding components. Each point represents the mean ± SEM from at
least 5 experiments done in duplicate. Panel B describes the concentration-dependent
uptake of [3H]2-chloroadenosine of cells treated for 10 min with 1 mM MMTS or 0.1%
DMSO (Control) and washed three times. Cells were incubated with a range of
concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate. * Significant difference from control Bmax for NBMPR binding studies and
control Vmax for uptake studies (Student's t test for paired samples, P <0.05)
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Figure 4.37. Treatment of C378S with MTSET and MTSES: NBMPR binding to C378S is
insensitive to MTSET. Effects of MTSET and MTSES on [3H]NBMPR binding (Panel A)
and [3H]2-chloroadenosine (Panel B) uptake by hENT1-C378S expressed in PK15-NTD
cells. Cells were incubated with either 5 mM MTSET (blue squares), or 5 mM MTSES
(green squares) for 10 min, washed extensively, and then incubated with a range of
concentrations of [3H]NBMPR in the presence and absence of 10 µM NBTGR to define
total and nonspecific binding. Specific binding was calculated as the difference between
the total and nonspecific binding components. Each point represents the mean ± SEM
from at least 5 experiments done in duplicate. Panel B describes the concentrationdependent uptake of [3H]2-chloroadenosine of cells treated for 10 min with either 5 mM
MTSET or 5 mM MTSES and washed three times. Cells were then incubated with a range
of concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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Figure 4.38. Characterization of PK15-C414S. [3H]NBMPR binding of PK15-C414S cells
(Panel A) and PK15-C414S membranes (Panel B) and [3H]2-chloroadenosine uptake of
PK15-C414S cells (Panel C). For panels A and B, cells and membranes were incubated
with a range of concentrations of [3H]NBMPR (abscissa) in the presence (nonspecific
binding) and absence of 10 µM NBTGR (total binding). Specific binding was determined
by total bound minus non-specific bound. Each point represents the mean ± SEM from at
least four experiments done in duplicate. For panel C, cells were incubated with a range
of concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake
(Mediated) was calculated as the difference between the total and non-mediated
uptake components. Each point represents the mean ± SEM of the cellular accumulation
of [3H]2-chloroadenosine from at least four independent experiments conducted in
duplicate.
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Figure 4.39. Treatment of C414S with MMTS and MTSES. Effects of MMTS (Panel A and
B) and MTSES (Panel C and D) on [3H]NBMPR binding and on [3H]2-chloroadenosine
uptake of hENT1-C414S expressed in PK15-NTD cells. For Panel A and C, cells were
incubated with either 1 mM MMTS (Panel A), or 5 mM MTSES (Panel C) for 10 min,
washed extensively, and then incubated with a range of concentrations of [ 3H]NBMPR in
the presence and absence of 10 µM NBTGR to define total and nonspecific binding. For
Panel B and D, cells were incubated with either 1 mM MMTS (Panel B) or 5 mM MTSES
(Panel D) for 10 min, washed extensively, and then incubated with a range of
concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Each point represents the mean ±
SEM of the cellular accumulation of [3H]2-chloroadenosine from at least four
independent experiments conducted in duplicate. * Significant difference from control
Bmax for NBMPR binding studies and control Vmax for uptake studies (Student's t test for
paired samples, P <0.05)
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Figure 4.40. Treatment of C414S with MTSET: enhanced inhibition of NBMPR binding.
Effects of MTSET on [3H]NBMPR binding by hENT1-C414S expressed in PK15-NTD cells.
Cells were incubated with 5 mM MTSET (blue squares) or 0.5% DMSO (black circles) for
10 min, washed extensively, and then incubated with a range of concentrations of
[3H]NBMPR in the presence and absence of 10 µM NBTGR to define total and
nonspecific binding. Specific binding was calculated as the difference between the total
and nonspecific binding components. Each point represents the mean ± SEM from at
least 5 experiments done in duplicate. * Significant difference from control Bmax
(Student's t test for paired samples, P <0.05).
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conformational change allowing greater access to the MTSET-sensitive cysteine to cause
inhibition of [3H]NBMPR.

4.5.8.2 Mutation of C378 and C414 to serines:
The significant decrease seen in [3H]NBMPR Bmax by 50 ± 9% from MTSET treatment on
C414S mutant (Figure 4.40) indicated the presence of a second cysteine residue being
modified. Given that removal of C378 eliminated MTSET sensitivity (Figure 4.37A) and is
predicted to lie extracellularly (Figure 2.1), we proposed that C378 was the cysteine
being accessed for hydrophilic thiol modification. To test this idea, a double mutant,
C378S - C414S was created on the wild-type hENT1 template and its activity and
sensitivity to MTS reagents determined. Double mutant hENT1-C378S-414S expressing
cells bound [3H]NBMPR with a Kd of 0.22 ± 0.03 nM to a Bmax of 4.6 ± 0.6 X 10-5 ENT1
sites/cell

(Figure

4.41A,

Table

4.2).

hENT1-C378S-414S

transported

[3H]2-

chloroadenosine at a Vmax and Km of 21 ± 5 pmol/ µl/s and 87 ± 18 µM (Figure 4.41B,
Table 4.2), respectively providing a Vmax/Bmax ratio of 4.5 ± 1.1 X 10-5 pmol/ENT1/s.

4.5.8.2.1 C378-414S MTS treatments:
After treatment with MMTS, [3H]NBMPR Bmax increased by 65 ± 15 % and [3H]2chloroadenosine Vmax showed a drastic decrease of 69 ± 8 % (Figure 4.42A, 4.42B).
However, treatment with MTSET had no effect on either [ 3H]NBMPR binding or [3H]2chloroadenosine uptake (Figure 4.43A, 4.43B) emphasizing the role of C378 in MTSET
actions on wild-type hENT1. MTSES treatment also had no effect on [ 3H]NBMPR binding
or [3H]2-chloroadenosine uptake (Figure 4.42C, 4.42D).

4.5.9 Mutation of C416 and C439 to serines and alanines:
Cells stably transfected with the C416S and C439S mutant constructs did not produce
measurable level of hENT1 protein function, as determined by lack of 2-chloroadenosine
uptake, NBMPR binding and immunoblotting, even though mRNA for the mutant hENT1
was clearly identified in these cells. The next approach in identifying the importance of
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Figure 4.41. Characterization of PK15-C378-C414S. [3H]NBMPR binding (Panel A) and
[3H]2-chloroadenosine uptake (Panel B) of PK15-C378-414S cells. Cells were incubated
with a range of concentrations of [3H]NBMPR (abscissa) in the presence (nonspecific
binding) and absence of 10 µM NBTGR (total binding). Specific binding was determined
by total bound minus non-specific bound. Each point represents the mean ± SEM from at
least four experiments done in duplicate. Panel B shows the [3H]2-chloroadenosine
uptake of PK15-C378-414S cells that were incubated with a range of concentrations of
[3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or absence (Total uptake)
of 5 µM dipyridamole/NBTGR. Transporter-mediated uptake (Mediated) was calculated
as the difference between the total and non-mediated uptake components. Each point
represents the mean ± SEM of the cellular accumulation of [3H]2-chloroadenosine from
at least four independent experiments conducted in duplicate.
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Figure 4.42. Treatment of C378-414S with MMTS and MTSES. Effects of MMTS (Panel A
and B) and MTSES (Panel C and D) on [3H]NBMPR binding and on [3H]2-chloroadenosine
uptake of hENT1-C378-414S expressed in PK15-NTD cells. For Panel A and C, cells were
incubated with either 1 mM MMTS (Panel A), or 5 mM MTSES (Panel C) for 10 min,
washed extensively, and then incubated with a range of concentrations of [ 3H]NBMPR in
the presence and absence of 10 µM NBTGR to define total and nonspecific binding. For
Panel B and D, cells were incubated with either 1 mM MMTS (Panel B) or 5 mM MTSES
(Panel D) for 10 min, washed extensively, and then incubated with a range of
concentrations of [3H]2-chloroadenosine for 5 s in the presence (Non-mediated) or
absence (Total uptake) of 5 µM dipyridamole/NBTGR. Each point represents the mean ±
SEM of the cellular accumulation of [3H]2-chloroadenosine from at least four
independent experiments conducted in duplicate. * Significant difference from control
Bmax for NBMPR binding studies and control Vmax for uptake studies (Student's t test for
paired samples, P <0.05)
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Figure 4.43. Treatment of C378-414S with MTSET: NBMPR binding to C378-414S is
insensitive to MTSET. Effects of MTSET of [3H]NBMPR binding (Panel A) and [3H]2chloroadenosine (Panel B) uptake by hENT1-C378-414S expressed in PK15-NTD cells.
Cells were incubated with either 5 mM MTSET or 0.5% DMSO (Control) for 10 min,
washed extensively, and then incubated with a range of concentrations of [ 3H]NBMPR in
the presence and absence of 10 µM NBTGR to define total and nonspecific binding.
Specific binding was calculated as the difference between the total and nonspecific
binding components. Each point represents the mean ± SEM from at least 5 experiments
done in duplicate. Panel B describes the concentration-dependent uptake of [3H]2chloroadenosine of cells treated for 10 min with 5 mM MTSET or 0.5% DMSO (Control)
and washed three times. Cells were incubated with a range of concentrations of [ 3H]2chloroadenosine for 5 s in the presence (Non-mediated) or absence (Total uptake) of 5
µM dipyridamole/NBTGR. Transporter-mediated uptake (Mediated) was calculated as
the difference between the total and non-mediated uptake components. Each point
represents the mean ± SEM of the cellular accumulation of [3H]2-chloroadenosine from
at least four independent experiments conducted in duplicate.
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C416 and C439 was to employ an alternate mutation to alanine (C416A, C439A);
however, these mutants were also not expressed in PK15-NTD cells.

4.5.9.1 Inhibition of palmitoylation
We tested the idea that the cytoplasmically located C416 could be a target for cysteine
specific palmitoylation and therefore removal of this residue may lead to improper
protein targeting at the membrane and loss of transporter expression. However
treatment of wild-type hENT1 cells with 100 µM 2-Bromohexadecanoic acid (2-Br), a
known blocker of palmitoylation, for 24 and 48 hrs in serum-free media lead to no
changes in [3H]NBMPR binding and [3H]2-chloroadenosine uptake (Figure 4.44A, 4.44B).
These results indicated that hENT1 expression and function is unaffected by the
palmitoylation blockade by 2-Br.

4.5.9.2 Transient transfection of C416A and C439A
The two remaining cysteine mutants, PK15-C416A and PK15-C439A were analyzed
through transient transfection methods. Transient transfection of empty-p3xFLAG
vector showed no quantifiable binding of [3H]NBMPR while transfection of C416A
showed specific binding with a Kd of 0.1 ± 0.02 nM and Bmax of 4.6 ± 2.3 X 105 ENT1
sites/cell similar to wild-type (Figure 4.45A, Table 4.2). C439A bound [3H]NBMPR with a
Kd of 0.5 ± 0.1 nM and Bmax of 8.6 ± 1.4 X 105 ENT1 sites/cell (Figure 4.45B, Table 4.2) and
transported [3H]2-chloroadenosine with a Vmax of 8.4 ± 0.8 pmol/ µl/s and Km of 165 ±
32 µM (Figure 4.45C, Table 4.2). However, C416A showed no transport of [3H]2chloroadenosine (Figure 4.45C) indicating a crucial role of C416 in hENT1 function in this
mammalian expression model.
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Figure 4.44. Treatment of PK15-hENT1 with 2-bromohexadecanoic acid (2-Br). Effects
of 100 µM 2-Br treatment for 24 and 48 hrs on [3H]NBMPR binding (Panel A) and [3H]2chloroadenosine uptake (Panel B) by wild-type hENT1 expressed in PK15-NTD cells.
Transfected cells were incubated and grown in serum-free media treated with 100 µM
2-Br., a palmitoylation inhibitor or Control (DMSO) for 24 or 48 hrs. Cells were
harvested, washed and subjected to either [3H]NBMPR binding (Panel A) or [3H]2chloroadenosine uptake (Panel B) assays. Each point represents the mean ± SEM from at
least
four
independent
experiments
conducted
in
duplicate.
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Figure 4.45. Characteristics of PK15-C416A and PK15-C439A: PK15-416A does not
transport 2-chloroadenosine. [3H]NBMPR binding of PK15-C416A (Panel A), PK15-C439A
(Panel B) cells and [3H]2-chloroadenosine uptake of PK15-C416A and PK15-C439A cells
(Panel C). Cells were incubated with a range of concentrations of [3H]NBMPR in the
absence (total binding) and presence (nonspecific binding) of 10 µM NBTGR. Specific
binding was calculated as the difference between the total and nonspecific binding
components. Each point represents the mean ± SEM from at least five experiments done
in duplicate. Panel C shows the [3H]2-chloroadenosine uptake of PK15-C416A and PK15C439A cells that were incubated with a range of concentrations of [ 3H]2chloroadenosine for 5 s in the presence (Non-mediated) or absence (Total uptake) of 5
µM dipyridamole/NBTGR. Transporter-mediated uptake (Mediated) was calculated as
the difference between the total and non-mediated uptake components. Each point
represents the mean ± SEM of the cellular accumulation of [3H]2-chloroadenosine from
at least four independent experiments conducted in duplicate.
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4.5.9.3 Plasma membrane expression with biotinylation and FTH-SAENTA
Cell surface biotinylation analysis and SDS-Page Western blotting analysis were utilized
to determine C416A expression at the cell membrane (Figure 4.46A). Expression of
C416A-hENT1 was probed with anti-FLAG Ab, with Na+/K+-ATPase used as a plasma
membrane marker. Furthermore, 79 ± 6.7% of the specific binding of NBMPR to cells
expressing C416A could be inhibited by the membrane-impermeable FTH-SAENTA,
indicating that the majority of the hENT1-C416A protein was processed to the plasma
membrane. Similar levels of FTH-SAENTA mediated inhibition at the membrane of
plasma membrane hENT1 protein was found for cells expressing the wild-type hENT1
(85 ± 1.4%) and C439A (80 ± 4.4%) (Figure 4.46B). These results indicate that mutation of
C416A caused a loss in transport capability (either loss of substrate binding affinity
and/or translocation function) rather than a loss of transporter expression at the plasma
membrane.
4.5.9.4 Competitive inhibition of [3H]NBMPR binding by 2-chloroadenosine
To test whether the loss of transport function of C416A was due to a loss of substrate
binding affinity and/or translocation mechanism, we performed inhibitor assays using 2chloroadenosine as a competitive blocker of [3H]NBMPR binding. Given that the
substrate translocation site and the NBMPR binding site are essentially overlapping, the
ability of the substrate to effectively and competitively remove NBMPR from its site
indicates its affinity for the transporter (essentially Ki = Km). Unlabelled 2chloroadenosine was able to inhibit the binding of [3H]NBMPR with similar affinity in
both the hENT1-WT and hENT1-C416A transfectants (Figure 4.47). Given that the ability
of a substrate to inhibit the binding of [ 3H]NBMPR generally reflects its affinity as a
hENT1 substrate, this finding suggests that the loss of [ 3H]2-chloroadenosine transport
by hENT1-C416A was not due to a decline in transporter substrate affinity. Therefore,
the C416A mutant may be compromised in terms of its substrate translocation
mechanism.
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Figure 4.46. Analysis of the plasma membrane expression of PK15-hENT1 and PK15C416A via biotinylation and FTH-SAENTA competition assays. Panel A shows the
expression of C416A at the plasma membrane. Immunoblot analysis of cell surface
biotinylated samples obtained from untransfected PK15-NTD cells or those transfected
with hENT1 or C416A. Expression of hENT1 and C416A mutant was determined with
mouse anti-FLAG antibodies (1:2,500) (Top panel). Blots were stripped and probed with
anti-Na+, K+-ATPase antibody (1:2,500) (Bottom panel). Panel B shows the quantification
of cell-surface hENT1 by competitive inhibition assay of NBMPR and FTH-SAENTA. Cells
transfected with hENT1, C416A, or C439A were incubated with 5 nM [3H]NBMPR for 45
min in the absence or presence of either 100 nM FTH-SAENTA or 1 mM NBTGR. Cell
surface binding was calculated from Total binding (absence of inhibitors) subtracted
from the non-specific binding (1 mM NBTGR) and intracellular binding (FTH-SAENTA).
Each bar represents the mean ± SEM of three independent experiments.
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Figure 4.47. 2-chloroadenosine can effectively block NBMPR binding to C416A.
Inhibition of [3H]NBMPR binding to PK15-hENT1 and PK15-C416A with a range of
concentrations of 2-chloroadenosine. Data are shown as percent of control binding
where control is determined as specific binding of 0.5 nM [3H]NBMPR in the absence of
substrate. Each point represents the mean ± SEM of at least three experiments done
in duplicate.
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4.5.9.5 C416A and C439A MTS treatments
The effects of these mutations on the sensitivity of hENT1 to MTSET and MTSES were
then assessed in isolated membranes prepared from cells transiently transfected with
C416A or C439A. Both cysteine mutants retained [3H]NBMPR binding activity (C416A
Bmax =2.2 ± 0.4 pmol/mg, Kd = 0.08 ± 0.008 nM; C439A Bmax = 2.4 ± 0.2 pmol/mg, Kd = 0.3
± 0.06 nM) (Figure 4.48A, Table 4.3) similar to that seen for wild-type hENT1. MTSES and
MTSET inhibited [3H]NBMPR binding to the C439A mutant, similar to that seen for the
wild-type hENT1 (Figure 4.48B, 4.48C, Table 4.3). However, MTSES did not inhibit
[3H]NBMPR binding in the C416A mutant (Figure 4.49, Table 4.3). Additionally, the
effects of MTSET and MMTS were also diminished in the C416A mutant. These data
suggest that C416 is involved in the binding of NBMPR. However, co-treatment of
membranes expressing the wild-type hENT1 with MTSES and non-radiolabelled NBMPR
(10 nM) or the hENT1 substrate adenosine (10 mM) did not prevent the inhibitory
effects of MTSET on [3H]NBMPR binding (Figure 4.50A, 4.50B).

4.6 Summary of Cysteine Mutants
For the single cysteine mutants, neither the loss of the residue nor introduction of a
serine in that position altered hENT1 ability to bind NBMPR (Table 4.2). Surprisingly, the
importance of C416 was identified as a critical residue for protein expression together
with C439 (TM11), given that both of these mutants showed no measurable activity or
expression in our stable cell lines. Additionally, mutation of C416 to alanine caused a loss
of 2-chloroadenosine transport mechanism while the ability to recognize the substrate
and inhibitor NBMPR was retained. Additionally, mutation of Cys222 in TM 6 eliminated
the effect of MMTS on NBMPR binding (Figure 4.24A). We therefore have addressed the
first hypothesis in identifying the cysteine targeted by neutral thiol modification to cause
a change in hENT1 function. MTSET inhibition of [3H]NBMPR binding is abolished in C378
(Figure 4.37A) and is even more pronounced in the C414S mutant (Figure 4.40). Given
that C378 is the only cysteine predicted to lie in the extracellular space, we postulated
that removal of the downstream intracellular located C414 may cause a conformational
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Figure 4.48. Cell membrane treatment of C439A with MTSET and MTSES. [3H]NBMPR
binding by PK15-hENT1, PK15-C416A, and PK15-C439A cell membranes (Panel A) and
the effects of MTSET (Panel B) and MTSES (Panel C) on [3H]NBMPR binding by hENT1C439A cell membranes. Membranes were incubated with a range of concentrations of
[3H]NBMPR in the absence (total binding) and presence (nonspecific binding) of 10 µM
NBTGR. Each point represents the mean ± SEM from at least five experiments done in
duplicate. For Panel B and C, membranes were incubated with either 5 mM MTSET (blue
squares), or 5 mM MTSES (green squares) for 10 min, washed extensively, and then
incubated with a range of concentrations of [3H]NBMPR in the presence and absence of
10 µM NBTGR to define total and nonspecific binding. Each point represents the mean ±
SEM from at least 5 experiments done in duplicate. * Significant difference from control
Bmax (Student's t test for paired samples, P <0.05).
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Figure 4.49. Treatment of C416A with MMTS, MTSET, MTSES: NBMPR binding to C416A
is insensitive to MTS reagents. Effects of MMTS, MTSET, and MTSES on [3H]NBMPR
binding by hENT1-C416A expressed in PK15-NTD cell membranes. Membranes were
incubated with either 1 mM MMTS, 5 mM MTSET, or 5 mM MTSES for 10 min, washed
extensively, and then incubated with a range of concentrations of [ 3H]NBMPR in the
presence and absence of 10 µM NBTGR to define total and nonspecific binding. Bmax
were calculated from nonlinear regression analysis was used to fit hyperbolic curves to
the site-specific binding of [3H]NBMPR plotted against the free [3H]NBMPR
concentration at steady-state. Each bar represents the mean± SEM from at least four
experiments done in duplicate. * Significant difference from their respective untreated
control Bmax (Student's t test for paired samples, P <0.05).
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Table 4.3. Effects of MTS reagents on [3H]NBMPR binding (Bmax) by cell membranes
transfected with hENT1 and with C416A or C439A cysteine mutants. Membranes were
prepared from cells 24 hr following transfection with the indicated hENT1 construct.
The isolated membranes were then assessed for their level of site-specific [3H]NBMPR
binding as described for Fig. 4.48. Values shown are the means ± SEM from at least three
independent experiments conducted in duplicate. * Significant difference from control
(Student's t test for paired samples, P <0.05).

[3H]NBMPR Binding
Bmax (pmol/mg)
Cell Line

MTS Reagent Control
Treated
hENT1-WT MMTS
1.24 ± 0.34

C416A

C439A

Treated
1.03 ± 0.17

MTSET

3.15 ± 0.94

0.78 ± 0.28*

MTSES

3.19 ± 1.51

1.92 ± 0.85*

MMTS

1.23 ± 0.19

1.42 ± 0.29

MTSET

2.73 ± 1.17

2.30 ± 1.14

MTSES

2.33 ± 0.97

2.34 ± 0.97

MMTS

0.99 ± 0.23

0.78 ± 0.08

MTSET

4.29 ± 1.78
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Figure 4.50. NBMPR and adenosine are unable to protect against MTSES effects in
membranes. Crude membranes isolated from PK15-NTD cells transfected with hENT1
were incubated for 10 min at room temperature with 0.5% DMSO (control), 10 nM
NBMPR (Panel A) or 1 mM adenosine (Panel B), 5 mM MTSES, or the combination of 10
nM NBMPR and 5 mM MTSES or 1 mM adenosine and 5 mM MTSES. After extensive
washing to remove NBMPR/adenosine and unreacted MTSES, membranes were exposed
to a range of concentrations of [3H]NBMPR in the presence and absence of 10 µM
NBTGR to define the site-specific binding. Each point is the mean ± SEM from at least
four experiments conducted in duplicate. * Significant difference from control Bmax
(Student's t test for paired samples, P <0.05).
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change in the protein to increase accessibility to C378. Therefore, we performed a
double mutation of C378S and C414S and tested MTSET inhibition of NBMPR binding.
Removal of C378 in addition to C414 eliminated the [3H]NBMPR binding inhibition seen
in both wild-type and C414S mutant (Figure 4.43A). This provided more evidence that
C378 was the extracellularly located residue interacting with MTSET to inhibit binding.
Additionally, this result suggested a structural cooperation between the two residues in
two different domains (TM9 and intracellular loop 5) in forming the NBMPR binding
pocket. Lastly, in cell membrane preparations, mutation of C416 to serine abolished the
inhibitory effects of MTSES on NBMPR binding seen in wildtype hENT1 (Figure 4.49). This
identified C416 as the intracellular residue responsible for negatively charged thiol
modification indirectly involved in the NBMPR binding structure and supported the
second hypothesis of this study. Given that neither 10 nM NBMPR nor 10 mM adenosine
were able to protect against MTSES effects (Figure 4.50A, 4.50B), we infer that C416
does not directly interact with the ligand but may induce an indirect conformational
change in structure.

4.7 SCAM analysis of Extracellular loop 5
The preceding data in section 4.5 revealed a role for the C-terminus of hENT1 in NBMPR
binding and substrate uptake. These date suggest a functional interaction between C378
(TM9) and C414 (IL5), C416 as a critical amino acid involved in hENT1 functionality also
located in IL5, and C378 as the target residue for MTSET inhibition of NBMPR binding.
Therefore, it is of interest to determine how this C-terminal region of hENT1 interacts
functionally and structurally with the TM3-6 region that has been defined previously as
the part of hENT1 critical to transporter function and ligand binding [134]. As thus, or
third hypothesis in Chapter 2 was that residues in extracellular loop 5 are involved in the
extracellular binding pocket of hENT1. To determine their roles in hENT1 functionality,
we used the MTSET-insensitive C378S mutant transporter as the background template,
and the 16 residues of EL5 sequentially replaced with cysteines and then tested for their
ability to bind NBMPR and transport 2-chloroadenosine in transiently transfected PK15
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cells. Each mutant was also assessed for MTSET accessibility to determine whether they
could be located for thiol modification.
4.7.1 Assessment of [3H]NBMPR binding for EL5 mutants
The 16 EL5-cysteine mutants were individually assessed for their ability to bind NBMPR
in whole cells. Figure 4.51A showing [3H]NBMPR binding to PK15-N379C in cells is a
representation of the nature of the analysis performed on the other 15 EL5 mutants. All
of the 16 mutants were able to bind NBMPR with high affinity (Figure 4.51B) indicating
that neither loss of these residues nor the introduction of cysteine at that position
abrogated the NBMPR binding site in a critical manner.
4.7.2 Assessment of [3H]2-chloroadenosine uptake for EL5 mutants
The 16 EL5-cysteine mutants were also individually assessed for their ability to transport
[3H]2-chloroadenosine. Figure 4.52A showing [3H]2-chloroadenosine uptake of PK15I380C into cells is a representation of the nature of the analysis performed on the other
15 EL5 mutants. Our results indicate that eleven of the EL5-cysteine mutants were able
to transport [3H]2-chloroadenosine however, N379C, F390C, E391C, H392C, and D393C
showed no measurable uptake of [3H]2-chloroadenosine (Figure 4.52B).

4.7.2.1 Expression of N379C, F390C, E391C, H392C, and D393C at the membrane
To determine whether the loss of function from the five EL5-cysteine mutants was due
to a loss of expression at the plasma membrane, we performed FTH-SAENTA inhibition
assays. Extracellular binding sites for NBMPR were calculated from transfected cells
incubated with and without FTH-SAENTA which is membrane impermeable and hence
will block the binding of NBMPR at extracellular sites. N379C, F390C, E391C, H392C, and
D393C all showed high levels of hENT1 expression at the plasma membrane at
approximately the same levels as seen with wild-type hENT1 (Figure 4.53).
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Figure 4.51. EL5 mutants bind NBMPR with high affinities. Binding affinities of
[3H]NBMPR to wild-type hENT1, hENT1-C378S, and hENT1-extracellular loop 5 cysteine
mutants. Binding affinities were determined from nonlinear regression analysis used to
fit hyperbolic curves to the site-specific binding of [3H]NBMPR plotted against the free
[3H]NBMPR concentration at steady-state (example of the analysis shown in Panel A).
Panel B depicts the binding affinities (Kd) shown in nM; solid bars represent the mean±
SEM from at least six experiments done in duplicate. * Indicates a significant difference
from WT affinity (P < 0.05 one-way ANOVA : Dunnett’s post-test) *** Indicates a
significant difference from WT affinity (P <0.001 one way ANOVA: Dunnett’s post-test)
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Figure 4.52. N379C, F390C, E391C, H392C, and D393C show no measurable uptake of
[3H]2-chloroadenosine. Transport affinities of [3H]2-chloroadenosine to wild-type
hENT1, hENT1-C378S, and hENT1-extracellular loop 5 cysteine mutants. Transport
affinities were determined from non-linear regression analysis of Michaelis-Menten
fitted uptake, calculated as the difference between the total and non-mediated uptake
components (example of the analysis shown in Panel A). Panel B depicts the substrate
affinity shown in µM; solid bars represents the mean ± SEM from at least three
experiments done in duplicate. * Indicates a significant difference from WT affinity (P <
0.05 one-way ANOVA : Dunnett’s post-test) where five EL5 mutants showed no
transport of [3H]2-chloroadenosine.
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Figure 4.53. Quantification of cell-surface hENT1 by competitive inhibition assay of
NBMPR and FTH-SAENTA of N379C, F390C, E391C, H392C, or D393C. Cells transfected
with N379C, F390C, E391C, H392C, or D393C were incubated with 5 nM [3H]NBMPR for
45 min in the absence or presence of either 100 nM FTH-SAENTA or 1 mM NBTGR. Cell
surface binding was calculated from Total binding (absence of inhibitors) subtracted
from the non-specific binding (1 mM NBTGR) and intracellular binding (FTH-SAENTA).
Each bar represents the mean ± SEM of three independent experiments.
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4.7.2.2 Competitive inhibition with 2-chloroadenosine
To determine whether the loss of [3H]2-chloroadenosine transport was due to a loss of
transport mechanism or a loss of substrate affinity for the transporter, we performed
competitive inhibition assays using non-labeled 2-chloroadenosine as our competitive
inhibitor. 2-chloroadenosine was able to inhibit the binding of [ 3H]NBMPR with similar
affinity to the N379C, F390C, E391C, H392C, and D393C mutants (Figure 4.54). This
suggests that the loss of [3H]2-chloroadenosine transport by these five mutants was not
due to a loss of substrate recognition of the transporter but rather to the disruption of
the translocation mechanism.

4.7.3 Effects of MTSET on extracellular loop five mutants
To determine if amino acids in EL5 when mutated to cysteine were sensitive to MTSET
modification, PK15-EL5 mutants were treated with 5 mM MTSET and tested for
[3H]NBMPR binding as depicted in Figure 4.55A using the N379C mutant as an example
of how the analyses were performed. Treatment of MTSET caused an inhibition of
NBMPR binding in all EL5-cysteine mutants except for V389C. Inhibition of binding
ranged from 10-50% decreases in Bmax (Figure 4.55B).

4.7.3.1 Protection against the effects of MTSET on extracellular loop five mutants with
NBMPR
To determine whether residues in EL5 that were sensitive to MTSET could be protected
from thiol modification, cells were co-incubated with NBMPR and MTSET. Figure 4.56A
showing [3H]NBMPR binding to PK15-I380C after co-incubation with NBMPR and MTSET
is a representation of the protection experiments performed on the rest of the EL5
mutants.

Our results indicated that co-incubation with NBMPR blocked MTSET

inhibitory effects on N379C (Figure 4.56B). This indicated that NBMPR may have direct
contact or be in very close vicinity with N379C where its binding can block MTSET
modification.
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Figure 4.54. 2-chloroadenosine can effectively block NBMPR binding to N379C, F390C,
E391C, H392C, or D393C. Inhibition of [3H]NBMPR binding to PK15-N379C, PK15-F390C,
PK15-E391C, PK15-H392C, and PK15-D393C with a range of concentrations of 2chloroadenosine. Data are shown as percent of control binding where control is
determined as specific binding of 0.5 nM [3H]NBMPR in the absence of substrate. Each
point represents the mean ± SEM of at least three experiments done in duplicate.
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Figure 4.55. NBMPR binding of all EL5 mutants except V389C are sensitive to MTSET.
Effects of MTSET on [3H]NBMPR binding by hENT1-mutants expressed in PK15-NTD
cells. Cells were treated with 5 mM MTSET for 10 min, washed extensively, and then
assessed for [3H]NBMPR as mentioned in methods. Bmax were calculated from nonlinear
regression analysis was used to fit hyperbolic curves to the site-specific binding of
[3H]NBMPR plotted against the free [3H]NBMPR concentration at steady-state as
depicted in Panel A. Panel B depicts the inhibition of specific binding of [3H]NBMPR to
PK15-hENT1 and EL5 mutants calculated from their respective controls (DMSO treated);
solid bars represents the mean± SEM from at least three experiments done in duplicate.
The blue box indicates the residue insensitive to MTSET inhibition of NBMPR binding.
* Significant difference from each mutants respective control Bmax (Student's t test for
paired samples, P <0.05).
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Figure 4.56. NBMPR is able to protect N379C against MTSET effects in cells. Coincubation of MTSET with 10 nM NBMPR. PK15-hENT1 cells transfected with wild-type
hENT1 or cysteine mutants were incubated for 10 min at room temperature with 0.5%
DMSO (control), 10 nM NBMPR (+NBMPR), 5 mM MTSET (+MTSET) or the combination
of 5 mM MTSET+ 10 nM NBMPR. After extensive washing to remove NBMPR and unreacted MTSET, cells were exposed to a range of concentrations of [3H]NBMPR in the
presence and absence of 10 µM NBTGR to define the site-specific binding as shown in
Panel A for the I380C mutant. Panel B depicts the inhibition of specific binding of
[3H]NBMPR to PK15-hENT1 and EL5 mutants calculated from their respective controls
(DMSO treated); solid bars represents the mean ± SEM from at least three experiments
done in duplicate. Blue box indicated where NBMPR was able to protect against MTSET
effects. * Significant difference from MTSET treated inhibition of NBMPR binding Bmax
(Student's t test for paired samples, P <0.05).
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4.7.3.2 Protection against the effects of MTSET on extracellular loop five mutants with
adenosine
To determine if modified cysteines in EL5 could also become protected by a substrate,
cells were co-incubated with adenosine and MTSET and then tested for changes in
[3H]NBMPR binding. Figure 4.57A showing [3H]NBMPR binding to PK15-N379C after coincubation with adenosine and MTSET is a representation of the protection experiments
performed on the rest of the EL5 mutants. In this manner, the separate binding
determinants could be distinguished for substrates and inhibitors. Co-incubation of
adenosine blocked MTSET inhibitory effects on R384C, Y385C, L386C (Figure 4.57B).
These residues are predicted to be in the middle of the extracellular loop and could
therefore have direct contact with adenosine to prevent that large positively charged
reagent to react.

4.8 Summary of EL5 mutants
For the 16 individual cysteine mutations in EL5, all 16 mutants retained the ability to
bind NBMPR with high affinity. This indicated that none of the amino acids in EL5 are
critical for NBMPR to bind. However, five of the 16 mutants lost the ability to transport
2-chloroadenosine (N379C, F390C, E391C, H392C, and D393C). This loss of transport was
attributed to a complication in the transport mechanism as the mutant transporters
were expressed at the membrane and retained the ability of 2-chloroadenosine to
inhibit NBMPR binding. Finally, it was found that all residues except for V389C were
sensitive to MTSET inhibition of binding indicating that modification at those sites
impacted NBMPR binding. NBMPR co-incubation protected N379C indicating that it may
be in close proximate location to the inhibitor recognition site. Additionally, adenosine
co-incubation protected R384C, Y385C, and L386C indicating their possible involvement
in adenosine interactions with the transporter.
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Figure 4.57. Adenosine protects R384C, Y385C, and L386C against MTSET effects in
cells. Co-incubation of MTSET with 1 mM adenosine. PK15-hENT1 cells transfected with
wild-type hENT1 or cysteine mutants were incubated for 10 min at room temperature
with 0.5% DMSO (control), 1 mM adenosine, 5 mM MTSET, or the combination of 5 mM
MTSET + 1 mM adenosine. After extensive washing to remove adenosine and un-reacted
MTSET, cells were exposed to a range of concentrations of [3H]NBMPR in the presence
and absence of 10 µM NBTGR to define the site-specific binding as depicted in Panel A
with the N379C mutant. Panel B depicts the inhibition of specific binding of [3H]NBMPR
to PK15-hENT1 and EL5 mutants calculated from their respective controls (DMSO
treated); solid bars represents the mean± SEM from at least three experiments done in
duplicate. Blue box indicated where adenosine was able to protect against MTSET
effects. * Significant difference from MTSET treated inhibition of NBMPR binding Bmax
(Student's t test for paired samples, P <0.05).
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Chapter 5: Discussion
In mammalian cells, nucleoside and nucleoside analogue transport processes are
mediated through two major protein families termed CNTs and ENTs [42, 51]. A major
contributor to these transport processes is the hENT1 subtype which is selectively
inhibited by NBMPR at nanomolar concentrations and by coronary vasodilators with
high affinities [114-117]. Functionally, TM 3 to 6 have been observed to be necessary for
inhibitor binding [134, 135]. This region of TM3-6 is also predicted to be the site where
substrates are recognized for transport. Results from human and rat chimeric studies
where mutants missing TM3-6 were unable to bind NBMPR or transport uridine. In this
manner, the NBMPR binding site and the substrate translocation pathway are suggested
to overlap since NBMPR is able to competitively inhibit substrate transport [86, 133,
136]. Conversely, increasing concentrations of substrates competitively inhibit NBMPR
binding to hENT1. This indicates that the functional substrate binding site of hENT1 and
the site to which NBMPR binds are within the same region.
The coronary vasodilators, which act as ENT1 inhibitors, were also found to
inhibit both NBMPR binding and nucleoside transport in a competitive manner and the
region of TM3-6 is again indicated in their sensitivities [82, 179, 186]. However,
mutagenesis studies on hENT1 involving TM1 and TM11 (outside of the TM3-6 domains)
have indicated the possibility that these TM domains are relatively proximal to each
other [100, 187]. Mutagenesis of Leu442 in TM11 altered sensitivities to NBMPR and
dipyridamole when Met33 in TM1 was first mutated to isoleucine. This suggested that
regions outside of TM3-6 also play essential structural and functional roles for hENT1.
However, information on how hENT1 folds into the membrane as well as the important
functional features of hENT1 is still unknown. Understanding how the TM domains and
loops are arranged will allow for the development of effective isoform-specific inhibitors
and generation of selective cytotoxic nucleoside analogues targeted for hENT1. The
current inhibitors of nucleoside transport, except for NBMPR, are not selective for the
ENT1 subtype and may inhibit several subfamilies of nucleoside transporters, which may
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not be favorable for targeted therapies. The same is true for the cytotoxic nucleoside
analogues, as they are able to use multiple families of nucleoside transporters to
produce their effects which could be unfavorable for host cell preservation [188].
Therefore, the physiological and pharmacological properties of these agents are
dependent on their specificity and selectivity to nucleoside transporters. Due to the
unavailability of 3-D crystal structures of hENT1, structure function studies on hENT1
rely heavily on mutagenesis approaches.
Prior to this thesis, it was suggested that cysteines may play an important role for
ENT1 function since treatment with thiol modifying reagents such as pCMBS and NEM
altered NBMPR binding and substrate translocation [157, 171, 172, 174]. However, the
location and contribution of these residues remained unknown. This study explored the
hENT1 permeant site by targeting cysteine residues and the region of the C-terminus to
better understand the specific functional determinants involved in transporter activity.
Since hENT1 is an integral membrane protein and not readily isolated for biophysical
analysis, the relationships between various regions of the protein have not yet been
delineated. An approach commonly used for such intransigent proteins, is cysteine
scanning mutagenesis to assess the aqueous accessibility of various regions of the
protein given that cysteines can be targeted for chemical modification with a wide
variety of sulfhydryl modifying reagents. The use of this technique has been applied to
several integral membrane proteins such as P-glycoprotein (Pgp) and glucose
transporter (Glut1) to reveal information on protein topology and ligand binding
domains [168, 189-191]. For example, cysteine scanning mutagenesis of the Glut1
transporter found predicted exofacial residues of TM 7 to be accessible to the external
aqueous environment and provided support for the placement of TM7 in the glucose
permeation pathway. However, this approach requires a clear understanding of the
roles of endogenous cysteines in transporter function, which has been addressed in this
study. Additionally, although it is known that TM3-6 are critical for hENT1 transporter
function, it is also important to determine if and how other regions contribute to the
binding pocket as recent evidence points toward the involvement of these flanking
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domains of hENT1. We targeted the region of EL5 and found it to be indirectly involved
in the NBMPR binding pocket as well having singular residues critical in substrate
translocation.

5.1 Wild-type hENT1 is sensitive to neutral and positively charged thiol modification
To initially assess the involvement of cysteine residues in hENT1 function, we used the
sulfhydryl modifiers MMTS, MTSET, and MTSES (Figure 1.12) to probe with free
accessible thiols and determine their relative location and purpose. The reaction of MTS
reagents to free sulfhydryls is via a nucleophilic attack of the thiolate anion (RS-) to the
disulfide bond (-S-S-) of the MTS reagent resulting in the formation of a mixed disulfide.
The present study supports previous work from our lab where the neutral and therefore
membrane permeable sulfhydryl reagent MMTS, like NEM, caused an increase in
NBMPR Bmax of hENT1 in whole cells (Figure 4.5A) [174]. In contrast with what was
observed with NEM, this same treatment caused a decrease in the maximal rate of
uptake of [3H]2-chloroadenosine (Figure 4.5C). This finding is contrary to general dogma
in the field that changes in NBMPR binding site numbers reflect changes in ENT1mediated transport capacity [86]. Under many conditions, it has been shown that
NBMPR binding sites are proportional to Vmax values for nucleoside uptake in
erythrocytes suggesting that the presence of NBMPR-binding sites can be used as a
measure of functional ENT1 transporters [192]. However, our study demonstrates that
this assumption should be confirmed before further analyses are taken. While such
striking conflicting results have not been reported previously, there have been reports
where changes in nucleoside uptake did not correlate with the changes in the amount of
transporter present at the cell membrane. Our data imply that the ‘increased’ NBMPR
binding sites induced by MMTS treatment are not actually functional transporters at the
plasma membrane [71]. This suggests that not all hENT1 exhibiting high-affinity
[3H]NBMPR binding are necessarily functional transporters, and may reflect different
hENT1 subpopulations within the cell as previously described [67, 193-195].

One

possibility is that MMTS treatment may have caused an increase in NBMPR binding sites
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found within membranes of intracellular organelles. It has been shown that expression
of hENT1 has been found in nuclear membranes, endoplasmic reticulum, and
mitochondria suggesting that there is a mix of subpopulations of hENT1. These
transporters have also been shown to be functionally active at those sites, suggesting
that they play a role in the transport of nucleosides between the cytosol and lumen of
these organelles.
In times of high growth and energy consumption, it is possible that the increased
presence of these transporters is needed to fuel these processes. Additionally,
nucleoside analogues, which exhibit clinical mitochondrial toxicity, have been correlated
to nucleoside transporter expression at mitochondrial membranes [196-198]. In one
case, the overexpression of hENT1 in MDCK cells resulted in enhanced mitochondrial
toxicity of the hepatitis B uridine analog Fialuridine (FIAU)[97]. According to this
reasoning, the separate effects of MMTS on hENT1 function may be due to its
modification of transporters found in two separate membrane populations. The
difference between MMTS treatments in whole cells versus membranes from cells
pretreated with MMTS may also be explained in this way. A reduction in the number of
binding sites was observed in membrane preparations of cells pre-treated with MMTS
(Figure 4.6A), indicating the loss of intracellular compartments (such as nuclei and
mitochondria) by differential centrifugation may be involved in the loss of the Bmax
enhancement. It may be possible that MMTS is modifying those transporters in whole
cell experiments to cause an increase in Bmax and this hENT1 population is lost during cell
membrane preparations. Furthermore, incubating cells with MMTS in 50 mM Tris at a
pH of 8.2 eliminated the ability of MMTS to enhance the binding of [3H]NBMPR (Figure
4.7C). This indicated that basic pH either increased hydrolysis of the thiol modifier
destroying the active reagent or caused de-protonation of the protein causing thiol
moieties to become unreactive. To test this hypothesis, we compared the effects of
varying pH on [3H]NBMPR binding and [3H]2-chloroadenosine uptake by hENT1. Our
results found that buffers of basic pH (both Tris and NMG) enhanced [3H]NBMPR Bmax by
approximately 50% compared to [3H]NBMPR binding in pH 7.4 indicating that the
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transporter was sensitive to enhanced pH and hydrogen ion concentrations (Figure 4.9A,
4.9B). The result that pH altered NBMPR binding and not substrate transport (Figure
4.9C) indicates that the increase in binding sites may not reflect functional transporters
at the plasma membrane but may be due to exposing previously hidden binding sites.
In addition to the MMTS enhancement of NBMPR binding in whole cells, we
observed a decrease in NBMPR binding with MTSET, the positively charged reagent
(Figure 4.13A). Prior to this study, sulfhydryl reagents used to probe ENT1 have included
those that were neutral (NEM) or negatively charged (pCMBS) [157, 172, 174, 199, 200].
As mentioned previously, pCMBS had no effect on ENT1 in intact cells in the same way
that the negatively charged MTSES had no effect in the present study (Figure 4.12A,
4.12C). However, positively charged MTSET appeared able to access and modify a
cysteine in intact cells which caused changes in both [3H]NBMPR binding and [3H]2chloroadenosine uptake. This indicates that there is a cysteine that can be accessed by
MTSET located in a hydrophilic region or extracellularly that has an impact on the
permeation site or pathway. Either blocking of a cysteine thiol or the introduction of a
large positively charged alkyl group caused a change in transporter conformation to alter
the number of NBMPR binding sites as well as substrate uptake velocity. An increase in
Vmax with MTSET treatment may result from an increase in mobility of the transporter
due to increased plasticity (Figure 4.13C). Transporter plasticity has been shown to have
an impact on substrate translocation rates in hENT2 as mutational analysis at residue
isoleucine 33 to methionine was found to have increased Vmax values for purine
nucleosides [187]. Additionally, mutation of methionine 89 to cysteine and
phenylalanine 334 to tyrosine of hENT1 both increase Vmax relative to wild-type hENT1,
indicating that they possessed increased rates of catalytic turnover [138, 143]. In our
case, it is possible that MTSET modifies a cysteine in a manner that causes a minor
distortion at the NBMPR binding site, while making the substrate binding site more
transport active. These findings suggest that there are two separate cysteines involved
in hENT1 ligand conformation; one located in a region that is accessible only to MMTS
and another in an extracellular, possibly negatively charged region accessible to MTSET.
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Given that C378 is the only cysteine predicted to lie at the extracellular face of the
transporter shown in Figure 2.1 ( and potentially close to negatively charged residues
E391 and D393 on the opposite end of extracellular loop 5), it was predicted as being the
target residue for the membrane impermeable reagent MTSET (Figure 5.1). The present
study also highlighted again the contribution of intracellular cytoplasmic cysteines to the
transport/binding competence of hENT1. Treatment with MMTS, MTSES, and MTSET all
caused a significant decrease in NBMPR binding Bmax in broken cell preparations (Figure
4.5B, 4.12B, 4.13B) showing that modification of intracellular cysteines produces an
impact on NBMPR binding, known to be located on the exofacial surface. As previously
mentioned, the negatively charged reagent pCMBS has been shown in multiple models
to modify intracellularly located cysteine(s) to cause a decrease in NBMPR binding to
ENT1. Given that C414 and C416 are predicted to be located on the 5 th intracellular loop
of hENT1, it is suggested that they are the possible targets of this type of modification.

5.2 Assessment of single cysteine to serine mutants
To determine which of any of the ten cysteines in hENT1 were important for its function
and which are implicated in MTS mediated effects, site-directed mutagenesis was used
to replace cysteine residues with serines or alanines. We found the transport and
binding activities of the C87S, C193S, C213S, C222S, C297S, C333S, C378S, and C414S
mutants to be comparable to that of wild-type hENT1. This indicated that none of these
residues are crucial for substrate binding or protein expression. Though there were
some significant differences in the affinity of [3H]NBMPR and [3H]2-chloroadenosine for
the various mutants, these relatively minor differences in affinity (under 2-fold in most
cases) likely reflect subtle shifts in the overall structure of the inhibitor/substrate
binding domains due to minor disruptions of the hydrogen bonding network maintaining
tertiary structure. Specifically, C87S, C193S, C222S and C297S each had a slightly higher
affinity for [3H]NBMPR relative to the wild-type ENT1. Additionally, C87S and C193S had
a significantly higher affinity for [3H]2-chloroadenosine in the cellular uptake transport
assays, as did C333S and C414S. This indicated that mutation of these residues into
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Figure 5.1 Predicted topology of hENT1 with C378 highlighted in grey as the target
residue for positively charged thiol modification with MTSET (+). Negatively charged
amino acids found in predicted extracellular regions are highlighted in blue and
suggested to be in close vicinity to C378. Residues highlighted with orange are residues
that have been implicated in enhanced Vmax of substrate transport similar to the effect
of
MTSET
on
hENT1
[3H]2-chloroadenosine
uptake
in
cells.
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serines could have produced a change in the conformation of hENT1 for increased
substrate affinity.
However, mutation of C416 or C439 to either a serine or alanine was not
tolerated in our stable mammalian cell model where there was no ENT1 expression
observed either via NBMPR binding or Western blotting. These results suggest important
roles for C416 located in the 5th intracellular loop and C439 located in TM11 in the
proper post-transcriptional processing of the hENT1 protein. These results differ from
previous studies with mENT1Δ11, the functional mENT1 splice variant that is truncated
after TM8, where loss of the last three TM helices and associated loops did not alter its
expression or basic functionality [157]. Additionally, our results diverges from those of
previous studies on the ENT parasitic homologs in Plasmodium falciparum ENT1
(PfENT1) and Leishmania donovani ENT (LdNT1.1) [201, 202] where expression and
function of cysteine-less versions of ENT1 have been described. This difference could
reflect species differences in ENT1 structure/processing, or the different heterologous
expression models used. A recent study has also demonstrated the activity of a cysteineless version of hENT1 (hENT1C-) in which all 10 endogenous cysteine residues were
mutated to serine [203]. However, this study utilized an enhanced expression vector
pGEMHE in Xenopus oocytes to characterize hENT1C-, where as in our model we have
utilized a mammalian expression system that may differ in cellular environment by
potentially employing more complex posttranslational modifications. Since cysteines can
be palmitoylated and contribute to protein trafficking and membrane tethering, we
tested the hypothesis that C416 and C439 were targets for this post-translational
modification. Though C416 was predicted to be palmitoylated (CSS-Palm 3.0), our study
determined that the palmitoylation inhibitor 2-Br had no effect on hENT1 function
(Figure 4.44) suggesting that C416 was not acting as a palmitoylation site. At closer
inspection, the location of C439 was noted to be adjacent to the conserved GxxxG motif.
The GxxxG motif often associates in helix-helix interactions specifically as a dimerization
arrangement [204-206]. It is possible that mutation of C439 abrogates this motif and
interrupts interactions that could be essential for protein folding and assembly.
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Unpublished work from our lab by Cunningham, F. et al., has validated the importance
of this motif. Mutation of G445 to leucine in hENT1 was not tolerated and could not be
expressed despite transfection of the cells being confirmed by mRNA extraction and
subsequent DNA sequencing, similarly to that observed here for C416S and C439A
mutants. Additionally, it is noted that the pig kidney epithelial cells used for expression
of human ENT1 may have modified cellular characteristics due to earlier methods on
selecting for nucleoside transporter deficiency.
Furthermore, an endoplasmic reticulum retention signal (KKVK) is found between
C416 and C439 (three amino acids downstream of C416) which could also explain their
ineffectual expression. This motif is used as a quality control signal within the cell to
determine whether proteins are destined for degradation, secretion, or expression [207,
208]. The proximity of these residues to the motif raises the possibility that
displacement or adjustment of the signal sequence may result in altered sorting and
trafficking of mutant proteins and therefore impacting their expression in our stable
mammalian cell models. However, transient expression of these constructs did result in
the expression of hENT1 protein as defined by immunoblotting and NBMPR binding. This
suggested that chronic expression of these mutant proteins was deleterious to cell
function and that they were degraded via the cellular unfolded-protein response
mechanisms.

5.2.1 Mutation of C416 to alanine alters the transport mechanism
With expression in transient transfection models, we assessed the ability of C416A and
C439A to bind [3H]NBMPR and transport [3H]2-chloroadenosine (Figure 4.45A, 4.45B).
We found C439 to bind NBMPR with relatively high affinity and transport [3H]2chloroadenosine as well (Figure 4.45C). Surprisingly the C416A mutant bound
[3H]NBMPR with high affinity, but was unable to transport [3H]2-chloroadenosine (Figure
4.45C). This suggested that the loss of C416 or introduction of alanine at that position
produced two separate effects at the inhibitor site and the substrate site. To determine
whether this change in transport competance was due to a loss of hENT1 expression at
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the plasma membrane, as NBMPR can bind to intracellular hENT1 sites in other cell
compartment membranes. C416A expression levels were measured at the plasma
membrane by cell surface biotinylation and FTH-SAENTA competition assays (Figure
4.46A, 4.45B) but no difference between wild-type hENT1 and C416A and C439A was
detected suggesting that C416A was found at the plasma membrane but was not
transporting.
To determine whether this loss of function was due to loss of recognition for the
substrate or due to loss of the transport mechanism, it was determined that 2chloroadenosine inhibited the binding of [3H]NBMPR both the hENT1-WT and hENT1C416A transfectants with similar affinity (Figure 4.47).

This indicates that 2-

chloroadenosine can still interact with hENT1-C416A with high affinity but is not able to
activate the transport mechanism. Given that the ability of a substrate to inhibit
[3H]NBMPR binding generally reflects its affinity as a hENT1 substrate, this finding
suggests that the loss of [3H]2-chloroadenosine transport by hENT1-C416A was not due
to a decline in transporter substrate affinity. Therefore, the C416A mutant may be
compromised in terms of its substrate translocation mechanism. A similar effect has
been observed for mutations at glycine 179 in TM5 where substitutions with amino acids
with large side chains such as leucine or valine eliminated transporter activity but had no
effect on membrane expression [139]. Once again, if using the ab initio model, the
endofacial ends of TM10 and TM5 are located are in close proximity to one another and
more importantly are positioned in a “V” shape within the membrane (Figure 5.2). Given
that C416 is close to the cytoplasmic end of TM10, it is possible that mutation at this site
alters the positioning of TM10 thereby shifting the hydrophilic space between TM5 and
10 and abolishing transport.
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Figure 5.2. Simulated topologies of hENT1 based on the ab initio model of LdNT1.1.
Panel A shows a side view of the generated figure of hENT1 with numbered
transmembrane helices based on the models described by Valdes et al., 2009. [156]
shown in Panel B. Cys416 is shown in the green circle off the predicted site of
intracellular loop 5. Dashed green lines illustrate the potential interaction between TM5
and TM10.

146
5.2.2 Cysteine 222 is responsible for MMTS effects
When the functional mutants were treated with MTS and then subjected to NBMPR
binding analysis, we found that mutation of the conserved cysteine at position 222
(C222) in TM 6 to serine resulted in the loss of MMTS sensitivity (Figure 4.24A). This
suggested that C222 is responsible for the enhancement of activity observed after
MMTS treatment of wild-type hENT1. For further validation, C222S was exposed to
MMTS and then membranes were isolated and NBMPR binding assays were performed.
Interestingly, C222S did not display the same decrease in NBMPR binding sites in the
membranes under these conditions as it did with experiments using the wild-type hENT1
cells (Figure 4.26A, 4.26B). As neither of the other charged thiol reagents (MTSET and
MTSES) enhanced NBMPR binding, it indicates that they were not able to access and
modify C222 because of its location. Since MMTS is a neutral membrane permeable
reagent and enhances NBMPR binding by targeting C222, it is reasonable to conclude
that C222 is located in a hydrophobic region and validates our first hypothesis in which
there is a cysteine in a hydrophobic domain that can be modified to alter hENT1
function. In support of this conclusion, it is worth noting that C222 is adjacent to
hydrophobic amino acids like isoleucine and leucine which can be critical for membrane
insertions and anchoring (Figure 5.3). For MMTS to modify C222, it is possible that loss
of the thiol functional group increases lipophilicity at the end of TM6 to free previously
hidden binding sites within the cell. However, when MMTS was applied directly to
broken cell preparations of C222S, the number of NBMPR binding sites still declined
similar to that observed using wild-type hENT1 cell membranes, indicating that C222S
was not responsible for the reduction in NBMPR binding under these conditions.
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Figure 5.3 Predicted topology of hENT1 with C222 highlighted in grey as the target
residue for neutral thiol modification with MMTS. Hydrophobic amino acids of
transmembrane 6 are highlighted in red and suggested to be in close vicinity to C222.
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Therefore, it is suggested that MMTS has a dual effect on NBMPR binding to
hENT1 involving at least two distinct cysteine residues. In intact cells, MMTS both
enhances NBMPR binding via modification of the intra-membrane C222, and inhibits
NBMPR binding via modification of another cysteine residue cytoplasmically located,
most likely C416. The enhancement of NBMPR binding via C222 is lost upon cell lysis and
subsequent differential centrifugation to prepare the membranes, leaving only the
inhibitory component. This suggests that the enhancing effect of MMTS relies on other
intracellular components, or it involves ENT1 proteins in intracellular compartments that
are lost during the membrane preparation. The effect of MMTS could not be reversed by
co-incubation of the cells with adenosine or NBMPR. Hence C222 that MMTS is
interacting with is either not directly part of the binding domain or MMTS can still gain
access to this residue in spite of the proximity of these agents. Furthermore, mutation of
C222 to serine was also able to abolish the effect that basic pH had on [3H]NBMPR
binding (Figure 4.28). This suggested that C222 was responsible for causing an increase
in [3H]NBMPR binding when cells were incubated in basic pH. It may be possible that
C222 becomes deprotonated in basic pH and that this change in reactivity of the residue
causes [3H]NBMPR to bind to more intracellular sites. Given that both MMTS and basic
pH increased Bmax, and both effects were abolished with mutation of C222, it is proposed
that the reactivity of this residue plays an important role in stabilizing the transporter to
the NBMPR conformation.
Additionally, C222S retained MMTS-inhibition of [3H]2-chloroadenosine Vmax
(Figure 4.24B) indicating that the residue was not the cysteine responsible for the
inhibition of substrate uptake. This suggests that C222 is not a shared residue between
the NBMPR binding site and the substrate translocation pathway and this in turn implies
a physical distinction between the NBMPR binding site from the substrate translocation
site. It is important to note that NBMPR has been shown to be a competitive inhibitor of
nucleoside transport in various models [179, 209], and nucleoside substrates are
competitive inhibitors of NBMPR binding [90, 210]. Therefore, there is clearly an overlap
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in the NBMPR and substrate binding sites of hENT1. Cysteine 222 appears either to be in
the distinctive NBMPR binding region, or is affecting NBMPR binding to that region via
MMTS-induced conformational changes. When looking for the cysteines involved in the
Vmax enhancement effect with MMTS, we found mutation of C193 (TM5), C297 (TM7), or
C333 (TM8) to serine led to a significant reduction of the MMTS effect on [ 3H]2chloroadenosine uptake. This study could not narrow down the search for the
implicated cysteine or cysteines. This could be in part due to MMTS acting with all three
cysteines or that these cysteines act in combination to produce those effects. These
results suggest that a distinct cysteine, or sets of cysteines, is involved in the effect of
the MTS reagents on substrate transport versus NBMPR binding.

5.2.3 Cysteine 378 is responsible for MTSET effects
When determining which cysteine was involved in MTSET effects, the function of C193S,
C213S, C297S, C333S, and C378S was observed to be insensitive to MTSET. Surprisingly,
mutation of C414 to serine produced an even greater inhibition in [3H]NBMPR binding
with MTSET treatment (Figure 4.40). Given that MTSET is a large membraneimpermeable positively charged reagent and that C193, C213, C297 and C333 are
located within TM regions (Figure 2.1), it was suggested that they were not involved in
MTSET effects but rather mutation of these residues could have altered transporter
conformation to bury C378 making its side chain inaccessible to MTSET. C378 is a
conserved residue that is predicted to be positioned at the interface of TM9 and the
extracellular loop indicating that it has a higher probability of interacting with a charged
reagent. Additionally, mutation of the intracellular C414 seemed to produce an
enhanced accessibility to the targeted residue. The region between C378 and C414
includes EL5 and TM10, therefore it is possible that TM10 plays an important structural
and/or functional link between these two residues.

To test this idea, a stably expressed functional double mutant of C378 and C414
to serines was produced and tested for MTSET sensitivity. The double mutant (C378S-

150
C414S) was insensitive to MTSET inhibition of NBMPR binding as previously observed for
the C378S mutant which indicated that C378 is likely the targeted residue (Figure 4.43A).
The structural and/or functional cooperation between C378 and C414 is a novel finding
as residues in the cytoplasmic domain are not known to show influences on the
extracellular binding domain. However, a recent finding by Yao et al. (2011) indicated
low amounts of nucleobase transport by wild-type hENT1 in an enhanced expression
vector pGEMHE and suggested that C414 was responsible for this nucleobase activity. It
must also be noted, that we have not found any evidence for nucleobase (hypoxanthine)
transport by recombinant hENT1 expressed in the PK15-NTD at concentrations of
nucleobases below 400 µM (unpublished data). Thus, the nucleobase transport
observed by hENT1 by Yao et al. may reflect the expression model used, or higher
concentrations of nucleobases than employed in previous studies are required to
measure observable transporter-mediated uptake. Therefore, we have found C378 to
possibly be in a region that is of anionic character so that, when modified with a
positively charged reagent, it inhibits binding of NBMPR. Since MTSET cannot cross the
membrane, this inhibition of NBMPR binding is therefore restricted to those sites found
at the plasma membrane supporting the conclusion that C378 resides in a hydrophilic or
extracellular environment. When reviewing the 2-D topology of hENT1, it is noted that
there are negative charges located near the membrane boundaries in EL4 and EL5 (E391,
D393) indicating that they may form a pocket of negatively charged environment near
the membrane that C378 may lie within (Figure 5.1). In this way, if EL4 and EL5 are
relative close, the adjoining TMs may also lie in close proximity and possibily TM7 and
TM10 may also be neighbors. Once again, when assessing the ab initio model of LdNT1.1
(Figure 1.11), the exofacial ends of TM7 and TM10 are shown to be adjacent with one
another and may contribute to the NBMPR binding domain (Figure 5.4).

The mENT1Δ11 variant that had lost the ability to covalently bind NBMPR, has
already indicated the importance of TM9-11 and EL5 in the NBMPR covalent
attachment. The results of the present study provide more evidence on this area of the
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transporter and indicate that C378 (located at the TM9 and EL5 interface) may be
adjacent to important determinants of NBMPR binding. Additionally, this study found
that residue C414 in intracellular loop 5 can be an important contributor to extracellular
regions of hENT1. Since C414 mutation to serine enhances the ability of MTSET
inhibition at C378, this suggests that modification at cytoplasmic portions of the
transporter impacts the extracellular side. As previously described, mutation of C416
(close to C414) in IL5 abrogated the translocation function, our results in this section
further validates the role of intracellular residues in impacting transporter function. This
suggests that the cytoplasmic ends of TM10 and 11 are conformationally linked to TM36 which has already been shown to partially form the active site of hENT1.
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C222

Figure 5.4. Simulated topology of hENT1 based on the ab initio model of LdNT1.1.
highlighting extracellular negatively charged amino acids. Cys378 is shown in the grey
circle at the TM9 interface, Cys 222 shown in the red cirble, blue circles indicate relative
positions of negatively charged amino acids. Representation of the side view of the
LdNT1.1 model described by Valdes
et al., 2009. [156]

153
5.2.4 Cysteine 416 is responsible for MTSES effects in membrane preparations
Cysteine mutants treated with MTSES in whole cells produced no effects in either
[3H]NBMPR binding or [3H]2-chloroadeonsine uptake as previously seen with wild-type
hENT1. This validated that effects observed in broken cell preparations are due to the
contribution of intracellularly located cysteines. When membrane preparations enriched
for cysteine mutants (C87S, C193S, C213S, C222S, C297S, C333S, C414S, and C439A)
were subjected to MTSES treatment, significant inhibition of NBMPR binding was
observed. The single cysteine mutant that was unaffected by MTSES treatment was
C416A (Figure 4.49). Thus, MTSES and MMTS treatment did not decrease [3H]NBMPR
binding in the C416A mutant and the effect of MTSET was significantly less relative to
wild-type hENT1. This indicates that C416 is in a cytoplasmic location, which supports
the 2-D topology model of hENT1 and substantiates the second hypothesis in this thesis
where it was proposed that there is a cytoplasmic-located cysteine that when modified
causes a change in hENT1 function. The conserved residues, C416 was also found to be
the targeted residue in IL5 for thiol modification that is involved in the NBMPR binding
pocket. In effect, since neither adenosine nor NBMPR alone could protect against these
effects (Figure 4.50A, 4.50B), it is suggested that there is no direct interaction and hence
C416 most likely does not line the permeation pathway nor lie in the inhibitor binding
site. The alternating access mechanism proposed in Chapter 1 of this thesis suggests that
ENT1 has an extracellular and intracellular site that can alternate between the two
conformations depending on whether a substrate is bound.

It is also suggested that the extracellular site can bind NBMPR and other
inhibitors to lock it in that conformation. Therefore, it is possible that the location of IL5
is not directly part of the ligand binding site but that interaction with C416 with MTS
reagents may lock hENT1 in an inwardly faced conformation. The modification may be
the result of either introduction of a charged/uncharged alkyl group or loss of the
hydrogen bonding interactions of sulfhydryl groups. Given that C416 has already been
implicated in 2-chloroadenosine uptake mechanism but is still able to bind NBMPR with
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high affinity, it was proposed that C416 has an important function in the orientation of
TM helix 10 and 11 to TM 3-6, which is the previously recognized ligand binding domain.
It is possible that the packing of TMs helices around the solvent-accessible permeant
and inhibitor binding site requires the aid of C416. The recently published ab initio
model of the LdNT1.1, highlighted the structure to have one inner bundle of TM helices
(1, 2, 4, 5, 7, 8, 10, 11) encompassing a hydrophilic cavity and the remaining TMs (3, 6,
and 9) encircling the inner bundle [156]. Following this model, the results of the present
study indicate that the cytoplasmic link between TM10 and 11 (where C416 is located)
may actually not be central to ligand translocation or recognition but instead may have a
conformational role in keeping the TM helices stable for substrate interaction.
Therefore, it is possible that modification at C416 with MTS reagents may alter the angle
or rotation of these transmembrane domains causing the effects seen in NBMPR binding
(Figure 5.2).

5.3 Role of residues in EL5
With the results from the preceding studies highlighting the roles of TM9-11 and IL5 in
the structure and function of hENT1, examination was extended into the role of EL5. This
region of hENT1 has not been clearly defined in its function; however, evidence from
studies of CeENT1 revealed that an Ala and Thr in TM 1 and 11, respectively, impaired
uridine and adenosine transport and that L442 of hENT1 was involved in permeant
selectivity [100]. Recent studies have also identified Phe334, Asn338, (TM8) and Leu442
(TM11) of ENT1 as contributing to interactions with coronary vasodilators [100, 143].
Additionally, there is a multitude of evidence that extracellular loops can contribute in
the function of integral membrane proteins. For example, studies on the Na+/H+
exchanger 1 (NHE1) have found that its extracellular loop 2 (EL2) is implicated in
substrate and inhibitor sensitivities. Residues Pro153, Pro154 and Phe155 all found in
EL2 were critical for NHE1 activity [211]. Furthermore, the Cys-loop family of ligandgated ion channels have implicated extracellular residues to undergo conformational
changes that are critical in function [212-215]. There is also evidence of transporters
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such as hOCT2 that show the contribution of extracellular loops in protein folding,
membrane expression, and oligomeric assembly [216]. In our study, mutation of each
residue in EL5 to cysteine produced no change in the ability of hENT1 to bind
[3H]NBMPR. This indicated that none of the residues in EL5 are crucial points of contact
for NBMPR binding or that the cysteine introduced into that location retained the ability
to recognize [3H]NBMPR and perform the same hydrogen bonding capabilities or
retained the same flexibilities.

5.3.1 N379C, F390C, E391C, H392C, and D393C are critical in transporter function
When assessing EL5 mutants in their ability to transport [3H]2-chloroadenosine; N379C,
F390C, E391C, H392C, and D393C showed no uptake of the substrate (Figure 4.53). It is
important to note that N379, F390, H392, and D393 are conserved residues between
mammalian homologs of ENT1. To determine whether the loss of transport in these five
mutants was due to a loss of transporter expression at the membrane, FTH-SAENTA
inhibition assays were performed. In this manner, only the transporters expressed at the
plasma membrane would be inhibited by the membrane-impermeable analogue. The
results obtained showed all five non-functional mutants to have significant expression at
the plasma membrane, indicating that the loss of transport function was most likely due
to a change in substrate affinity or to a change in transport mechanism as previously
observed for the C416A mutant. To test these ideas, competitive inhibition assays were
performed using 2-chloroadenosine as the inhibitor against [3H]NBMPR binding. For all
five non-functional mutants, 2-chloroadenosine was able to inhibit NBMPR binding with
similar affinities (Figure 4.54) indicating that the substrate recognition site was still intact
and 2-chloroadenosine remained a competitive inhibitor but the mechanism for
transport was impaired. Given that the four residues are found in succession on one side
of the loop (F390C, E391C, H392C, and D393C), it is possible that these residues are
crucial in constructing part of the substrate translocation site. Additionally, E391 and
D393 are both predicted to be negatively charged at physiological pH, and are able to
form ionic bonds with positively charged amino acids or form ion dipole interactions
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with water. Removal of these strong ionic bonding partners in this region could cause
this drastic impact seen in hENT1 functionality. It is interesting to note that mutation of
the positively charged residues (K381, R383, and R384) to Cys in EL5 had no effect on
[3H]2-chloroadenosine uptake, suggesting that the negative charges of EL5 possess a
greater role in transporter function. Furthermore the asparagine residue (N379) can also
function as a chain crosslinker or in hydrogen bonding to water at the protein surface.
Since asparagines are often found in protein bends it is possible that abrogation of this
bend at the TM9 interface repositions the TM helix in a manner that reshapes the
translocation pathway. It has already been shown that C3-OH and C5-OH groups of the
sugar moieties of nucleoside analogues form strong interactions with hENT1 suggesting
a role for hydrogen bonding between the transporter and ligand. Therefore the
availability of these bonding partners via functional side chains of amino acids can have
a drastic impact on hENT1 function. The previously mentioned ab initio model of the
LdNT1.1 with one inner bundle of TM helices (1, 2, 4, 5, 7, 8, 10, 11) forming the
hydrophilic pore and the remaining TMs (3, 6, and 9) surrounding the inner bundle
suggests that the extracellular loop would link the inner bundle to the outer bundle
[156]. Results of this study when combined with this model, suggests that the residues
that are implicated in substrate uptake are located closer to the extracellular end of
TM10 which is predicted to form part of the hydrophilic pore.

5.3.2 MTSET effects on EL5 mutants
When testing the accessibility of the mutated residues in EL5 to MTSET, it was observed
that all mutants except for V389C to have some measurable inhibition of NBMPR binding
with MTSET treatment (Figure 4.55). Given that the majority of the EL5 residues can
become modified with MTSET indicates that EL5, although not directly involved in
NBMPR binding, is nevertheless close enough to the pocket to disrupt it when bulky
positively charged alkyl groups are attached. The maximal amount of inhibition was seen
at ~50% at R383C, indicating that it may be the closest residue to the hydrophilic binding
pocket and significantly block NBMPR binding when modified with a positively charged
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reagent. The observation that V389C was not sensitive to MTSET is surprising given that
adjacent residues are able to be sufficiently modified to inhibit binding. There may be
two reasons for this effect, one is that V389C is not accessible for modification or that
modification at this site does not impact NBMPR binding. However, MTSET inhibition at
15 out of the 16 EL5 mutants does support the extracellular location of this loop,
supporting the 2-D topology model of hENT1. Co-incubation of NBMPR with MTSET was
able to protect N379 from thiol modification indicating that the inhibitor NBMPR was
able to block the reaction at that site. Co-incubation of adenosine with MTSET produced
a separate set of amino acids that were protected from MTSET inhibition of binding:
R384C, Y385C, and L386C. Not surprisingly, these three residues are all found in
sequence within the middle or apex of EL5 which would have the greatest accessibility
to ligands. These results indicate that adenosine may bind in close vicinity or in direct
contact to these residues to prevent MTSET to attain access.

5.4 General conclusions
Human ENT1 is known to be the major facilitator of bi-directional nucleoside flux and
uptake of anti-cancer and anti-viral analogues. Based upon data from previous
glycosylation and hydropathy studies, hENT1 is predicted to have an intracellular Nterminus, extracellular C-terminus and 11 transmembrane domains. Human ENT1 is
thought to function as a simple carrier, where there is one exofacial site for nucleoside
or inhibitor interactions and an endofacial site for nucleoside flux. However, one of the
key issues related to the function of ENT transporters is the location and structure of the
permeation site. Previous studies using NEM and pCMBS have identified the importance
of cysteines in ENT1 function. In this thesis, we have found the neutral membranepermeable reagent MMTS to produce an enhancement of intracellular binding sites for
the prototypical probe NBMPR. This effect was due to modification of C222 found in TM
6 indicating that it was located in a hydrophobic environment. C222 was also found to
be responsible for the enhanced NBMPR binding of hENT1 in basic pH suggesting that
de-protonation of C222 causes the formation of new intracellular binding sites.
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Additionally, these studies are the first to show that a positively charged reagent,
MTSET, can inhibit NBMPR binding in intact cells, which indicated that there was a
cysteine residue accessible to the extracellular space. The cysteine responsible appears
to be C378 indicating that it is in an aqueous negatively charged environment close to
the inhibitor binding pocket. The predicted topology of hENT1 puts C378 near the
extracellular end of TM9; therefore results are consistant with this model and show it is
likely the single Cys residue accessible to positively charged modification. The
association of C378 and C414 has indicated the structural and/or functional linkage
between TM9 and IL5 where intracellular modifications can have a drastic impact on the
extracellular side of hENT1. Conjointly, the role of C416 has been made apparent and is
the first study to show the contribution of IL5 residues in the functionality of hENT1. This
study establishes C416 as the cytoplasmically located cysteine that modifies the
extracellular binding site and is susceptible to thiol modification by charged thiol
reagents in membranes. C416 is also implicated in the permeation site or pathway of 2chloroadenosine and has a central role in the substrate translocation mechanism. Lastly,
a functional role for EL5 has been revealed which has never been examined previously.
Mutational analysis found N379, F390, E391, H392, and D393 to have crucial functions
for the hENT1 translocation machinery. Furthermore, MTSET treatment of EL5 mutants
inhibited binding of NBMPR to hENT1, thereby suggesting that EL5 is in close proximity
to the inhibitor recognition site. Finding that there are two separate sets of residues that
can be protected from MTSET by using NBMPR or adenosine also indicated that the two
ligands interact with hENT1 at separate orientations and determinants. In this manner,
new regions of hENT1 have been identified that were previously not known to
contribute to its function. This is the first study to describe the importance of
extracellular loops in ENT1 function and will provide a basis for future targeting studies
on hENT1 structure-function.
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